Diabetic Retinopathy

On this page

Quick Reference

RxDrug of choiceAflibercept 2 mg intravitreal for CI-DME with severe vision loss (≤20/80) or first-line for PDR with VH

AltAlternativesRanibizumab 0.5 mg, bevacizumab 1.25 mg (off-label), faricimab 6 mg (bispecific anti-VEGF/Ang-2, up to q16w), dexamethasone intravitreal implant (Ozurdex 0.7 mg) for persistent DME

⊘AvoidAspirin for DR prevention (no benefit, increased bleeding); rapid glycemic improvement in active PDR (risk of early worsening); semaglutide in active PDR without monitoring

DxTest of choiceSpectral-domain optical coherence tomography (OCT) for diagnosing and monitoring diabetic macular edema; central subfield thickness ≥325 μm defines center-involved DME

ScKey scoreInternational Clinical Diabetic Retinopathy Severity Scale (ICDR), severe NPDR defined by the 4-2-1 rule (>20 hemorrhages in 4 quadrants, venous beading in ≥2 quadrants, or IRMA in ≥1 quadrant)

→When to referAcute vitreous hemorrhage, tractional retinal detachment, neovascular glaucoma, or persistent DME not responding to initial anti-VEGF therapy, refer to a retina specialist within 24 hours

Diabetic retinopathy is a leading cause of preventable blindness. Early detection through annual screening, aggressive systemic risk factor control (HbA1c <7%, BP <130/80, fenofibrate), and timely anti-VEGF therapy for vision-threatening disease can dramatically reduce progression and vision loss.

Diabetic retinopathy (DR) is a progressive microvascular complication of diabetes mellitus and a leading cause of preventable blindness in working-age adults worldwide. The disease progresses silently from nonproliferative stages (NPDR) to vision-threatening proliferative DR (PDR) and diabetic macular edema (DME), driven by hyperglycemia-induced metabolic injury, inflammation, and retinal ischemia. Comprehensive management requires dual approaches: aggressive systemic risk factor control (glycemic, blood pressure, lipid) and timely intraocular therapy, primarily anti-VEGF agents, to preserve vision. Screening adherence and early detection remain the most critical modifiable factors to prevent blindness.

Overview and Recommendations

Background

•Diabetic retinopathy (DR) is a progressive microvascular complication of diabetes mellitus, characterized by retinal capillary damage leading to vascular leakage, ischemia, and neovascularization. It affects approximately 103 million people globally, about 22% of all individuals with diabetes, and remains a leading cause of preventable blindness among working-age adults (20-74 years) in high-income countries.
•Chronic hyperglycemia drives four interconnected metabolic pathways, the polyol pathway, advanced glycation end products (AGEs) formation, protein kinase C (PKC) activation, and hexosamine pathway flux, that converge on mitochondrial overproduction of superoxide, generating oxidative stress and cellular injury. These pathways disrupt the neurovascular unit, with photoreceptor loss and pericyte death preceding clinically visible vasculopathy by months to years.
•Retinal ischemia stabilizes hypoxia-inducible factor-1α (HIF-1α), which transcriptionally upregulates vascular endothelial growth factor (VEGF), the master driver of pathological angiogenesis, leading to neovascularization of the disc (NVD) or elsewhere (NVE), vitreous hemorrhage, and tractional retinal detachment in proliferative DR (PDR).
•Two complementary classification systems guide clinical staging: the simplified International Clinical Diabetic Retinopathy (ICDR) scale, which categorizes severity as no DR, mild/moderate/severe NPDR, and PDR, and the more detailed Early Treatment Diabetic Retinopathy Study (ETDRS) scale (levels 10-85). Diabetic macular edema (DME) is classified separately based on optical coherence tomography as center-involved (CI-DME) or non-center-involved DME. Vision-threatening DR (VTDR) encompasses severe NPDR, PDR, and CI-DME and is the primary target for screening and intervention.

Evaluation

•Suspect diabetic retinopathy in any patient with diabetes, especially those with longer disease duration (>10 years), poor glycemic control (HbA1c > 7%), or concurrent hypertension. Most patients are asymptomatic until vision-threatening complications develop.
•Ask about recent visual symptoms: blurring, metamorphopsia, difficulty reading or recognizing faces (suggesting DME), or sudden floaters, flashes, or curtain-like vision loss (suggesting vitreous hemorrhage or retinal detachment). Note any history of prior laser, anti-VEGF injections, or vitrectomy.
•Examine visual acuity (best corrected) and perform a dilated fundus examination with slit-lamp biomicroscopy (78D or 90D lens). Look for microaneurysms, dot-and-blot hemorrhages, hard exudates, cotton-wool spots (NPDR), and neovascularization of the disc (NVD) or elsewhere (NVE), vitreous hemorrhage, or tractional retinal detachment (PDR). Examine the iris for rubeosis (neovascularization) suggesting neovascular glaucoma.
•Grade severity using the ICDR scale: no DR → no abnormalities; mild NPDR → microaneurysms only; moderate NPDR → more than microaneurysms but less than severe; severe NPDR → any of the 4-2-1 rule (>20 intraretinal hemorrhages in 4 quadrants, venous beading in ≥2 quadrants, or IRMA in ≥1 quadrant); PDR → neovascularization or vitreous/preretinal hemorrhage.
•Order spectral-domain optical coherence tomography (OCT) to assess for DME. Center-involved DME is defined by central subfield thickness (CST) ≥ 325 μm on spectral-domain OCT. Evaluate for qualitative biomarkers: disorganization of retinal inner layers (DRIL) predicts poor visual response to anti-VEGF therapy; hyperreflective foci, subretinal fluid, and ellipsoid zone disruption correlate with worse outcomes.
•If neovascularization is suspected or vision loss persists despite normal OCT, perform fluorescein angiography (FA) to detect retinal NV and capillary nonperfusion. Ultra-widefield FA captures peripheral ischemia beyond standard ETDRS fields and predicts progression risk. OCT angiography is a noninvasive alternative that visualizes capillary dropout and can distinguish active NV from quiescent fibrovascular proliferation.
•Assess systemic risk factors: measure HbA1c, blood pressure, serum lipids (especially LDL), and renal function (eGFR, urine albumin-to-creatinine ratio). Evaluate for obstructive sleep apnea, which independently increases DR risk (OR 1.45, 95% CI 1.20-1.75).
•In screening settings, use AI-based fundus photography (e.g., EyeArt, IDx-DR) as a triage tool to identify patients requiring specialist referral. AI systems achieve pooled sensitivity of 87-96% and specificity of 86-93% for referable DR (moderate NPDR or worse).
•Consider functional testing (multifocal ERG, microperimetry) in research settings or for unexplained visual complaints with minimal fundus findings; these reveal neuroretinal dysfunction before structural changes appear.
•Red flags requiring same-day referral to a retina specialist: sudden vision loss with floaters (acute vitreous hemorrhage from PDR), pain with elevated IOP and rubeosis (neovascular glaucoma), or progressive visual field loss suggesting tractional retinal detachment.

Management

•Initiate intensive systemic risk factor control as the foundation of DR management: target HbA1c <7% (or <6.5% in selected patients without hypoglycemia risk), blood pressure <130/80 mmHg, and LDL <100 mg/dL. The J-DOIT3 trial showed that such multifactorial intervention reduces retinopathy progression by 40% (HR 0.60, 95% CI 0.44-0.82).
•Consider fenofibrate (145 mg daily) as adjunctive systemic therapy to slow DR progression, especially in patients with early NPDR and dyslipidemia. The LENS trial demonstrated a 27% relative risk reduction in progression (HR 0.73, 95% CI 0.58-0.91; NNT = 16 over 4 years).
•For center-involved DME with vision loss, administer intravitreal anti-VEGF therapy as first-line treatment. Aflibercept 2 mg (5 monthly loading doses, then 2 mg every 8 weeks) is preferred for severe vision loss (≤20/80) based on DRCR.net Protocol T (mean gain +10.7 letters at 1 year). Alternatives: ranibizumab 0.5 mg (monthly ×3-5, then treat-and-extend) or bevacizumab 1.25 mg (off-label, monthly PRN). Faricimab 6 mg (bispecific anti-VEGF/anti-Ang-2) is noninferior to aflibercept and allows up to 16-week dosing intervals.
•For persistent DME despite anti-VEGF, consider dexamethasone intravitreal implant (0.7 mg, Ozurdex); the MEAD study showed 22% of treated eyes gained ≥15 letters vs 12% with sham (OR 2.1, P=0.016). Monitor for cataract and elevated IOP.
•For proliferative DR with vitreous hemorrhage or high-risk characteristics, administer intravitreal anti-VEGF as first-line therapy (aflibercept 2 mg monthly ×3 then q8w, or ranibizumab 0.5 mg monthly until regression). A meta-analysis of 5 RCTs confirmed anti-VEGF reduces vitrectomy need by 40% (RR 0.60, 95% CI 0.44-0.82; NNT = 12).
•Perform panretinal photocoagulation (PRP) if anti-VEGF is contraindicated, inaccessible, or if follow-up is uncertain. Deliver 1200-1600 burns (500 μm spot size, argon or frequency-doubled Nd:YAG 532 nm) in 2-4 sessions using pattern-scanning laser (PASCAL) to reduce pain. The ETDRS established that PRP reduces severe vision loss by 50% (from 26% to 13%).
•For severe NPDR without DME, consider proactive anti-VEGF therapy (e.g., aflibercept 2 mg q8w after 5 monthly doses) in high-risk patients (poor glycemic control, prior PDR in fellow eye). The PANORAMA trial showed this reduces 2-year progression to PDR or CI-DME from 43% to 16% (HR 0.32; NNT = 4).
•If vitreous hemorrhage does not clear within 4-6 weeks after anti-VEGF, or if tractional retinal detachment involves the fovea, perform pars plana vitrectomy (PPV). Administer preoperative intravitreal bevacizumab 1.25 mg 3-7 days before surgery to reduce intraoperative bleeding (RR 0.38, 95% CI 0.24-0.60) and shorten surgical time by ~27 minutes. Endolaser photocoagulation is applied to ischemic retina during surgery.
•For neovascular glaucoma (rubeosis with IOP >30 mmHg), emergently lower IOP with topical beta-blockers, alpha-agonists, and oral acetazolamide (500 mg IV or PO). Administer intravitreal bevacizumab 1.25 mg to regress iris NV within 48-72 hours, followed by PRP once media clears. If IOP remains >30 mmHg despite maximal therapy, place a glaucoma drainage implant (e.g., Ahmed valve).
•After initial treatment, monitor patients monthly using a treat-and-extend protocol (extend intervals by 2 weeks per visit, up to a maximum of 12-16 weeks) based on disease activity on OCT and clinical exam.
•Do NOT use aspirin for DR prevention or progression; the ASCEND-Eye trial (N=15,480) showed no benefit (HR 1.02, 95% CI 0.92-1.13) and increased gastrointestinal bleeding risk.
•Do NOT initiate rapid glycemic improvement in patients with active PDR or severe NPDR; the ACCORD Eye study found a 40% increased risk of early DR worsening (NNT = 25 for harm). Gradually lower HbA1c by <1% per month.
•Do NOT use semaglutide in patients with active PDR without careful monitoring; the SUSTAIN-6 trial reported a 76% increased risk of DR complications (HR 1.76, 95% CI 1.11-2.78).
•Refer to a retina specialist within 24 hours for: acute vitreous hemorrhage obscuring the macula, tractional retinal detachment involving/fovea-threatening, neovascular glaucoma, or severe vision loss due to DME not responding to initial therapy.

Board Review — High Yield

•Metabolic memory, Prior glycemic control continues to influence retinopathy risk years later via epigenetic modifications (DNA methylation, histone acetylation, microRNA dysregulation); the DCCT/EDIC study demonstrated this phenomenon.
•4-2-1 rule for severe NPDR, Intraretinal hemorrhages in 4 quadrants, venous beading in 2 quadrants, or IRMA in 1 quadrant; this defines severe nonproliferative DR and carries a 13.5% 2-year risk of progression to PDR.
•VEGF axis, Hypoxia stabilizes HIF-1α, which transcriptionally upregulates VEGF-A (master driver of pathological angiogenesis). Anti-VEGF therapy (aflibercept, ranibizumab, bevacizumab) targets this pathway and is the standard of care for CI-DME and PDR.
•DRIL, Disorganization of retinal inner layers on OCT is a strong negative prognostic biomarker for visual outcomes after anti-VEGF therapy for DME (OR 2.8 for poor response).
•PANORAMA trial, Proactive aflibercept 2 mg every 8 weeks in severe NPDR reduced 2-year progression to PDR or CI-DME from 43% to 16% (NNT = 4), supporting early intervention in high-risk patients.
•Preoperative anti-VEGF before vitrectomy, Intravitreal bevacizumab 1.25 mg given 3-7 days before PPV reduces intraoperative bleeding (RR 0.38), shortens surgical time by 27 minutes, and decreases recurrent VH (RR 0.37).
•Neovascular glaucoma emergency, Rubeosis iridis with IOP >30 mmHg requires immediate IOP reduction (beta-blockers + acetazolamide), urgent intravitreal anti-VEGF, and PRP once media clears; if refractory, glaucoma drainage implant.
•ASCEND-Eye trial, Aspirin 100 mg daily showed no benefit for DR prevention or progression (HR 1.02, 95% CI 0.92-1.13) and increased bleeding risk, do not use for DR.
•Fenofibrate, The LENS trial demonstrated that fenofibrate 145 mg daily reduces DR progression by 27% (HR 0.73; NNT = 16 over 4 years), positioning it as an adjunctive systemic therapy for early DR and dyslipidemia.
•Semaglutide caution, SUSTAIN-6 trial found a 76% increased risk of DR complications with semaglutide (HR 1.76, 95% CI 1.11-2.78); use with caution in patients with active PDR.

Deep Dive — Evidence Details

Definition, Classification & Nomenclature

▸Diabetic retinopathy is defined as a progressive microvascular complication of diabetes leading to retinal capillary damage, ischemia, and neovascularization.
▸The International Clinical Diabetic Retinopathy (ICDR) severity scale classifies DR into no apparent retinopathy, mild/moderate/severe NPDR, and PDR, while diabetic macular edema is categorized by center involvement on OCT.
▸Vision-threatening DR (VTDR) includes severe NPDR, PDR, and center-involved DME and is the primary target for screening to prevent blindness.

HY High Yield: The 4-2-1 rule for severe NPDR: >20 hemorrhages in 4 quadrants, venous beading in ≥2 quadrants, or IRMA in ≥1 quadrant.

Diabetic retinopathy is a medical condition in which damage occurs to the retina due to diabetes. It is a leading cause of blindness in developed countries and one of the leading causes of sight loss in the world, even t — Diabetic retinopathy — Diabetic retinopathy is a medical condition in which damage occurs to the retina due to diabetes. It is a leading cause of blindness in developed coun...Wikipedia ↗

Diabetic retinopathy (DR) is a progressive microvascular complication of diabetes mellitus characterized by retinal capillary damage that leads to vascular leakage, ischemia, and neovascularization, and it remains a leading cause of preventable blindness in working-age adults worldwide ^[7]^B2a^[21]^B2c.

Also Called / Synonyms

Diabetic retinal disease (DRD) ^[24]^D5
Diabetic microangiopathy of the retina
Diabetic eye disease (colloquial)
Retinopathy of diabetes (historical)

Classification Systems

Two complementary classification systems guide clinical staging and treatment decisions: the International Clinical Diabetic Retinopathy (ICDR) severity scale and the more detailed Early Treatment Diabetic Retinopathy Study (ETDRS) scale ^[3]^B2b^[60]^D5. The ICDR scale is the most widely used in practice because of its simplicity and direct correlation with thresholds ^[61]^D5^[63]^D5.

ICDR Severity Level	Key Fundus Findings	Corresponding ETDRS Level
No apparent retinopathy	No abnormalities	Level 10
Mild NPDR	Microaneurysms only	Level 20
Moderate NPDR	More than microaneurysms but less than severe NPDR	Levels 31-43
Severe NPDR	Any of: >20 intraretinal hemorrhages in 4 quadrants, venous beading in ≥2 quadrants, or IRMA in ≥1 quadrant (4-2-1 rule)	Levels 47-53
Proliferative DR (PDR)	Neovascularization (disc or elsewhere), vitreous/preretinal hemorrhage	Levels 60-85

Diabetic macular edema (DME) is classified separately based on optical coherence tomography (OCT) as center-involved DME (CI-DME) or non-center-involved DME (non-CI-DME), with or without visual acuity loss ^[22]^D5^[23]^D5. DME can occur at any DR stage and is the most common cause of vision-threatening DR (VTDR) ^[23]^D5.

Vision-threatening DR (VTDR) encompasses severe NPDR, PDR, and CI-DME and is the primary target for screening and intervention ^[7]^B2a^[63]^D5.

Clinical Significance

DR affects approximately one-third of the estimated 537 million adults with diabetes globally, and its prevalence rises with diabetes duration and poor glycemic control ^[7]^B2a^[21]^B2c. The disease is a major driver of healthcare costs and disability, with PDR and DME conferring a 2- to 4-fold increased risk of cardiovascular disease and mortality ^[8]^B2a. Early detection through systematic screening reduces the risk of severe vision loss by 50-60% ^[11]^B2a^[63]^D5.

Pearl: The ICDR severity scale remains the most widely used clinical classification, but emerging biomarkers such as OCT-based retinal neurodegeneration and ultra-widefield imaging are refining risk stratification and enabling earlier identification of rapid progressors ^[24]^D5^[60]^D5.

Pathophysiology & Mechanism

▸Retinal neurodegeneration (ganglion cell loss, RNFL thinning) precedes visible vasculopathy and can be detected by OCT years before clinical retinopathy appears.
▸Hyperglycaemia drives four metabolic pathways (polyol, AGE, PKC, hexosamine) that converge on mitochondrial oxidative stress, initiating inflammation, BRB breakdown, and pericyte loss.
▸VEGF-A is the central mediator of pathological angiogenesis in PDR; anti-VEGF therapy improves vision by 5-12 ETDRS letters at 12 months, but non-VEGF cytokines (IL-6, ANGPTL4, Sema3E) contribute to persistent DME and fibrosis.

HY High Yield: Pericyte loss is the earliest histologic hallmark of diabetic retinopathy; it precedes acellular capillary formation and is driven by AGEs, oxidative stress, and loss of PDGF-B survival signalling [82].

Chronic hyperglycaemia initiates a cascade of metabolic, inflammatory, and vascular events that progressively disrupt the neurovascular unit of the retina, culminating in the clinical phenotypes of non-proliferative and proliferative diabetic retinopathy ^[82]^D5^[133]^D5.

Metabolic Pathways of Hyperglycaemic Damage

Hyperglycaemia drives four interconnected biochemical pathways that generate oxidative stress and cellular injury. The polyol pathway consumes NADPH, reducing antioxidant capacity and accumulating sorbitol, which induces osmotic stress in pericytes and Müller cells ^[136]^D5. Advanced glycation end products (AGEs) form through non-enzymatic glycation of proteins and lipids; AGEs cross-link extracellular matrix proteins and activate the receptor for AGEs (RAGE), triggering pro-inflammatory and pro-fibrotic signalling in retinal endothelial cells and pericytes ^[121]^D5. Protein kinase C (PKC) activation, particularly the β-isoform, increases vascular permeability and promotes expression of vascular endothelial growth factor (VEGF) and endothelin-1 ^[137]^D5. The hexosamine pathway flux modifies transcription factors and promotes O-GlcNAcylation of proteins, further impairing mitochondrial function. These pathways converge on mitochondrial overproduction of superoxide, the unifying mechanism of hyperglycaemic damage ^[118]^D5.

Neurodegeneration: The Earliest Retinal Injury

Retinal neurodegeneration precedes clinically detectable vasculopathy by months to years ^[107]^D5. Prospective OCT studies show progressive thinning of the ganglion cell-inner plexiform layer (GC-IPL) and peripapillary retinal nerve fibre layer (pRNFL) in diabetic patients without retinopathy, at rates of 1-2 μm/year ^[69]^B2b^[70]^B2b. This neuronal loss correlates with reduced brain-derived neurotrophic factor (BDNF) levels in aqueous humour and serum ^[131]^C4 and with peripheral nerve conduction deficits, indicating that diabetic retinal neurodegeneration is part of a systemic neuropathy ^[98]^C4^[100]^C4. Glutamate excitotoxicity, oxidative stress, and impaired neurotrophic support drive apoptosis of retinal ganglion cells and amacrine cells ^[107]^D5^[140]^D5. Müller cell dysfunction further compromises neuronal homeostasis, as these glial cells lose their ability to buffer potassium and recycle neurotransmitters ^[86]^D5.

Inflammation and the Blood-Retinal Barrier

Inflammation is a central driver of diabetic retinopathy from its earliest stages ^[72]^D5^[117]^D5. Hyperglycaemia upregulates adhesion molecules such as P-selectin and ICAM-1 on retinal endothelial cells, promoting leukocyte adhesion and infiltration (leukostasis) ^[101]^C4^[117]^D5. Activated microglia and Müller cells release a cascade of cytokines: interleukin-6 (IL-6), IL-8, tumour necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1), and serum amyloid A ^[103]^B3b^[126]^D5^[128]^C4. These mediators disrupt tight junction proteins, including claudin-1 and occludin, leading to breakdown of the inner blood-retinal barrier (BRB) and the hallmark leakage of diabetic macular oedema ^[72]^D5^[143]^D5. Complement activation, particularly through the alternative pathway, generates C3a and C5a, which amplify inflammation and contribute to capillary occlusion ^[111]^D5. The NLRP3 inflammasome is activated in retinal microglia and endothelial cells, processing IL-1β and IL-18 and perpetuating a vicious cycle of injury ^[135]^D5.

The VEGF Axis and Neovascularization

Retinal ischaemia stabilises hypoxia-inducible factor-1α (HIF-1α), which transcriptionally upregulates VEGF-A, the master driver of pathological angiogenesis ^[88]^D5^[73]^D5. VEGF-A binds VEGFR2 on endothelial cells, promoting proliferation, migration, and vascular permeability. VEGFR1, expressed on monocytes and pericytes, modulates these effects and contributes to microinflammation ^[83]^D5. In proliferative diabetic retinopathy (PDR), vitreous VEGF levels are markedly elevated, and fibrovascular membranes express VEGF, angiopoietin-like 4 (ANGPTL4), and semaphorin 3E (Sema3E), which correlate with nonperfusion area and macular volume ^[76]^C4^[97]^C4. Placental growth factor (PlGF), another VEGFR1 ligand, is also upregulated and synergises with VEGF-A ^[128]^C4. The clinical success of intravitreal anti-VEGF agents, aflibercept, ranibizumab, and , confirms VEGF as a critical therapeutic target; network meta-analyses show that anti-VEGF therapy improves visual acuity by a mean of +5 to +12 ETDRS letters at 12 months compared with laser ^[89]^A1a^[90]^A1a^[91]^A1a^[92]^A1a.

Capillary Nonperfusion and Ischaemia

Pericyte loss is the earliest structural microvascular change, leading to capillary weakening, microaneurysm formation, and eventual acellular capillaries ^[82]^D5. Endothelial cell death and capillary dropout produce areas of retinal nonperfusion, detectable by OCT angiography ^[54]^B3b^[81]^B2b. The extent of nonperfusion correlates with retinopathy severity and predicts progression to PDR ^[54]^B3b^[81]^B2b. En face Doppler OCT demonstrates reduced total retinal blood flow in eyes with advanced DR, reflecting progressive vasoregression ^[79]^C4. Endothelial-to-mesenchymal transition (EndoMT), driven by fibronectin and TGF-β, contributes to capillary obliteration and fibrosis ^[125]^D5.

Genetic and Epigenetic Modifiers

Heritability estimates for diabetic retinopathy range from 25% to 50% ^[114]^D5. Genome-wide association studies have identified susceptibility loci near genes involved in angiogenesis (VEGFA), inflammation (P-selectin, SELP), and lipid metabolism ^[74]^B3b^[77]^B3b^[101]^C4. A recent GWAS in a famine-exposed cohort revealed interaction between intrauterine nutritional stress and genetic variants in pathways of oxidative stress and mitochondrial function ^[141]^B2b. Epigenetic modifications, including DNA methylation, histone acetylation, and microRNA dysregulation, mediate the metabolic memory phenomenon, whereby prior glycaemic control continues to influence retinopathy risk years later ^[82]^D5^[113]^D5. Mitochondrial dysfunction, driven by defective mitophagy and UCP2-SIRT3 signalling, amplifies oxidative stress and cellular senescence ^[84]^D5^[120]^D5.

Pearl: Diabetic retinopathy is a neurovascular disease in which hyperglycaemia-induced metabolic injury, inflammation, and neurodegeneration precede and drive the microvascular pathology; anti-VEGF therapy effectively targets the final common pathway of neovascularisation, but early neuroprotective strategies remain an unmet need ^[107]^D5^[140]^D5^[144]^D5.

Key Mediators in Diabetic Retinopathy Pathogenesis

Mediator	Source	Primary Effect	Clinical Relevance
VEGF-A	Müller cells, RPE, endothelial cells	Angiogenesis, vascular permeability	Target of anti-VEGF therapy ^[73]^D5^[88]^D5
IL-6, IL-8, MCP-1	Microglia, Müller cells, leukocytes	Leukostasis, BRB breakdown	Elevated in aqueous humour in DME ^[126]^D5^[128]^C4
AGEs	Non-enzymatic glycation	Cross-linking, RAGE activation, oxidative stress	Correlate with DR severity ^[121]^D5
ANGPTL4	Retinal endothelial cells	Angiogenesis, nonperfusion	Elevated in PDR vitreous ^[76]^C4
TNF-α	Activated microglia	Endothelial injury, apoptosis	Synergises with hyperglycaemia to downregulate calnexin ^[142]^D5
Complement C3a, C5a	Systemic and local	Inflammation, capillary occlusion	Alternative pathway activation ^[111]^D5

Epidemiology, Etiology & Risk Factors

▸DR affects 22.27% of diabetics globally, with 1.07 million blind from the disease in 2020; prevalence varies 3-fold by region and is highest in Africa and the Middle East [149, 176].
▸Hyperglycemia is the dominant modifiable risk factor (RR 0.43 for intensive control in type 1 diabetes), but hypertension, dyslipidemia, smoking, and shorter axial length also independently predict DR [160, 191, 190, 165, 203].
▸Special populations, including Indigenous groups, pregnant women, and children, have distinct risk profiles that require tailored screening intervals [151, 209, 212].

HY High Yield: Rapid glycemic improvement (e.g., after bariatric surgery or intensive insulin initiation) can paradoxically worsen DR in the first 6-12 months; screen these patients within 3 months of metabolic change [162].

An estimated 103.12 million people had diabetic retinopathy (DR) globally in 2020, with 1.07 million blind from the disease and another 3.28 million living with moderate or severe vision impairment due to DR ^[149]^A1a^[176]^B2a. These numbers have risen sharply from 0.75 million blind in 2000, driven by the expanding diabetes pandemic ^[176]^B2a.

Global Burden and Demographics

DR affects 22.27% of all individuals with diabetes worldwide, and vision-threatening DR (VTDR), defined as severe nonproliferative DR, proliferative DR, or diabetic macular edema, occurs in 6.17% ^[149]^A1a. Regional prevalence varies more than threefold: highest in Africa (33.8%) and the Middle East (26.4%), lowest in Europe (17.3%) and North America (18.0%) ^[149]^A1a^[200]^D5. In the United States, 9.6 million people had DR in 2021, including 1.84 million with VTDR ^[181]^B2c. Disparities are stark: African Americans, Hispanics, and Indigenous populations carry a 1.5- to 3-fold higher burden than non-Hispanic whites, even after adjusting for diabetes duration and glycemic control ^[151]^A1a^[158]^B2c^[200]^D5^[206]^D5. DR is the leading cause of blindness among working-age adults (20-74 years) in high-income countries ^[206]^D5. Women have a slightly higher age-standardized prevalence of blindness from DR than men, though the sex difference narrows when accounting for longer female life expectancy ^[163]^B2a^[168]^B2a^[169]^B2a.

Temporal Trends

Age-standardized blindness prevalence from DR has declined by roughly 30% in high-income regions since 1990, owing to improved glycemic , widespread screening, and timely laser and anti-VEGF therapy ^[169]^B2a^[176]^B2a. However, the absolute number of people blind from DR continues to rise because of the growing diabetes population, from 0.75 million in 2000 to 1.07 million in 2020 ^[176]^B2a. In low- and middle-income countries, DR prevalence has increased in parallel with urbanization and lifestyle changes, and screening coverage remains below 30% in many regions ^[149]^A1a^[164]^B2a^[168]^B2a.

Risk Factors

Hyperglycemia is the dominant modifiable driver. Intensive glycemic control reduces DR incidence by 57% (RR 0.43, 95% CI 0.33-0.56) in type 1 diabetes and by 25% (RR 0.75, 95% CI 0.65-0.86) in type 2 diabetes ^[160]^A1a. Each 1% reduction in HbA1c lowers DR risk by approximately 40% ^[82]^D5. independently accelerates DR progression; tight blood pressure control reduces progression by 20% (RR 0.80, 95% CI 0.71-0.91) ^[191]^A1a. Dyslipidemia contributes through lipoprotein-mediated endothelial injury; fenofibrate reduces DR progression by 30% (RR 0.70, 95% CI 0.57-0.86) independent of lipid lowering ^[190]^A1a. Smoking increases DR risk by 42% (OR 1.42, 95% CI 1.15-1.75) ^[165]^A1a. Obesity and insulin resistance are associated with higher DR prevalence, though the relationship is partly mediated by glycemic control ^[82]^D5^[113]^D5. Shorter axial length (OR 0.81 per mm, 95% CI 0.70-0.95) and longer diabetes duration (OR 1.5 per 5 years) are strong non-modifiable predictors ^[203]^B3b^[218]^B2b. Genetic factors account for approximately 25% of DR risk, with variants in VEGF, AKR1B1, and RAGE implicated ^[114]^D5. Pregnancy can accelerate DR progression, especially in women with pre-existing moderate-to-severe NPDR ^[209]^B2b. Cataract surgery modestly increases DR progression risk (RR 1.28, 95% CI 1.10-1.49) ^[159]^A1a. Bariatric surgery may cause early DR worsening due to rapid glycemic improvement, though long-term risk is reduced ^[162]^A1a. GLP-1 receptor agonists show conflicting associations: reduces DR risk (HR 0.72, 95% CI 0.58-0.89) ^[155]^B3b, while has been linked to increased nonarteritic anterior ischemic optic neuropathy (OR 2.19, 95% CI 1.28-3.74) ^[157]^A1a^[197]^B3b. already carries a retinopathy prevalence of 7.9% (95% CI 5.2-11.3), suggesting that retinal damage begins before frank diabetes ^[14]^B2a.

Risk Factor	Measure of Association (95% CI)	Evidence Level
Hyperglycemia (per 1% HbA1c)	RR ~0.60 for progression	1a ^[160]^A1a
Hypertension (tight control)	RR 0.80 (0.71-0.91)	1a ^[191]^A1a
Dyslipidemia (fenofibrate)	RR 0.70 (0.57-0.86)	1a ^[190]^A1a
Smoking (current vs never)	OR 1.42 (1.15-1.75)	1a ^[165]^A1a
Diabetes duration (per 5 years)	OR 1.5 (1.3-1.7)	2b ^[218]^B2b
Shorter axial length (per mm)	OR 0.81 (0.70-0.95)	3b ^[203]^B3b
Pregnancy (pre-existing DR)	RR 2.0-3.0 for progression	2b ^[209]^B2b
Cataract surgery	RR 1.28 (1.10-1.49)	1a ^[159]^A1a
GLP-1 RA (tirzepatide)	HR 0.72 (0.58-0.89)	3b ^[155]^B3b
GLP-1 RA (semaglutide, NAION)	OR 2.19 (1.28-3.74)	1a ^[157]^A1a

Special Populations

Children and adolescents with type 1 diabetes have a lower DR prevalence (5-15%) than adults, but risk rises sharply after puberty and with diabetes duration >10 years; HbA1c >8.5% and hypertension are the strongest predictors ^[212]^B2a^[218]^B2b. Pregnant women with pre-existing diabetes require intensified surveillance: DR can worsen by 2-3 ETDRS steps during pregnancy, particularly in those with poor preconception glycemic control ^[209]^B2b. Indigenous populations globally, including Aboriginal Australians, Native Americans, and Maori, experience DR prevalence 2-3 times higher than non-Indigenous counterparts, driven by higher rates of obesity, insulin resistance, and limited access to screening ^[151]^A1a^[200]^D5.

Pearl: Hyperglycemia is the single most powerful modifiable risk factor for DR, with each 1% HbA1c reduction lowering risk by ~40%; however, rapid glycemic improvement (e.g., after bariatric surgery or intensive insulin initiation) can paradoxically cause early DR worsening, necessitating close ophthalmologic monitoring during the first 6-12 months ^[160]^A1a^[162]^A1a.

Clinical Presentation

▸Most patients are asymptomatic until vision-threatening complications (vitreous hemorrhage, DME, tractional RD) develop; low luminance visual acuity is an early functional marker.
▸Funduscopy, OCT, and FA/OCTA are complementary: funduscopy detects clinical signs, OCT quantifies DME and DRIL, and angiography reveals ischemia and neovascularization.
▸Red flags include sudden vision loss with floaters (vitreous hemorrhage), pain with elevated IOP (neovascular glaucoma), and progressive field loss (tractional RD).

HY High Yield: Low luminance visual acuity (LLVA) is more sensitive than standard BCVA for detecting early visual dysfunction in diabetic retinopathy; a low luminance deficit >10 letters suggests macular ischemia [202, 254].

! Warning: Sudden painless vision loss with floaters or a 'curtain' is a red flag for vitreous hemorrhage or retinal detachment; neovascular glaucoma presents with pain, redness, and elevated IOP, both require urgent ophthalmologic evaluation [247, 263].

Most patients with diabetic retinopathy are asymptomatic until vision-threatening complications develop ^[82]^D5. The disease progresses silently through nonproliferative stages, and the first symptom may be sudden vision loss from vitreous hemorrhage or macular edema. Understanding the spectrum of presenting symptoms and examination findings is essential for timely intervention.

Presenting Symptoms

Central vision loss, blurring, distortion, or a central scotoma, is the hallmark of diabetic macular edema (DME) or macular ischemia ^[115]^D5^[253]^D5. Patients often report difficulty reading, recognizing faces, or performing tasks requiring fine detail. Metamorphopsia (straight lines appearing wavy) may accompany DME when cystoid spaces distort the foveal contour ^[22]^D5. Floaters or a sudden “curtain” or “web” in the visual field signal vitreous hemorrhage from proliferative diabetic retinopathy (PDR) ^[247]^B2b^[263]^B2b. Peripheral vision loss is less common but can occur with extensive panretinal photocoagulation or advanced ischemia. Night vision difficulties and reduced contrast sensitivity are early functional deficits that precede visible retinopathy in many patients ^[115]^D5^[253]^D5. Color vision disturbances, particularly blue-yellow defects, are also described ^[253]^D5.

Importantly, low luminance visual acuity (LLVA), measured with a 2.0-log unit neutral density filter, is more sensitive than standard best-corrected visual acuity (BCVA) for detecting early visual dysfunction. LLVA declines before BCVA in eyes with diabetic macular ischemia, and the low luminance deficit (BCVA minus LLVA) correlates with capillary non-perfusion on OCT angiography ^[202]^B3b^[254]^C4.

Ophthalmic Examination Findings

Funduscopy remains the cornerstone of clinical detection. In nonproliferative diabetic retinopathy (NPDR), the examiner sees microaneurysms (the earliest clinically visible lesion), dot-and-blot hemorrhages, hard exudates (lipid deposits), and cotton-wool spots (nerve fiber layer infarcts) ^[82]^D5. Venous beading, intraretinal microvascular abnormalities (IRMA), and more extensive hemorrhages mark progression to severe NPDR ^[60]^D5. In PDR, neovascularization of the disc (NVD) or elsewhere (NVE) appears as fine, lacy networks that leak fluorescein on angiography and are prone to hemorrhage ^[82]^D5.

Optical coherence tomography (OCT) is essential for detecting DME. Central subfield thickness (CST) ≥325 μm on spectral-domain OCT defines center-involved DME ^[22]^D5. OCT also reveals disorganization of retinal inner layers (DRIL), a biomarker for poor visual prognosis, and subretinal fluid or hyperreflective foci ^[22]^D5^[236]^B2a. Fluorescein angiography (FA) demonstrates microaneurysm leakage, capillary non-perfusion, and neovascularization; ultra-widefield FA quantifies peripheral ischemia, which correlates with risk of progression ^[26]^D5^[254]^C4. OCT angiography (OCTA) noninvasively shows capillary dropout in the superficial and deep capillary plexuses, with geometric perfusion deficits increasing across DR severity ^[261]^C4.

Phenotypic Variants

Variant	Key Features	Frequency
Nonproliferative DR (NPDR)	Microaneurysms, hemorrhages, exudates, cotton-wool spots; no neovascularization	Most common; ~25% of diabetics ^[176]^B2a
Proliferative DR (PDR)	Neovascularization (NVD/NVE), vitreous hemorrhage, tractional	~5-10% of diabetics; leading cause of blindness ^[82]^D5
Diabetic Macular Edema (DME)	Retinal thickening involving or threatening the fovea; may occur at any DR stage	~7% of diabetics; most common cause of vision loss ^[22]^D5
Diabetic Macular Ischemia (DMI)	Enlarged foveal avascular zone, capillary non-perfusion on FA/OCTA; often coexists with DME	Underrecognized; up to 40% of eyes with DR ^[26]^D5

Red Flags

Sudden, painless vision loss, especially with floaters or a “shower” of spots, suggests acute vitreous hemorrhage from PDR and requires urgent evaluation ^[247]^B2b^[263]^B2b. Neovascular glaucoma presents with pain, redness, elevated intraocular pressure, and rubeosis iridis (new vessels on the iris); it is a sight-threatening emergency ^[82]^D5. Tractional retinal detachment causes progressive visual field loss and may involve the macula, necessitating prompt vitreoretinal surgery ^[258]^C4. Any patient with new-onset floaters, flashes, or curtain-like vision loss should undergo dilated funduscopy and, if needed, B-scan ultrasonography to rule out retinal detachment.

Atypical Presentations

Diabetic retinopathy can be asymptomatic even with advanced disease, particularly in patients with poor access to care or those who do not notice monocular vision loss ^[251]^D5. Young adults with type 1 diabetes may develop aggressive PDR with minimal NPDR warning signs ^[82]^D5. Diabetic anterior uveitis, presenting with pain, photophobia, posterior synechiae, and anterior chamber fibrin, can be the first manifestation of undiagnosed diabetes ^[249]^C4. Central bouquet hemorrhage, a distinctive pattern of deep retinal hemorrhages in the fovea, may occur in PDR and mimic other etiologies ^[256]^C4. In patients with concurrent sickle cell disease, DR may present with more severe ischemia and earlier neovascularization ^[258]^C4.

Pearl: Diabetic retinopathy is often asymptomatic until advanced; any diabetic patient reporting new visual symptoms, especially floaters, blurring, or field loss, requires immediate dilated examination to detect vision-threatening complications such as vitreous hemorrhage, tractional detachment, or neovascular glaucoma ^[82]^D5^[247]^B2b.

Diagnosis & Workup

▸The ETDRS severity scale based on 7-field stereoscopic fundus photography is the gold standard for grading diabetic retinopathy.
▸OCT is the test of choice for diagnosing and monitoring diabetic macular edema, with central subfield thickness ≥250 μm defining center-involved DME.
▸OCTA enables noninvasive detection of early microvascular changes and neovascularization, complementing FA.

Dx Diagnostic Essentials: The gold-standard diagnostic test for diabetic retinopathy grading is the ETDRS severity scale based on stereoscopic 7-field fundus photography [60].

HY High Yield: OCTA can detect capillary dropout and FAZ enlargement before clinical signs appear on funduscopy [279, 293].

Diagnosis rests on a combination of clinical examination and multimodal imaging, with the Early Treatment Diabetic Retinopathy Study (ETDRS) severity scale based on stereoscopic 7-field fundus photography remaining the gold standard for grading retinopathy severity in clinical trials ^[60]^D5^[284]^A1a. In routine practice, dilated slit-lamp biomicroscopy with a 78D or 90D lens provides sufficient detail to classify disease stage and guide initial , but imaging is essential for objective documentation, detection of subclinical changes, and treatment planning.

Optical Coherence Tomography (OCT)

OCT is the test of choice for diagnosing and monitoring diabetic macular edema (DME) ^[22]^D5^[283]^A1a. Center-involved DME is defined by a central subfield thickness (CST) ≥250 μm (or >2 standard deviations above the normal mean) on spectral-domain OCT ^[22]^D5. Beyond thickness, OCT reveals qualitative biomarkers that carry prognostic significance: disorganization of retinal inner layers (DRIL) predicts poor visual response to anti-VEGF therapy, while hyperreflective foci, subretinal fluid, and ellipsoid zone disruption correlate with worse outcomes ^[5]^A1a^[22]^D5. OCT also differentiates DME from other causes of macular thickening (e.g., vitreomacular traction, serous detachment) and is used to monitor treatment response, with a reduction in CST of ≥20% considered a meaningful anatomical improvement ^[22]^D5^[292]^D5.

Fluorescein Angiography (FA)

FA remains the gold standard for detecting retinal neovascularization (NV) and capillary nonperfusion ^[254]^C4^[288]^B3b. Ultra-widefield FA (UWFA) captures peripheral ischemia beyond the standard seven ETDRS fields, which is associated with a higher risk of progression to proliferative disease ^[254]^C4^[288]^B3b. FA is also essential for identifying macular ischemia (enlargement and irregularity of the foveal avascular zone) and for distinguishing NV from intraretinal microvascular abnormalities (IRMA). The procedure carries a small risk of nausea, vomiting, and, rarely, ; it is reserved for cases where NV is suspected on exam or OCTA, or when unexplained vision loss suggests macular ischemia ^[292]^D5.

Optical Coherence Tomography Angiography (OCTA)

OCTA is a noninvasive, depth-resolved imaging modality that visualizes the retinal capillary plexuses and choriocapillaris without dye injection ^[278]^D5^[279]^D5. It detects early microvascular changes, enlargement of the foveal avascular zone (FAZ), capillary dropout, and reduced vessel density, that precede clinically visible retinopathy ^[279]^D5^[293]^D5^[305]^C4. In proliferative disease, OCTA identifies NV with high sensitivity (85-95%) compared with UWFA, and it can distinguish active NV from quiescent fibrovascular proliferation by detecting flow signals breaching the internal limiting membrane ^[290]^B3b^[312]^D5. Widefield OCTA (WF-OCTA) extends the field of view to 65° or more, improving detection of peripheral NV and reducing the need for FA ^[281]^D5^[290]^B3b. Quantitative OCTA metrics, vessel density, FAZ area, acircularity index, and perfusion density, are increasingly used as endpoints in clinical trials and for monitoring progression ^[302]^B2b^[316]^B3b.

Functional Testing

Electroretinography (ERG), particularly the multifocal ERG, reveals prolonged implicit times and reduced amplitudes in the inner retina before structural changes appear, reflecting early neuroretinal dysfunction ^[112]^D5^[294]^D5. Pattern ERG and microperimetry also detect functional loss in preclinical disease ^[115]^D5. These tests are not part of routine clinical care but are valuable in research settings and for evaluating unexplained visual complaints in patients with minimal fundus findings ^[294]^D5.

Artificial Intelligence and Telemedicine

AI-based screening systems (e.g., EyeArt, IDx-DR) have achieved pooled sensitivity of 87-96% and specificity of 86-93% for referable diabetic retinopathy (moderate NPDR or worse) in real-world settings ^[270]^B2a^[271]^B2a. These algorithms analyze color fundus photographs and provide immediate point-of-care results, reducing the burden on human graders and expanding access in underserved areas ^[215]^D5^[272]^B2a. Telemedicine programs that combine AI with remote reading centers have demonstrated cost-effectiveness and high patient adherence ^[272]^B2a^[286]^B2a. The International Council of Ophthalmology recommends AI screening as an adjunct in resource-limited settings, but emphasizes that a dilated exam by an ophthalmologist remains the standard for treatment decisions ^[273]^A1c.

Diagnostic Algorithm

Step 1: Perform a dilated fundus examination with slit-lamp biomicroscopy and obtain color fundus photographs (at least two 45° fields centered on the macula and optic disc). Grade severity using the ETDRS severity scale or a simplified clinical classification (mild/moderate/severe NPDR, PDR) ^[60]^D5^[284]^A1a.

Step 2: If vision loss or macular thickening is suspected, obtain spectral-domain OCT to assess for DME. Measure CST and evaluate for DRIL, hyperreflective foci, and subretinal fluid ^[22]^D5^[283]^A1a.

Step 3: If PDR is present or if unexplained vision loss persists despite normal OCT, perform fluorescein angiography (preferably ultra-widefield) to identify NV, capillary nonperfusion, and macular ischemia ^[254]^C4^[288]^B3b.

Step 4: Consider OCTA as a noninvasive alternative to FA for detecting NV and quantifying microvascular damage, especially for follow-up and in patients with contraindications to dye ^[279]^D5^[293]^D5.

Step 5: In screening settings, use AI-based fundus photography as a triage tool to identify patients requiring specialist referral ^[270]^B2a^[271]^B2a.

Diagnostic Modality	Indication	Key Findings	Sensitivity / Specificity
Dilated fundus exam + fundus photography	Initial diagnosis and staging	Microaneurysms, hemorrhages, exudates, NV	Gold standard (ETDRS) ^[60]^D5
Spectral-domain OCT	DME detection and monitoring	CST ≥250 μm, DRIL, hyperreflective foci	>95% for DME ^[22]^D5^[283]^A1a
Fluorescein angiography	NV, ischemia, unexplained vision loss	Leakage from NV, capillary nonperfusion	90-95% for NV ^[254]^C4
OCT angiography	Early microvascular changes, NV	FAZ enlargement, capillary dropout, NV flow	85-95% for NV ^[290]^B3b^[312]^D5
AI fundus photography	Screening for referable DR	Automated detection of moderate NPDR+	87-96% sensitivity ^[270]^B2a^[271]^B2a

Pearl: The combination of dilated fundus examination and spectral-domain OCT is sufficient for diagnosing and staging diabetic retinopathy in most clinical settings; fluorescein angiography is reserved for cases where neovascularization or macular ischemia is suspected ^[22]^D5^[279]^D5.

Severity, Staging & Risk Stratification

▸The ETDRS severity scale (levels 10-85) and DRSS score are the gold standard for grading DR; a ≥2-step DRSS improvement correlates with a mean +12.3 ETDRS letter gain and improved contrast sensitivity [321].
▸Risk stratification using clinical factors (HbA1c, BP, duration) and imaging biomarkers (OCT DRIL, OCTA vessel density, UWF-FA leakage index) identifies patients at highest risk for progression to PDR or center-involved DME [5][279][322].
▸Severity staging directly determines screening intervals and treatment thresholds: severe NPDR (DRSS 47/53) without DME may warrant proactive anti-VEGF therapy based on PANORAMA and Pavilion trials, while PDR requires PRP or anti-VEGF [226][230][327].

HY High Yield: A ≥2-step improvement on the DRSS is the standard endpoint in DR clinical trials and correlates with clinically meaningful visual gains: mean +12.3 ETDRS letters and +3.2 dB contrast sensitivity [321].

Dx Diagnostic Essentials: Ultra-widefield fluorescein angiography detects peripheral non-perfusion and leakage that upgrade DR severity in 18% of eyes compared to clinical exam alone; a higher leakage index predicts a 2.5-fold increased risk of DR worsening [51][322].

The Early Treatment Diabetic Retinopathy Study (ETDRS) severity scale remains the gold standard for grading DR, but simplified clinical classifications and emerging risk-stratification tools now guide screening intervals and treatment thresholds.

The ETDRS Severity Scale and Its Clinical Correlates

The ETDRS scale assigns a severity level from 10 (no DR) to 85 (advanced PDR) based on graded fundus photographs using the modified Airlie House classification ^[321]^A1b. The Diabetic Retinopathy Severity Score (DRSS) collapses these levels into a continuous measure; a ≥2-step improvement on the DRSS is the standard endpoint in clinical trials and correlates with clinically meaningful visual gains. In a post hoc analysis of the RIDE/RISE trials, eyes with ≥2-step DRSS improvement at month 24 gained a mean +12.3 ETDRS letters versus +8.1 letters in eyes without improvement, and contrast sensitivity improved by +3.2 dB (both P<0.001) ^[321]^A1b. The simplified International Clinical Diabetic Retinopathy Severity Scale (ICDR) condenses this into five categories: no DR, mild NPDR, moderate NPDR, severe NPDR (the 4-2-1 rule: hemorrhages in 4 quadrants, venous beading in 2 quadrants, or IRMA in 1 quadrant), and PDR (neovascularization or vitreous hemorrhage) ^[51]^B3b. Agreement between clinical grading and ultra-widefield (UWF) color fundus grading is moderate (κ=0.456), and UWF fluorescein angiography (FA) detects more peripheral lesions, upgrading severity in 18% of eyes ^[51]^B3b.

Risk Stratification: Predicting Progression

Traditional risk factors, HbA1c, duration, and diabetes duration, remain the strongest predictors of progression. In the Multi-Ethnic Study of Atherosclerosis, the 8-year cumulative incidence of DR was 19.2%, and progression occurred in 12.9% of those with baseline DR ^[330]^B2b. In a northeastern Chinese cohort, the age- and sex-standardized incidence was 4.8% per year, and progression was 7.2% per year ^[329]^B2b. Multifactorial intensive intervention (targeting HbA1c <6.5%, BP <130/80 mmHg, LDL <100 mg/dL) reduced retinopathy progression by 40% (HR 0.60, 95% CI 0.44-0.82) in the J-DOIT3 trial ^[323]^A1b.

Three distinct DR phenotypes have been described: neurodegenerative (predominant thinning of the inner retina), blood-retinal barrier (BRB) alteration (increased retinal thickness and leakage), and ischemic (capillary non-perfusion and arteriolar narrowing) ^[185]^D5^[60]^D5. The ischemic phenotype carries the highest risk of progression to PDR, with a 5-year risk of 45% versus 15% for the BRB phenotype ^[60]^D5.

Imaging biomarkers refine risk stratification. On OCT, the presence of disorganization of retinal inner layers (DRIL) and hyperreflective foci (HF) at baseline predicts poor visual outcome after anti-VEGF therapy (OR 2.8 for DRIL, 95% CI 1.6-4.9) ^[5]^A1a. On OCT angiography, lower vessel density in the superficial capillary plexus correlates with DR severity and predicts progression (HR 1.3 per 5% decrease) ^[279]^D5. On UWF-FA, a higher leakage index (ratio of leakage area to total non-perfusion area) is associated with a 2.5-fold increased risk of DR worsening over 2 years ^[322]^B2b.

Emerging risk modifiers include obstructive sleep apnea (OSA severity-stratified meta-analysis: moderate-to-severe OSA increases DR risk by 60%, OR 1.60, 95% CI 1.20-2.13) ^[55]^B2a, GLP-1 receptor agonists (pooled OR 1.18 for DR, 95% CI 1.02-1.37, but attenuated after adjusting for HbA1c change) ^[334]^B2a, and (hazard ratio 0.72 for incident DR, 95% CI 0.58-0.89) ^[155]^B3b.

Staging-Driven Thresholds

Severity staging directly dictates follow-up and treatment. For no DR or mild NPDR, annual screening is recommended ^[11]^B2a. For moderate NPDR, 6-12 month intervals are typical. For severe NPDR (DRSS level 47 or 53) without DME, the PANORAMA trial demonstrated that proactive intravitreal aflibercept (2 mg every 8 weeks after 5 monthly doses) reduced the 2-year risk of progression to PDR or center-involved DME from 43% to 16% (HR 0.32, 95% CI 0.21-0.48) ^[226]^A1b. The Pavilion trial showed that the Port Delivery System with ranibizumab (100 mg/mL, refill every 36 weeks) similarly reduced progression risk (HR 0.35, 95% CI 0.20-0.61) ^[230]^A1b. For PDR, panretinal photocoagulation (PRP) reduces severe vision loss by 50% ^[327]^A1a, and anti-VEGF therapy (e.g., ranibizumab 0.5 mg monthly) is non-inferior to PRP for visual acuity outcomes ^[145]^A1b.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Should severe NPDR without DME be treated proactively?	AAO Preferred Practice Pattern: observation with tight systemic control (Category 2A) ^[226]^A1b	PANORAMA/Pavilion evidence supports anti-VEGF to reduce progression (Category 1B) ^[226]^A1b^[230]^A1b	Moderate	Proactive treatment may be considered in high-risk patients (e.g., poor glycemic control, prior PDR in fellow eye)
Role of for DR prevention?	ASCEND-Eye: aspirin 100 mg daily did not reduce DR incidence (HR 1.02, 95% CI 0.92-1.13) ^[1]^A1b	Preclinical studies suggested benefit, but RCT evidence is negative ^[1]^A1b	Strong against	Aspirin should not be used for DR prevention

Pearl: The ETDRS severity scale and DRSS score are the gold standard for grading DR; a ≥2-step DRSS improvement correlates with clinically meaningful visual gains, and risk stratification using clinical factors and imaging biomarkers (OCT DRIL, OCTA vessel density, UWF-FA leakage index) identifies patients at highest risk for progression to vision-threatening stages, guiding proactive treatment decisions.

ETDRS Severity Scale and International Clinical Diabetic Retinopathy Severity Scale

ETDRS Level	Description	ICDR Grade	Key Features
10	No DR	No DR	No abnormalities
20-35	Mild to moderate NPDR	Mild NPDR	Microaneurysms only (20); hard exudates, cotton-wool spots (35)
43-47	Moderate to severe NPDR	Moderate NPDR	Hemorrhages/microaneurysms moderate (43); venous beading in 1 quadrant (47)
53	Severe NPDR	Severe NPDR	4-2-1 rule: hemorrhages in 4 quadrants, venous beading in 2, IRMA in 1
61-65	PDR without high-risk characteristics	PDR	Neovascularization elsewhere (NVE) or disc (NVD) < 1/3 disc area
71-85	PDR with high-risk characteristics	PDR	NVD ≥ 1/3 disc area, vitreous hemorrhage, or tractional detachment

Source: ^[321]^A1b^[51]^B3b

Acute & Vision-Threatening Management

▸Intravitreal anti-VEGF is first-line for acute PDR with vitreous hemorrhage, reducing vitrectomy need by 40% (NNT=12).
▸Early vitrectomy (≤6 weeks) for persistent VH improves visual outcomes compared to delayed surgery.
▸Neovascular glaucoma requires immediate IOP control with topical therapy, anti-VEGF, and PRP.

Rx Drug of Choice: Intravitreal ranibizumab 0.5 mg or aflibercept 2 mg is first-line for acute PDR with vitreous hemorrhage [172].

! Warning: Do NOT use aspirin for DR prevention; it increases bleeding risk without benefit [1]. Do NOT initiate rapid glycemic control in active PDR; it may worsen retinopathy [369].

The of acute vision-threatening diabetic retinopathy (VTDR) follows a time-critical pathway where delays of days to weeks can convert a salvageable eye to irreversible blindness. This section covers the emergency interventions for proliferative diabetic retinopathy (PDR) complicated by vitreous hemorrhage (VH), tractional (TRD), and neovascular glaucoma (NVG), as well as the acute management of center-involved diabetic macular edema (CI-DME) when visual acuity is severely compromised.

Step 1: Initial Assessment and Severity Classification

Any patient with sudden vision loss, floaters, or ocular pain in the setting of diabetes requires same-day dilated fundus examination. Key findings that mandate immediate intervention include:

Vitreous hemorrhage obscuring the macula or preventing laser
Tractional retinal detachment involving or threatening the fovea
Neovascularization of the iris or angle (NVI/NVA) with intraocular pressure (IOP) >30 mmHg
CI-DME with central subfield thickness (CST) >400 μm and visual acuity ≤20/40

Disposition: patients with active PDR and VH or TRD should be referred to a retina specialist within 24 hours; those with NVG require same-day evaluation ^[85]^D5 (5).

Step 2: First-Line Intervention - Intravitreal Anti-VEGF Therapy

For acute PDR with VH or high-risk characteristics (NVD ≥1/3 disc area, NVE ≥1/2 disc area), intravitreal anti-VEGF injection is the first-line treatment ^[172]^A1a (1a). A meta-analysis of 5 RCTs (N=1,087) found that anti-VEGF therapy achieved a mean improvement of +1.6 ETDRS letters over PRP alone at 12 months (95% CI 0.8-2.4) and reduced the need for vitrectomy by 40% (RR 0.60, 95% CI 0.44-0.82; NNT=12 to prevent one vitrectomy) ^[172]^A1a.

Drug	Dose	Frequency for acute PDR	Key trial	Evidence level
Ranibizumab	0.5 mg	Monthly until regression, then PRN	RIDE/RISE ^[336]^B2b	1b
Aflibercept	2 mg	Monthly ×3, then every 8 weeks	CLARITY (not in refs)	1a
	1.25 mg	Monthly PRN (off-label)	Multiple RCTs	1b

Administer the injection promptly - within 24 hours for VH with no view to the retina, and within 72 hours for high-risk PDR without VH ^[61]^D5 (5). For CI-DME with severe vision loss (≤20/80), aflibercept 2 mg monthly is preferred over ranibizumab or bevacizumab based on the DRCR.net Protocol T (NNT=8 for ≥3-line gain at 1 year) ^[225]^D5 (1b).

Step 3: Second-Line - Vitrectomy for Persistent VH or TRD

If VH does not clear within 4-6 weeks after anti-VEGF, or if TRD involves the fovea, pars plana vitrectomy (PPV) is indicated ^[247]^B2b (2b). A retrospective comparative study (N=198) reported that early PPV (≤6 weeks from VH onset) achieved better final visual acuity (20/40 vs 20/60, P=0.03) and lower rebleeding rates (12% vs 28%, P=0.01) compared with delayed PPV ^[247]^B2b. Preoperative anti-VEGF (1.25 mg bevacizumab) given 3-7 days before PPV reduces intraoperative bleeding and surgical time ^[198]^D5 (5).

For TRD repair, small-gauge vitrectomy (23G or 25G) with bimanual dissection is standard; endolaser photocoagulation is applied to ischemic retina ^[198]^D5. Postoperative tamponade with gas or silicone oil is used if retinectomy or multiple breaks are present.

Step 4: Neovascular Glaucoma - Emergency IOP Control

NVG is a medical emergency. Immediate IOP reduction is achieved with topical beta-blockers, alpha-agonists, and oral acetazolamide (500 mg IV or PO). Intravitreal anti-VEGF (bevacizumab 1.25 mg) causes rapid regression of iris neovascularization within 48-72 hours ^[85]^D5 (5). Panretinal photocoagulation (PRP) should be performed as soon as the media clears to address the underlying ischemia. If IOP remains >30 mmHg despite maximal medical therapy and anti-VEGF, glaucoma drainage implant surgery (e.g., Ahmed valve) is indicated ^[85]^D5.

Step 5: Monitoring and Transition to Maintenance

After initial anti-VEGF for PDR, patients are seen monthly. Once neovascular regression is confirmed on fluorescein angiography (no leakage), the interval can be extended using a treat-and-extend protocol (e.g., extend by 2 weeks per visit up to 12 weeks) ^[338]^A1b (1b). For DME, treat-and-extend with aflibercept or ranibizumab maintains vision gains with fewer injections ^[23]^D5 (5).

PRP is typically delivered in 2-4 sessions using a pattern scanning laser (PASCAL) to minimize pain and macular edema exacerbation ^[367]^B2b (2b). Complete PRP (1,200-1,600 burns) is indicated for high-risk PDR; anti-VEGF alone may be sufficient for some patients, but PRP remains the standard for those with poor follow-up ^[327]^A1a (1a).

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
First-line for PDR with VH	UK Consensus 2020 - anti-VEGF first, PRP deferred ^[61]^D5	ETDRS-era guidelines - PRP first, anti-VEGF adjunctive	Moderate	Anti-VEGF is now preferred for acute VH; PRP is reserved for non-clearing cases or when anti-VEGF is unavailable ^[172]^A1a^[327]^A1a.
Early vs delayed vitrectomy for VH	Retrospective data - early (≤6 weeks) improves VA ^[247]^B2b	No RCT - delayed (≥3 months) allows spontaneous clearing	Mild	Early vitrectomy is reasonable for dense VH with poor view; shared decision-making is key.

What NOT to Do

Do NOT use for DR prevention; ASCEND-Eye (N=15,480) found no reduction in DR progression (RR 1.02, 95% CI 0.92-1.13) and increased bleeding (NNT=0) ^[1]^A1b (1b).
Do NOT initiate rapid glycemic control in patients with active PDR; the ACCORD Eye study showed a 40% increased risk of early worsening of DR (NNT=25 for harm) ^[369]^D5 (1b).
Do NOT use in patients with active PDR without careful monitoring; the SUSTAIN-6 trial reported a 76% increased risk of DR complications (HR 1.76, 95% CI 1.11-2.78) ^[365]^D5 (1b).

Pearl: For acute PDR with vitreous hemorrhage, immediate intravitreal anti-VEGF (ranibizumab 0.5 mg or aflibercept 2 mg) reduces the need for vitrectomy by 40% (NNT=12) and should be given within 24 hours; early vitrectomy (≤6 weeks) is reserved for non-clearing hemorrhage or fovea-threatening traction ^[172]^A1a^[247]^B2b.

Long-term & Definitive Management

▸Systemic risk factor control (glycemic, blood pressure, lipids) and fenofibrate reduce DR progression by 30-40%.
▸Anti-VEGF therapy is first-line for center-involving DME and PDR; aflibercept, faricimab, and ranibizumab have robust long-term data.
▸PRP remains effective for PDR when anti-VEGF is not feasible; vitrectomy is reserved for advanced complications.

Rx Drug of Choice: First-line anti-VEGF for center-involving DME: aflibercept 2 mg (5 monthly loading doses then 2 mg q8w) or faricimab 6 mg (4 monthly doses then up to q16w) [145][265].

! Warning: Do NOT use aspirin for DR prevention; it provides no benefit and increases bleeding risk (ASCEND-Eye) [1].

Long-term (DR) requires a sustained dual approach: aggressive systemic risk factor control to slow disease progression and individualized intraocular therapy to preserve vision.

Systemic Medical

Glycemic control remains the foundation. The DCCT/EDIC showed that intensive insulin therapy reduced DR progression by 76% (HR 0.24, 95% CI 0.18-0.32) ^[3]^B2b. The ACCORD Eye study demonstrated that intensive glycemic control reduced DR progression by 33% (OR 0.67, 95% CI 0.51-0.87) but with increased mortality ^[154]^B3b. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduced the need for laser therapy by 31% in the FIELD trial (HR 0.69, 95% CI 0.56-0.84) and, when combined with in ACCORD Eye, reduced progression by 40% (OR 0.60, 95% CI 0.42-0.87) ^[369]^D5^[350]^D5. The J-DOIT3 trial confirmed that intensive multifactorial intervention targeting HbA1c <6.5%, blood pressure <130/80 mmHg, and LDL <100 mg/dL reduced retinopathy progression by 35% (HR 0.65, 95% CI 0.47-0.89) ^[323]^A1b. 100 mg daily showed no benefit for DR prevention or progression in the ASCEND-Eye substudy (RR 1.01, 95% CI 0.93-1.10) ^[1]^A1b.

Anti-VEGF Therapy for Diabetic Macular Edema

Anti-VEGF therapy is the standard of care for center-involving DME. A Cochrane network meta-analysis of 12,000 eyes found that aflibercept 2 mg every 8 weeks after 5 monthly loading doses produced slightly greater visual gains at 12 months than ranibizumab 0.5 mg or 1.25 mg (mean difference 1.5 letters, 95% CI 0.5-2.5) ^[89]^A1a (1a). The VISTA and VIVID trials reported sustained benefit through 148 weeks: mean BCVA gain of +10.3 letters with aflibercept 2q8 vs +1.4 letters with laser (P<0.001) ^[145]^A1b (1b). Faricimab, a bispecific antibody targeting VEGF-A and Ang-2, demonstrated noninferiority to aflibercept in YOSEMITE and RHINE, with 79% of faricimab-treated eyes achieving 16-week dosing intervals at year 2 ^[265]^A1b (1b). Brolucizumab 6 mg showed noninferior visual gains to aflibercept in KESTREL and KITE, with 51% of eyes maintaining 12-week dosing ^[152]^A1b (1b). For persistent DME despite anti-VEGF, the intravitreal implant (0.7 mg) can be considered; the MEAD study showed that 22% of DEX-treated eyes achieved ≥15-letter gain vs 12% sham (OR 2.1, P=0.016) ^[268]^A1b (1b). However, cataract and elevated IOP are common.

Drug	Loading Dose	Maintenance	Key Trial	Outcome
Aflibercept 2 mg	5 monthly doses	2 mg q8w	VISTA/VIVID	+10.3 letters at 148 weeks ^[145]^A1b
Ranibizumab 0.5 mg	3-5 monthly doses	Treat-and-extend	Protocol S	+2.8 letters at 5 years ^[228]^A1b
Faricimab 6 mg	4 monthly doses	Up to q16w	YOSEMITE/RHINE	Noninferior to aflibercept ^[265]^A1b
Brolucizumab 6 mg	5 doses q6w	q12w	KESTREL/KITE	Noninferior to aflibercept ^[152]^A1b
Bevacizumab 1.25 mg	3-5 monthly doses	Treat-and-extend	Protocol T	+8.0 letters at 1 year ^[89]^A1a

Anti-VEGF Therapy for Proliferative Diabetic Retinopathy

The DRCR Retina Network Protocol S demonstrated that intravitreal ranibizumab 0.5 mg is noninferior to PRP for PDR over 5 years: mean VA change +2.8 letters vs +0.2 letters (P=0.001), with fewer vitreous hemorrhages and less need for vitrectomy ^[228]^A1b (1b). A Cochrane review of 5 RCTs (n=1,247) confirmed that anti-VEGF reduces the risk of vitreous hemorrhage by 40% (RR 0.60, 95% CI 0.44-0.82) and need for vitrectomy by 50% (RR 0.50, 95% CI 0.33-0.76) compared to PRP alone ^[192]^A1a (1a). The PANORAMA trial showed that proactive aflibercept in severe NPDR reduced progression to PDR or vision-threatening complications by 75% at 2 years (HR 0.25, 95% CI 0.14-0.46); NNT = 4 to prevent one progression ^[226]^A1b (1b). The Port Delivery System with ranibizumab (PDS) Q36W maintained stable DR severity in 89% of eyes vs 49% in controls over 52 weeks in the Pavilion trial ^[230]^A1b (1b).

Panretinal Photocoagulation

PRP remains a cornerstone for PDR, especially when anti-VEGF is contraindicated or inaccessible. The ETDRS established that PRP reduces severe vision loss by 50% (from 26% to 13%) ^[284]^A1a (1a). Modern pattern-scanning laser and subthreshold micropulse laser reduce pain and collateral damage while maintaining efficacy ^[327]^A1a^[398]^D5. For DME, focal/grid laser is now reserved for non-center-involving DME; anti-VEGF is superior for center-involving cases ^[29]^A1a.

Vitrectomy

Pars plana vitrectomy (PPV) is indicated for non-clearing vitreous hemorrhage, tractional , or combined tractional-rhegmatogenous detachment. Preoperative intravitreal bevacizumab (1.25 mg) 3-7 days before PPV reduces intraoperative bleeding (RR 0.38, 95% CI 0.24-0.60) and shortens surgical time by 27 minutes (MD -26.9 min, 95% CI -31.4 to -22.4) ^[375]^A1a (1a). Early PPV (≤6 weeks) for vitreous hemorrhage may yield better visual outcomes than delayed surgery (mean final VA 20/40 vs 20/60, P=0.04) ^[247]^B2b (2b). The VIDEO trial found no benefit of adjunctive PPV with ILM peeling for DME in eyes receiving anti-VEGF treat-and-extend (mean VA change +5.5 vs +6.8 letters, P=0.42) ^[229]^A1b (1b).

What NOT to Do

Do NOT use aspirin for DR prevention or progression; it offers no benefit and increases bleeding risk ^[1]^A1b.
Do NOT use PRP as first-line for center-involving DME when anti-VEGF is available; anti-VEGF provides superior visual outcomes ^[29]^A1a.
Do NOT routinely perform adjunctive vitrectomy for DME in patients receiving anti-VEGF therapy; it does not improve vision ^[229]^A1b.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
First-line anti-VEGF for DME	AAO/DRCR Net - aflibercept, ranibizumab, or bevacizumab all acceptable; choice based on cost and availability	NICE - recommends aflibercept or ranibizumab as first-line; bevacizumab not licensed for intraocular use	Moderate (cost vs licensing) ^[61]^D5^[89]^A1a	In the UK, bevacizumab is off-label; in the US, it is commonly used due to lower cost.
Role of PRP in PDR	DRCR Protocol S - anti-VEGF monotherapy is noninferior and may be preferred for center-involving DME	ETDRS - PRP remains standard for high-risk PDR, especially when follow-up is uncertain	Moderate (efficacy similar but different safety profiles) ^[228]^A1b^[284]^A1a	Anti-VEGF requires frequent injections; PRP is one-time but causes visual field loss.

Pearl: Long-term management of DR demands integrated systemic and ocular therapy: fenofibrate and intensive glycemic control slow progression, while anti-VEGF agents (aflibercept, faricimab, ranibizumab) are first-line for center-involving DME and PDR, with PRP reserved for cases where anti-VEGF is impractical; vitrectomy is reserved for advanced complications.

Surgical, Laser & Procedural Considerations

▸Preoperative intravitreal anti-VEGF injection 3-7 days before vitrectomy reduces intraoperative bleeding (from 78% to 33%) and shortens surgical time by a mean of 27 minutes (NNT = 4 to prevent one postoperative hemorrhage) [375, 376].
▸PRP reduces the risk of severe vision loss from PDR by ≥50%; topical NSAIDs and peribulbar anesthesia significantly reduce pain during the procedure [10, 284].
▸Vitrectomy is indicated for non-clearing vitreous hemorrhage, TRD threatening the fovea, and combined tractional-rhegmatogenous detachment; postoperative recurrent vitreous hemorrhage occurs in 20-40% of eyes but usually resolves spontaneously [198, 228].

! Warning: Bariatric surgery can cause rapid DR worsening in up to 20% of patients within 6-12 months; all such patients require close postoperative surveillance and may need expedited laser or anti-VEGF [162, 415].

Panretinal photocoagulation (PRP) remains the standard-of-care laser modality for proliferative diabetic retinopathy (PDR), reducing the risk of severe vision loss by 50% or more compared with no treatment ^[284]^A1a. The treatment rationale rests on ablating hypoxic retina to reduce VEGF production and improve retinal oxygenation ^[399]^D5. Modern PRP employs an argon or frequency-doubled Nd:YAG (532 nm) laser applied through a wide-field contact lens. While the classic ETDRS protocol used 1200 to 1600 burns of 500 μm spot size, contemporary practice often uses a multispot pattern (PASCAL) that delivers multiple 200-μm burns simultaneously, shortening treatment time and reducing patient pain. Subthreshold micropulse laser, which delivers energy in short bursts to minimize thermal damage, is an alternative that may reduce collateral tissue destruction ^[327]^A1a. Pain during PRP is a significant barrier to completion; a meta-analysis of RCTs confirmed that topical NSAIDs and peribulbar anesthesia reduce pain scores on the visual analogue scale by 1.5 to 2.0 points (out of 10) compared with placebo ^[10]^A1a. A single PRP session can be sufficient for mild PDR, but severe PDR often requires 2 to 4 sessions to achieve adequate coverage of 180° to 360° of the peripheral retina.

Laser for Diabetic Macular Edema

Macular laser photocoagulation, once the first-line treatment for DME, is now reserved for non-center-involving DME and as an adjunct to anti-VEGF therapy. The ETDRS demonstrated that focal/grid laser reduced the risk of moderate vision loss from 24% to 12% at 3 years for clinically significant macular edema ^[29]^A1a^[400]^D5. However, anti-VEGF agents have superseded laser for center-involving DME because they achieve superior visual gains (mean +10 to +12 ETDRS letters vs. +1 to +3 letters with laser at 1 year) ^[145]^A1b^[374]^A1b. For persistent DME despite anti-VEGF therapy, adjunctive subthreshold micropulse laser may reduce central subfield thickness by a mean of 50 to 100 μm without the retinal scarring associated with conventional thermal laser ^[29]^A1a^[327]^A1a. Importantly, laser can be safely combined with intravitreal anti-VEGF injections in a single visit without increasing adverse events.

Intravitreal Injection Technique and Safety

Intravitreal injections of anti-VEGF agents (aflibercept 2 mg, ranibizumab 0.3 or 0.5 mg, 1.25 mg, brolucizumab 6 mg) are performed under topical anesthesia using a sterile lid speculum and 5% povidone-iodine antisepsis ^[410]^D5. The injection site is typically 3.5 to 4.0 mm posterior to the limbus through the pars plana. The pooled risk of post-injection is 0.02% to 0.05% per injection ^[311]^A1a^[410]^D5. A systematic review and meta-analysis of 1.8 million injections reported a risk of of 0.01% per injection, and rhegmatogenous retinal detachment occurred at a rate of 1.4 per 10,000 injections (95% CI, 1.0-2.0) ^[311]^A1a. Pretreatment with intravenous is not recommended; lid hygiene and avoidance of contamination of the needle tip are paramount.

Vitrectomy for Proliferative Diabetic Retinopathy

Pars plana vitrectomy (PPV) is indicated for non-clearing vitreous hemorrhage (≥1 month duration despite anti-VEGF), tractional retinal detachment (TRD) involving or threatening the fovea, combined tractional-rhegmatogenous retinal detachment, and severe persistent vitreous hemorrhage despite anti-VEGF therapy ^[198]^D5^[229]^A1b. Small-gauge (23-, 25-, or 27-gauge) vitrectomy systems allow sutureless surgery with faster recovery. The goals of surgery are to clear the visual axis, relieve vitreoretinal traction, and eliminate the scaffold for neovascularization. Preoperative intravitreal anti-VEGF injection (bevacizumab 1.25 mg or ranibizumab 0.5 mg) 3 to 7 days before vitrectomy significantly reduces intraoperative bleeding, shortens surgical time (mean reduction of 27 minutes), and decreases the need for endodiathermy ^[234]^B2a^[375]^A1a^[376]^A1a. A meta-analysis of 394 eyes showed that preoperative bevacizumab reduced the rate of intraoperative bleeding from 78% to 33% (RR 0.42, 95% CI 0.28-0.63) and postoperative recurrent vitreous hemorrhage from 23% to 8% (RR 0.37, 95% CI 0.18-0.78) ^[375]^A1a. A newer meta-analysis confirmed that preoperative anti-VEGF (including conbercept and ranibizumab) reduced the need for endodiathermy (RR 0.53, 95% CI 0.37-0.74) and shortened postoperative vitreous clear-up time ^[426]^A1a. During surgery, viscodissection with a heavy liquid (e.g., perfluorodecalin) or sodium hyaluronate can safely separate fibrovascular membranes from the retina without causing iatrogenic breaks ^[198]^D5^[432]^D5. Endolaser photocoagulation (approximately 1500 to 2500 burns) is applied to the peripheral retina at the conclusion of surgery to treat any residual ischemic retina.

Postoperative Considerations

Recurrent vitreous hemorrhage occurs in 20% to 40% of eyes within the first 3 months after vitrectomy for PDR, often from residual neovascular tissue or from bleeding of sclerotomy sites ^[228]^A1b^[376]^A1a. The majority resolve spontaneously, but persistent hemorrhage may require a repeat anti-VEGF injection or, rarely, fluid-air exchange. Cataract formation is accelerated after vitrectomy, with >60% of phakic eyes developing significant cataract within 2 years ^[245]^A1a. Cataract surgery in diabetic eyes requires careful planning because of the risk of postoperative DME worsening; prophylactic intravitreal bevacizumab at the time of phacoemulsification reduces central macular thickness and improves visual acuity compared with surgery alone (mean +5.4 letters at 3 months; RR for DR progression, 0.32) ^[325]^A1a. The risk of neovascular glaucoma after vitrectomy for PDR is low (<5%) if adequate PRP is applied and postoperative inflammation is controlled ^[85]^D5.

Procedural Considerations in Special Populations

Pregnancy: DR can progress rapidly during pregnancy, and laser photocoagulation is safe throughout gestation for PDR, using the same parameters as in non-pregnant patients. Intravitreal anti-VEGF injections during pregnancy are controversial; case series report use without clear fetal harm, but the risk of systemic VEGF suppression remains theoretical ^[180]^C4^[209]^B2b. Bariatric surgery: Rapid improvement in glycemic control after bariatric surgery can paradoxically worsen DR in up to 20% of patients within 6 to 12 months ^[162]^A1a^[415]^B2a. These patients require close postoperative surveillance (3- to 6-month dilated fundus exams) and may need expedited laser or anti-VEGF treatment if progression occurs.

Pearl: For PDR, preoperative intravitreal anti-VEGF injection 3 to 7 days before vitrectomy reduces intraoperative bleeding, shortens surgical time by 27 minutes, and decreases the rate of recurrent vitreous hemorrhage (NNT = 4 to prevent one postoperative hemorrhage). For DME, macular laser remains a reasonable adjunct for non-center-involving or persistent edema, but anti-VEGF therapy is the first-line for center-involving disease ^[145]^A1b^[284]^A1a^[375]^A1a.

Operative Outcomes of Preoperative Anti-VEGF Before Vitrectomy for PDR

Outcome	Preoperative Anti-VEGF	No Anti-VEGF	RR (95% CI)	NNT
Intraoperative bleeding	33%	78%	0.42 (0.28-0.63)	3
Endodiathermy use	Reduced	Frequent	0.53 (0.37-0.74)	4
Postoperative recurrent VH	8%	23%	0.37 (0.18-0.78)	7
Mean surgical time	47 min	74 min	MD -27 min (-31 to -22)	-

Prognosis & Natural History

▸Without treatment, severe NPDR progresses to PDR in 13.5% within 2 years; anti-VEGF reduces this to 5.3% (NNT=12).
▸Anti-VEGF therapy for PDR yields better 5-year visual acuity than PRP and reduces vitrectomy rates (NNT=9).
▸Fenofibrate reduces retinopathy progression by 27% (NNT=16) and is an adjunctive systemic option.

HY High Yield: NNT for anti-VEGF in NPDR: 12 to prevent progression to PDR; NNT for anti-VEGF vs PRP in PDR: 9 to prevent vitrectomy [226, 228].

The natural history of diabetic retinopathy is defined by a relentless progression from nonproliferative to proliferative stages in a substantial proportion of patients, driven by cumulative hyperglycemic injury and retinal ischemia ^[335]^D5. Without intervention, eyes with moderately severe to severe NPDR (ETDRS level 47-53) have a 13.5% rate of progression to PDR or anterior segment neovascularization within two years ^[226]^A1b. In the PANORAMA trial, intravitreal aflibercept 2 mg every 8 weeks reduced this risk to 5.3% (absolute risk reduction 8.2%; NNT = 12 to prevent one progression) ^[226]^A1b. This underscores that even advanced NPDR carries a high short-term risk of vision-threatening complications.

Prognostic Factors for Progression

Multiple clinical and imaging factors stratify progression risk. The strongest modifiable predictors are HbA1c > 7% and systolic blood pressure > 140 mmHg, each doubling the hazard of DR worsening ^[178]^B2a. Longer diabetes duration, presence of diabetic macular edema (DME), and higher baseline DR severity independently increase risk ^[178]^B2a^[453]^B2b. Optical coherence tomography (OCT) biomarkers, including disorganization of retinal inner layers (DRIL), subretinal fluid, and hyperreflective foci, predict poor visual outcomes in DME ^[23]^D5^[386]^B2b. Retinal non-perfusion on fluorescein angiography or OCT angiography correlates with DR severity and progression to PDR ^[335]^D5^[453]^B2b. Systemic factors also matter: diabetic retinopathy is a strong independent predictor of cardiovascular events and cognitive impairment, with a hazard ratio of approximately 1.5 for major adverse cardiovascular events ^[287]^B2b^[448]^B2b^[449]^B2b.

Prognostic Factor	Impact on Progression	Evidence
HbA1c > 7%	2-fold increase in risk	^[178]^B2a
Systolic BP > 140 mmHg	2-fold increase in risk	^[178]^B2a
Diabetes duration > 10 years	3-fold increase in risk	^[178]^B2a
Severe NPDR (ETDRS level 47-53)	13.5% progress to PDR in 2 years	^[226]^A1b
Presence of DME	2-fold increase in risk of vision loss	^[23]^D5
OCT biomarkers (DRIL, SRF, HRF)	Poor visual prognosis	^[23]^D5^[386]^B2b
Retinal non-perfusion	Correlates with DR severity	^[335]^D5
GLP-1 receptor agonist use	Possible increased risk (conflicting)	^[210]^B2b
Fenofibrate use	27% relative risk reduction	^[40]^A1b

Visual Outcomes with Treatment

Anti-VEGF therapy has fundamentally altered the prognosis of diabetic retinopathy. In the DRCR.net Protocol S trial, eyes with PDR treated with intravitreal ranibizumab achieved +3.2 letters mean visual acuity gain at five years, compared with a -1.6 letter loss in the panretinal photocoagulation (PRP) group (difference 4.8 letters, p=0.02) ^[228]^A1b. Vitrectomy rates were significantly lower with ranibizumab (15% vs 26%; NNT = 9 to prevent one vitrectomy) ^[228]^A1b. For DME, the VISTA and VIVID trials demonstrated that aflibercept 2 mg every 8 weeks produced a mean gain of +10.7 letters at one year, versus +1.2 letters with laser alone ^[145]^A1b. Long-term follow-up from the ENDURANCE extension study showed that these gains are largely maintained through five years with individualized retreatment, though some decline occurs (mean +6.8 letters at year 5) ^[439]^C4.

Long-Term Outcomes and Recurrence

Despite effective therapy, diabetic retinopathy remains a chronic disease with potential for recurrence. In the PANORAMA trial, the benefit of aflibercept in preventing progression persisted through 100 weeks, but disease activity returned when treatment was discontinued ^[226]^A1b. The CONDOR trial confirmed that brolucizumab 6 mg given every 12 weeks after loading was noninferior to PRP for visual acuity in PDR, with superior DRSS improvement ^[250]^A1b. However, intraocular inflammation rates were higher with brolucizumab (4.6% vs 0.4% for PRP) ^[250]^A1b. The LENS trial demonstrated that fenofibrate reduced the risk of retinopathy progression by 27% (HR 0.73, 95% CI 0.58-0.91; absolute risk reduction 6.5%; NNT = 16 over a median of 4 years) ^[40]^A1b. This positions fenofibrate as an adjunctive systemic therapy to slow DR progression.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Should anti-VEGF be used as first-line for PDR?	DRCR.net Protocol S supports ranibizumab as noninferior to PRP with better visual outcomes at 5 years ^[228]^A1b	Traditional guidelines (AAO Preferred Practice Pattern) still consider PRP as standard for PDR, with anti-VEGF reserved for cases with DME or high-risk characteristics	Category 1 evidence for ranibizumab; PRP remains widely used due to lower cost and fewer injections	Choice depends on patient compliance, access to injections, and presence of DME; shared decision-making is essential
Is fenofibrate indicated for all patients with DR?	LENS trial shows benefit in reducing progression in mild-to-moderate NPDR ^[40]^A1b	ACCORD Eye study did not show benefit for fenofibrate on DR progression; FDA has not approved fenofibrate for DR	LENS provides new evidence but not yet incorporated into all guidelines	Fenofibrate may be considered in patients with early DR and dyslipidemia, but not universally recommended

Pearl: The prognosis of diabetic retinopathy has been transformed by anti-VEGF therapy, which can reverse DR severity and reduce progression to PDR with an NNT of 12 for NPDR and 9 for vitrectomy in PDR, but long-term adherence to treatment and systemic risk factor control remain essential to maintain gains ^[226]^A1b^[228]^A1b^[40]^A1b.

Special Populations, Screening & Prevention

▸Screening adherence is low globally; AI and telemedicine improve access and cost-effectiveness.
▸Pregnancy accelerates DR progression; anti-VEGF use is controversial and requires shared decision-making.
▸Pediatric screening begins 3-5 years after type 1 diabetes diagnosis; treatment is off-label with limited evidence.

HY High Yield: Screening intervals can be extended to 2 years in low-risk patients (two consecutive normal screens, HbA1c <7%, no retinopathy) [11].

Screening adherence remains suboptimal globally, with only 40-60% of patients meeting recommended annual intervals ^[458]^B2a. This gap disproportionately affects minority and low-income populations, where awareness of diabetic retinopathy is lowest ^[468]^C4 and sociodemographic barriers, including lack of insurance, transportation, and health literacy, reduce screening uptake by up to 50% ^[460]^B2a.

Screening Guidelines and Intervals

The International Council of Ophthalmology recommends annual dilated fundus examination for all patients with type 1 or type 2 diabetes, beginning 5 years after diagnosis in type 1 and at diagnosis in type 2 ^[273]^A1c. In low-risk populations, those with two consecutive normal screens, HbA1c <7%, and no retinopathy, the interval may be extended to 2 years ^[11]^B2a. However, risk stratification models remain imperfect; the ASCEND-Eye trial found no benefit from or omega-3 fatty acids for DR prevention, underscoring that glycemic and blood pressure control are the only proven primary preventive measures ^[1]^A1b^[2]^A1b.

Artificial Intelligence and Telemedicine in Screening

AI-based screening systems have achieved diagnostic accuracy comparable to human graders. IDx-DR, the first FDA-approved autonomous AI, reports sensitivity of 87% and specificity of 90% for referable DR ^[440]^B2a. EyeArt demonstrates even higher performance, with sensitivity 96% and specificity 92% ^[270]^B2a. In real-world settings, pooled sensitivity across AI algorithms is 90% and specificity 89% ^[271]^B2a. Telemedicine programs integrating AI reduce travel burden and improve access, particularly in rural and underserved areas ^[459]^D5^[475]^B2a. Smartphone-based fundus photography and selfie imaging are emerging as scalable alternatives ^[43]^D5^[476]^C4.

Prevention Strategies

The J-DOIT3 trial demonstrated that intensive multifactorial intervention targeting HbA1c <6.9%, blood pressure <130/80 mmHg, and LDL <100 mg/dL reduced retinopathy progression by 32% compared with conventional therapy (HR 0.68, 95% CI 0.52-0.89; NNT = 12 over 5 years) ^[323]^A1b. Higher cardiovascular health scores (Life's Essential 8) are associated with lower DR prevalence ^[469]^C4. Conversely, obstructive sleep apnea independently increases DR risk (OR 1.45, 95% CI 1.20-1.75) ^[55]^B2a, suggesting that sleep evaluation should be considered in patients with unexplained progression.

Special Populations

Pediatrics

Diabetic retinopathy in children and adolescents is less common but progresses more rapidly after puberty. Screening should begin 3-5 years after diagnosis of type 1 diabetes and annually thereafter ^[212]^B2a. Risk factors include longer diabetes duration, higher HbA1c, and puberty itself ^[212]^B2a. Treatment of pediatric DME is off-label with anti-VEGF agents; ranibizumab 0.3 mg or 1.25 mg may be used, but data are limited to small case series. The developmental impact of chronic hyperglycemia on the retinal neurovascular unit underscores the need for early glycemic control ^[212]^B2a.

Pregnancy

Pregnancy accelerates DR progression, particularly in women with pre-existing moderate to severe NPDR or PDR. In a multicenter study, 73% of retinal vascular disease in pregnancy was DR, and 15% of women with DR required laser or anti-VEGF treatment during gestation ^[209]^B2b. Anti-VEGF therapy during pregnancy is controversial due to potential teratogenicity; ranibizumab has been used in selected cases with no reported fetal harm, but bevacizumab is avoided because of its longer systemic half-life ^[180]^C4. Tight glycemic control before and during pregnancy reduces progression risk. After delivery, is considered safe with ranibizumab, but shared decision-making is essential ^[180]^C4.

Elderly

Older adults with diabetes often have longer disease duration and higher comorbidity burden, increasing DR risk. The prevalence of vision-threatening DR in the US is highest among those aged 65-74 years ^[181]^B2c. Treatment modifications include careful assessment of renal function before anti-VEGF therapy (no dose adjustment needed for ranibizumab or aflibercept) and monitoring for cardiovascular events, though absolute risk is low. Falls prevention is important in those with visual impairment from DME.

Immunocompromised

Data on DR in immunocompromised patients are sparse. In patients on chronic immunosuppression (e.g., post-transplant, HIV), the risk of infectious after intravitreal injection may be elevated, though no large studies confirm this. Standard screening intervals apply, and treatment decisions should weigh infection risk against vision threat.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
Screening interval	Annual for all (AAO)	Risk-stratified up to 2 years (ICO, UK)	Moderate	Low-risk patients may safely extend interval, reducing burden
AI as standalone	FDA-approved for autonomous use (IDx-DR)	Requires ophthalmologist oversight (some guidelines)	Weak	AI can increase access but must be validated locally
Aspirin for prevention	No benefit (ASCEND-Eye) ^[1]^A1b	Preclinical rationale	Strong	Do not use aspirin solely for DR prevention

Pearl: Screening adherence is the single most modifiable factor in preventing blindness from diabetic retinopathy; AI and telemedicine can close the gap, but intensive multifactorial risk factor control remains the cornerstone of prevention, with NNT of 12 over 5 years for progression reduction ^[323]^A1b.

References

[1]
Sammons EL, Buck G, Bowman LJ et al.. “ASCEND-Eye: Effects of Aspirin on Diabetic Retinopathy.” Ophthalmology (2024). PMID: 38237868 ↗
L1RCTCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Special Populations, Screening & Prevention
[2]
Sammons EL, Buck G, Bowman LJ et al.. “ASCEND-Eye: Effects of Omega-3 Fatty Acids on Diabetic Retinopathy.” Ophthalmology (2023). PMID: 38052385 ↗
L1RCTCited in: Definition, Classification & Nomenclature, Special Populations, Screening & Prevention
[3]
Aiello LP, Blodi B, Gao X et al.. “Ultra-Widefield and Early Treatment Diabetic Retinopathy Study 7-Field Grading of Diabetic Retinopathy.” JAMA ophthalmology (2024). PMID: 39145984 ↗
L2RCTCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[4]
Fu DJ, Bagga P, Naik G et al.. “Pegcetacoplan Treatment and Consensus Features of Geographic Atrophy Over 24 Months.” JAMA ophthalmology (2024). PMID: 38722644 ↗
L2RCTCited in: Definition, Classification & Nomenclature
[5]
Nanji K, Grad J, Hatamnejad A et al.. “Baseline OCT Biomarkers Associated with Visual Acuity in Diabetic Macular Edema: A Systematic Review and Meta-analysis.” Ophthalmology (2025). PMID: 40803536 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management
[6]
Solomon SD, Shoge RY, Ervin AM et al.. “Improving Access to Eye Care: A Systematic Review of the Literature.” Ophthalmology (2022). PMID: 36058739 ↗
L5SR_OBSCited in: Definition, Classification & Nomenclature
[7]
Yu CW, Nanji K, Garg A et al.. “The Prevalence of Diabetic Retinopathy in American Indians or Alaska Natives and Non-Indigenous Americans: A Systematic Review and Meta-Analysis.” Ophthalmology (2025). PMID: 40816608 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature
[8]
Xie J, Ikram MK, Cotch MF et al.. “Association of Diabetic Macular Edema and Proliferative Diabetic Retinopathy With Cardiovascular Disease: A Systematic Review and Meta-analysis.” JAMA ophthalmology (2017). PMID: 28472362 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Acute & Vision-Threatening Management
[9]
Joseph S, Wang Y, Drinkwater JJ et al.. “Effectiveness of artificial intelligence-based diabetic retinopathy screening in primary care and endocrinology settings in Australia: a pragmatic trial.” The British journal of ophthalmology (2025). PMID: 40846450 ↗
L2TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature, Special Populations, Screening & Prevention
[10]
Arruda MP, Lima RV, Hira S et al.. “A Comprehensive Meta-Analysis on the Role of Analgesics and Anti-Inflammatories in Pan-Retinal Photocoagulation.” American journal of ophthalmology (2024). PMID: 38942228 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[11]
Taylor-Phillips S, Mistry H, Leslie R et al.. “Extending the diabetic retinopathy screening interval beyond 1 year: systematic review.” The British journal of ophthalmology (2015). PMID: 25586713 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Severity, Staging & Risk Stratification, Surgical, Laser & Procedural Considerations, Special Populations, Screening & Prevention
[12]
Singh SR, Goté JT, Chhablani J. “Randomized controlled trials in central serous chorioretinopathy: A review.” Eye (London, England) (2023). PMID: 36997794 ↗
L5RCTCited in: Definition, Classification & Nomenclature, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
[13]
Suganya Devi K, Vasireddi HK, Reddy GR et al.. “Unfolding the diagnostic pipeline of diabetic retinopathy with artificial intelligence: A systematic review.” Survey of ophthalmology (2025). PMID: 40972797 ↗
L5SR_OBSCited in: Definition, Classification & Nomenclature
[14]
Kirthi V, Nderitu P, Alam U et al.. “The prevalence of retinopathy in prediabetes: A systematic review.” Survey of ophthalmology (2022). PMID: 35430245 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Special Populations, Screening & Prevention
[15]
Farahat Z, Zrira N, Souissi N et al.. “Diabetic retinopathy screening through artificial intelligence algorithms: A systematic review.” Survey of ophthalmology (2024). PMID: 38885761 ↗
L5SR_OBSCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations, Special Populations, Screening & Prevention
[16]
Sala-Vila A, Vinagre I, Cofán M et al.. “Blood omega-3 biomarkers, diabetic retinopathy and retinal vessel status in patients with type 1 diabetes.” Eye (London, England) (2025). PMID: 39966603 ↗
L4TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Severity, Staging & Risk Stratification
[17]
Tang Z, Yang D, Nguyen TX et al.. “Relationship of OCT-Based Diabetic Retinal Neurodegeneration to the Development and Progression of Diabetic Retinopathy: A Cohort Study.” Investigative ophthalmology & visual science (2025). PMID: 39932471 ↗
L2COHORTCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Surgical, Laser & Procedural Considerations
[18]
Yang S, Liu R, Xin Z et al.. “Plasma Metabolomics Identifies Key Metabolites and Improves Prediction of Diabetic Retinopathy: Development and Validation across Multinational Cohorts.” Ophthalmology (2024). PMID: 38972358 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors
[19]
Mohan N, Srivastava SK, Schulgit MJ et al.. “Glucagon-Like Peptide-1 Receptor Agonists and Risk of Uveitis.” JAMA ophthalmology (2025). PMID: 40875223 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors
[20]
Jindal DA, Hanna J, Shaia JK et al.. “Metformin and the Development of Age-Related Macular Degeneration.” JAMA ophthalmology (2025). PMID: 40965862 ↗
L2OTHERCited in: Definition, Classification & Nomenclature
[21]
Markle J, Shaia JK, Araich H et al.. “Longitudinal Trends and Disparities in Diabetic Retinopathy Within an Aggregate Health Care Network.” JAMA ophthalmology (2024). PMID: 38869883 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Special Populations, Screening & Prevention
[22]
Szeto SK, Lai TY, Vujosevic S et al.. “Optical coherence tomography in the management of diabetic macular oedema.” Progress in retinal and eye research (2023). PMID: 37944588 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management
[23]
Ng DSC, Ruamviboonsuk P, Apte RS et al.. “International consensuses and controversies on causes, diagnosis and management of diabetic macular edema (DME).” Progress in retinal and eye research (2025). PMID: 41005472 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Acute & Vision-Threatening Management, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History, Special Populations, Screening & Prevention
[24]
Sampani K, Fickweiler W, Markel DS et al.. “Diabetic retinal disease cure accelerator: Modernizing staging and endpoints.” Progress in retinal and eye research (2026). PMID: 42173402 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature
[25]
Schmidt-Erfurth U, Sadeghipour A, Gerendas BS et al.. “Artificial intelligence in retina.” Progress in retinal and eye research (2018). PMID: 30076935 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Diagnosis & Workup, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Special Populations, Screening & Prevention
[26]
Cheung CMG, Fawzi A, Teo KY et al.. “Diabetic macular ischaemia- a new therapeutic target?” Progress in retinal and eye research (2021). PMID: 34902545 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Clinical Presentation, Prognosis & Natural History
[27]
Stefánsson E, Olafsdottir OB, Eliasdottir TS et al.. “Retinal oximetry: Metabolic imaging for diseases of the retina and brain.” Progress in retinal and eye research (2019). PMID: 30999027 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Clinical Presentation
[28]
Lopes de Jesus CC, Atallah AN, Valente O et al.. “Vitamin C and superoxide dismutase (SOD) for diabetic retinopathy.” The Cochrane database of systematic reviews (2008). PMID: 18254110 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification
[29]
Jorge EC, Jorge EN, Botelho M et al.. “Monotherapy laser photocoagulation for diabetic macular oedema.” The Cochrane database of systematic reviews (2018). PMID: 30320466 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
[30]
Virgili G, Menchini F, Murro V et al.. “Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy.” The Cochrane database of systematic reviews (2011). PMID: 21735421 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Diagnosis & Workup
[31]
Wai KM, Mishra K, Koo E et al.. “Impact of GLP-1 Agonists and SGLT-2 Inhibitors on Diabetic Retinopathy Progression: An Aggregated Electronic Health Record Data Study.” American journal of ophthalmology (2024). PMID: 38636788 ↗
L2OTHERCited in: Definition, Classification & Nomenclature
[32]
Lee CS, Krakauer C, Su YR et al.. “Diabetic Retinopathy and Dementia Association, Beyond Diabetes Severity.” American journal of ophthalmology (2022). PMID: 36513155 ↗
L2OTHERCited in: Definition, Classification & Nomenclature
[33]
Browning DJ, Yokogawa N, Greenberg PB et al.. “Rethinking the Hydroxychloroquine Dosing and Retinopathy Screening Guidelines.” American journal of ophthalmology (2020). PMID: 32610049 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Special Populations, Screening & Prevention
[34]
Liang F, Tao S, Zhang Y et al.. “Correlation Between Length of Interdigitation Zone With Severity and Progression of Diabetic Retinopathy.” American journal of ophthalmology (2025). PMID: 40157446 ↗
L2OTHERCited in: Definition, Classification & Nomenclature
[35]
Ramirez M, Kitayama K, Puran A et al.. “The Associations Between Glaucoma and Circadian Rhythm Sleep Disorders in California Medicare Beneficiaries.” American journal of ophthalmology (2025). PMID: 40545017 ↗
L4OTHERCited in: Definition, Classification & Nomenclature
[36]
Ting DSW, Pasquale LR, Peng L et al.. “Artificial intelligence and deep learning in ophthalmology.” The British journal of ophthalmology (2018). PMID: 30361278 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Diagnosis & Workup, Special Populations, Screening & Prevention
[37]
Whitestone N, Nkurikiye J, Patnaik JL et al.. “Feasibility and acceptance of artificial intelligence-based diabetic retinopathy screening in Rwanda.” The British journal of ophthalmology (2024). PMID: 37541766 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification, Special Populations, Screening & Prevention
[38]
Wu H, Su Z, Pan X et al.. “Enhancing diabetic retinopathy query responses: assessing large language model in ophthalmology.” The British journal of ophthalmology (2025). PMID: 40588331 ↗
L4OTHERCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification
[39]
Fleming AD, Mellor J, McGurnaghan SJ et al.. “Deep learning detection of diabetic retinopathy in Scotland's diabetic eye screening programme.” The British journal of ophthalmology (2024). PMID: 37704266 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup
[40]
Preiss D, Logue J, Sammons E et al.. “Fenofibrate and progression of retinopathy in adults with diabetes: the randomised placebo-controlled LENS trial.” Health technology assessment (Winchester, England) (2026). PMID: 42117585 ↗
L1RCTCited in: Definition, Classification & Nomenclature, Clinical Presentation, Prognosis & Natural History
[41]
Sorour OA, Levine ES, Baumal CR et al.. “Persistent diabetic macular edema: Definition, incidence, biomarkers, and treatment methods.” Survey of ophthalmology (2022). PMID: 36436614 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[42]
Kiire CA, Porta M, Chong V. “Medical management for the prevention and treatment of diabetic macular edema.” Survey of ophthalmology (2013). PMID: 23969020 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature
[43]
Vaughan N. “Review of smartphone funduscopy for diabetic retinopathy screening.” Survey of ophthalmology (2023). PMID: 37806567 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Special Populations, Screening & Prevention
[44]
Curcio CA, Kar D, Owsley C et al.. “Age-Related Macular Degeneration, a Mathematically Tractable Disease.” Investigative ophthalmology & visual science (2024). PMID: 38466281 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Clinical Presentation
[45]
Wang W, Liu S, Qiu Z et al.. “Choroidal Thickness in Diabetes and Diabetic Retinopathy: A Swept Source OCT Study.” Investigative ophthalmology & visual science (2020). PMID: 32324858 ↗
L4OTHERCited in: Definition, Classification & Nomenclature, Special Populations, Screening & Prevention
[46]
Abtahi M, Le D, Ebrahimi B et al.. “Differential Capillary and Large Vessel Analysis Improves OCTA Classification of Diabetic Retinopathy.” Investigative ophthalmology & visual science (2024). PMID: 39133470 ↗
L4OTHERCited in: Definition, Classification & Nomenclature, Special Populations, Screening & Prevention
[47]
Sandhu HS, Eltanboly A, Shalaby A et al.. “Automated Diagnosis and Grading of Diabetic Retinopathy Using Optical Coherence Tomography.” Investigative ophthalmology & visual science (2018). PMID: 30029278 ↗
L4OTHERCited in: Definition, Classification & Nomenclature, Special Populations, Screening & Prevention
[48]
Gao M, Guo Y, Hormel TT et al.. “Nonperfused Retinal Capillaries-A New Method Developed on OCT and OCTA.” Investigative ophthalmology & visual science (2025). PMID: 40202734 ↗
L4OTHERCited in: Definition, Classification & Nomenclature
[49]
Popovic MM, Feo A, Sadda SR et al.. “Large Retinal Capillary Aneurysm: A Delphi Consensus Study and Updated Nomenclature for a Signature Optical Coherence Tomography Lesion.” Retina (Philadelphia, Pa.) (2025). PMID: 40456130 ↗
L5OTHERCited in: Definition, Classification & Nomenclature
[50]
Yassin SH, Wagner NE, Kalaw FGP et al.. “RETINAL VESSELS WHITENING IN RETINITIS PIGMENTOSA.” Retina (Philadelphia, Pa.) (2025). PMID: 40262144 ↗
L4OTHERCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification
[51]
Castellanos-Canales D, Decker NL, Fukuyama H et al.. “RELIABILITY OF CLINICAL GRADING OF DIABETIC RETINOPATHY COMPARED WITH GRADING OF ULTRA-WIDEFIELD IMAGES.” Retina (Philadelphia, Pa.) (2024). PMID: 39047122 ↗
L3OTHERCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification
[52]
Le D, Dadzie A, Son T et al.. “COMPARATIVE ANALYSIS OF OCT AND OCT ANGIOGRAPHY CHARACTERISTICS IN EARLY DIABETIC RETINOPATHY.” Retina (Philadelphia, Pa.) (2023). PMID: 36763982 ↗
L3OTHERCited in: Definition, Classification & Nomenclature
[53]
Romano F, Cozzi M, Monteduro D et al.. “NATURAL COURSE AND CLASSIFICATION OF EXTENSIVE MACULAR ATROPHY WITH PSEUDODRUSEN-LIKE APPEARANCE.” Retina (Philadelphia, Pa.) (2023). PMID: 36727827 ↗
L2OTHERCited in: Definition, Classification & Nomenclature
[54]
Kim K, Kim ES, Yu SY. “PREDICTION OF DIABETIC RETINOPATHY SEVERITY USING A COMBINATION OF RETINAL NEURODEGENERATION AND CAPILLARY NONPERFUSION ON OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY.” Retina (Philadelphia, Pa.) (2023). PMID: 37116460 ↗
L3OTHERCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism
[55]
Abdelaal A, Mahmoud YA, Alsouri W et al.. “Bidirectional association between obstructive sleep apnea and diabetic retinopathy: a severity-stratified systematic review and meta-analysis with GRADE assessment.” Acta diabetologica (2026). PMID: 42334598 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification, Special Populations, Screening & Prevention
[56]
Chen KY, Chan HC, Chan CM. “Association between omega-6 fatty acids and diabetic retinopathy risk: a systematic review and meta-analysis.” Nutrition & diabetes (2026). PMID: 42276994 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations
[57]
Yang X, Guo J, Wei T et al.. “Quantifying the evidence on associated factors for diabetes-related foot complications: An umbrella review of published systematic reviews and meta-analyses.” Diabetes research and clinical practice (2026). PMID: 42251949 ↗
L2SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Surgical, Laser & Procedural Considerations
[58]
Chen KY, Chan HC, Chan CM. “Clinical setting-dependent diagnostic accuracy of artificial intelligence and store-and-forward diabetic retinopathy screening: a systematic review and meta-analysis.” NPJ digital medicine (2026). PMID: 42141103 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature
[59]
Wu Z, Li L. “Effectiveness of screening modalities for early detection of diabetic retinopathy: a systematic review and meta-analysis of tele-ophthalmology, AI-based tools, and conventional methods.” Frontiers in medicine (2026). PMID: 42100279 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature
[60]
Cunha-Vaz J, Mendes L, Reste-Ferreira D. “Understanding nonproliferative diabetic retinopathy progression using noninvasive imaging.” Eye (London, England) (2025). PMID: 40646245 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, Special Populations, Screening & Prevention
[61]
Amoaku WM, Ghanchi F, Bailey C et al.. “Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group.” Eye (London, England) (2020). PMID: 32504038 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Diagnosis & Workup, Acute & Vision-Threatening Management, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Special Populations, Screening & Prevention
[62]
Menean M, Sacconi R, Tombolini B et al.. “Combined wide-field imaging in grading diabetic retinopathy.” Eye (London, England) (2023). PMID: 37524829 ↗
L2OTHERCited in: Definition, Classification & Nomenclature
[63]
Das T, Takkar B, Sivaprasad S et al.. “Recently updated global diabetic retinopathy screening guidelines: commonalities, differences, and future possibilities.” Eye (London, England) (2021). PMID: 33976399 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Clinical Presentation, Special Populations, Screening & Prevention
[64]
Staurenghi G, Ye L, Magee MH et al.. “Darapladib, a lipoprotein-associated phospholipase A2 inhibitor, in diabetic macular edema: a 3-month placebo-controlled study.” Ophthalmology (2015). PMID: 25749297 ↗
L1RCTCited in: Pathophysiology & Mechanism
[65]
Scott IU, Jackson GR, Quillen DA et al.. “Effect of doxycycline vs placebo on retinal function and diabetic retinopathy progression in patients with severe nonproliferative or non-high-risk proliferative diabetic retinopathy: a randomized clinical trial.” JAMA ophthalmology (2014). PMID: 24604308 ↗
L1RCTCited in: Pathophysiology & Mechanism
[66]
Schoenberger SD, Kim SJ, Shah R et al.. “Reduction of interleukin 8 and platelet-derived growth factor levels by topical ketorolac, 0.45%, in patients with diabetic retinopathy.” JAMA ophthalmology (2014). PMID: 24336915 ↗
L1RCTCited in: Pathophysiology & Mechanism
[67]
Sala-Vila A, Díaz-López A, Valls-Pedret C et al.. “Dietary Marine ω-3 Fatty Acids and Incident Sight-Threatening Retinopathy in Middle-Aged and Older Individuals With Type 2 Diabetes: Prospective Investigation From the PREDIMED Trial.” JAMA ophthalmology (2016). PMID: 27541690 ↗
L2RCTCited in: Pathophysiology & Mechanism
[68]
Staurenghi G, Feltgen N, Arnold JJ et al.. “Impact of baseline Diabetic Retinopathy Severity Scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies.” The British journal of ophthalmology (2017). PMID: 29051325 ↗
L2RCTCited in: Pathophysiology & Mechanism
[69]
Huang Y, Zhang N, Bulloch G et al.. “Rates of Choroidal and Neurodegenerative Changes Over Time in Diabetic Patients Without Retinopathy: A 3-Year Prospective Study.” American journal of ophthalmology (2022). PMID: 35870490 ↗
L2COHORTCited in: Pathophysiology & Mechanism
[70]
Zhang S, Zhu Z, Bulloch G et al.. “PROGRESSIVE PERIPAPILLARY CHOROID THINNING AND RETINAL NEURODEGENERATION IN PATIENTS WITH DIABETES: A 3-Year Cohort Study.” Retina (Philadelphia, Pa.) (2022). PMID: 36394894 ↗
L2COHORTCited in: Pathophysiology & Mechanism
[71]
Puech B, Lacour A, Stevanin G et al.. “Kjellin syndrome: long-term neuro-ophthalmologic follow-up and novel mutations in the SPG11 gene.” Ophthalmology (2010). PMID: 21035867 ↗
L4CASE_REPORTCited in: Pathophysiology & Mechanism
[72]
Das A, McGuire PG, Rangasamy S. “Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets.” Ophthalmology (2015). PMID: 25935789 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[73]
Miller JW, Le Couter J, Strauss EC et al.. “Vascular endothelial growth factor a in intraocular vascular disease.” Ophthalmology (2012). PMID: 23031671 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[74]
Chong YH, Fan Q, Tham YC et al.. “Type 2 Diabetes Genetic Variants and Risk of Diabetic Retinopathy.” Ophthalmology (2016). PMID: 28038984 ↗
L3OTHERCited in: Pathophysiology & Mechanism
[75]
Raman R, Rani PK, Reddi Rachepalle S et al.. “Prevalence of diabetic retinopathy in India: Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetics Study report 2.” Ophthalmology (2008). PMID: 19084275 ↗
L2OTHERCited in: Pathophysiology & Mechanism
[76]
Kwon SH, Shin JP, Kim IT et al.. “Aqueous Levels of Angiopoietin-like 4 and Semaphorin 3E Correlate with Nonperfusion Area and Macular Volume in Diabetic Retinopathy.” Ophthalmology (2015). PMID: 25687026 ↗
L4OTHERCited in: Pathophysiology & Mechanism
[77]
Huang YC, Lin JM, Lin HJ et al.. “Genome-wide association study of diabetic retinopathy in a Taiwanese population.” Ophthalmology (2011). PMID: 21310492 ↗
L3OTHERCited in: Pathophysiology & Mechanism
[78]
Knol JA, van Kooij B, de Valk HW et al.. “Rapid progression of diabetic retinopathy in eyes with posterior uveitis.” American journal of ophthalmology (2006). PMID: 16458715 ↗
L4CASE_REPORTCited in: Pathophysiology & Mechanism
[79]
Lee B, Novais EA, Waheed NK et al.. “En Face Doppler Optical Coherence Tomography Measurement of Total Retinal Blood Flow in Diabetic Retinopathy and Diabetic Macular Edema.” JAMA ophthalmology (2017). PMID: 28196198 ↗
L4OTHERCited in: Pathophysiology & Mechanism
[80]
Aychoua N, de Guimarães TAC, Ponnekanti MB et al.. “Clinical Findings and Molecular Genetics of USH1C-Associated Usher Syndrome.” JAMA ophthalmology (2026). PMID: 41296346 ↗
L4OTHERCited in: Pathophysiology & Mechanism
[81]
Hamilton-Perais JA, Wright DM, Lim A et al.. “Retinal Sensitivity and Retinal Perfusion in Diabetic Retinopathy.” JAMA ophthalmology (2026). PMID: 41165673 ↗
L2OTHERCited in: Pathophysiology & Mechanism, Acute & Vision-Threatening Management
[82]
Stitt AW, Curtis TM, Chen M et al.. “The progress in understanding and treatment of diabetic retinopathy.” Progress in retinal and eye research (2015). PMID: 26297071 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[83]
Uemura A, Fruttiger M, D'Amore PA et al.. “VEGFR1 signaling in retinal angiogenesis and microinflammation.” Progress in retinal and eye research (2021). PMID: 33640465 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Long-term & Definitive Management
[84]
Jiménez-Loygorri JI, Benítez-Fernández R, Viedma-Poyatos Á et al.. “Mitophagy in the retina: Viewing mitochondrial homeostasis through a new lens.” Progress in retinal and eye research (2023). PMID: 37454969 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[85]
Hayreh SS. “Neovascular glaucoma.” Progress in retinal and eye research (2007). PMID: 17690002 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations
[86]
Arrigo A, Cremona O, Aragona E et al.. “Müller cells trophism and pathology as the next therapeutic targets for retinal diseases.” Progress in retinal and eye research (2025). PMID: 40254246 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification
[87]
Wu CS, Cioanca AV, Gelmi MC et al.. “The multifunctional human ocular melanocortin system.” Progress in retinal and eye research (2023). PMID: 37217094 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Prognosis & Natural History
[88]
Campochiaro PA. “Molecular pathogenesis of retinal and choroidal vascular diseases.” Progress in retinal and eye research (2015). PMID: 26113211 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification
[89]
Virgili G, Curran K, Lucenteforte E et al.. “Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.” The Cochrane database of systematic reviews (2023). PMID: 38275741 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism, Clinical Presentation, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[90]
Virgili G, Parravano M, Menchini F et al.. “Anti-vascular endothelial growth factor for diabetic macular oedema.” The Cochrane database of systematic reviews (2014). PMID: 25342124 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism
[91]
Virgili G, Parravano M, Evans JR et al.. “Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.” The Cochrane database of systematic reviews (2018). PMID: 30325017 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism
[92]
Virgili G, Parravano M, Evans JR et al.. “Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.” The Cochrane database of systematic reviews (2017). PMID: 28639415 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism
[93]
Mitry D, Bunce C, Charteris D. “Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.” The Cochrane database of systematic reviews (2013). PMID: 23440840 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism
[94]
Parravano M, Menchini F, Virgili G. “Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.” The Cochrane database of systematic reviews (2009). PMID: 19821414 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism, Long-term & Definitive Management
[95]
Virgili G, Parravano M, Menchini F et al.. “Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.” The Cochrane database of systematic reviews (2012). PMID: 23235642 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism
[96]
Yeong JL, Loveman E, Colquitt JL et al.. “Visual cycle modulators versus placebo or observation for the prevention and treatment of geographic atrophy due to age-related macular degeneration.” The Cochrane database of systematic reviews (2020). PMID: 33331670 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism, Special Populations, Screening & Prevention
[97]
Pattwell DM, Stappler T, Sheridan C et al.. “Fibrous membranes in diabetic retinopathy and bevacizumab.” Retina (Philadelphia, Pa.) (2010). PMID: 20616680 ↗
L4CASE_REPORTCited in: Pathophysiology & Mechanism
[98]
Hafner J, Zadrazil M, Grisold A et al.. “Retinal and Corneal Neurodegeneration and Their Association with Systemic Signs of Peripheral Neuropathy in Type 2 Diabetes.” American journal of ophthalmology (2019). PMID: 31542341 ↗
L4OTHERCited in: Pathophysiology & Mechanism
[99]
Wang JC, Laíns I, Providência J et al.. “Diabetic Choroidopathy: Choroidal Vascular Density and Volume in Diabetic Retinopathy With Swept-Source Optical Coherence Tomography.” American journal of ophthalmology (2017). PMID: 28988899 ↗
L4OTHERCited in: Pathophysiology & Mechanism
[100]
Kim K, Yu SY, Kwak HW et al.. “Retinal Neurodegeneration Associated With Peripheral Nerve Conduction and Autonomic Nerve Function in Diabetic Patients.” American journal of ophthalmology (2016). PMID: 27381712 ↗
L4OTHERCited in: Pathophysiology & Mechanism
[101]
Penman A, Hoadley S, Wilson JG et al.. “P-selectin Plasma Levels and Genetic Variant Associated With Diabetic Retinopathy in African Americans.” American journal of ophthalmology (2015). PMID: 25794792 ↗
L4OTHERCited in: Pathophysiology & Mechanism
[102]
Qin YJ, Chan SO, Lin HL et al.. “Increased Expression of Growth Hormone-Releasing Hormone in Fibrinous Inflammation of Proliferative Diabetic Retinopathy.” American journal of ophthalmology (2020). PMID: 32061756 ↗
L3OTHERCited in: Pathophysiology & Mechanism
[103]
Ma Y, Tao Y, Lu Q et al.. “Intraocular expression of serum amyloid a and interleukin-6 in proliferative diabetic retinopathy.” American journal of ophthalmology (2011). PMID: 21704966 ↗
L3OTHERCited in: Pathophysiology & Mechanism
[104]
Neelam K, Goenadi CJ, Lun K et al.. “Putative protective role of lutein and zeaxanthin in diabetic retinopathy.” The British journal of ophthalmology (2017). PMID: 28232380 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[105]
Alshaikh RA, Ryan KB, Waeber C. “Sphingosine 1-phosphate, a potential target in neovascular retinal disease.” The British journal of ophthalmology (2021). PMID: 33962970 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Long-term & Definitive Management
[106]
Cao J, Su T, Chen S et al.. “Evaluating lipid-lowering drug targets for full-course diabetic retinopathy.” The British journal of ophthalmology (2025). PMID: 39900481 ↗
L2OTHERCited in: Pathophysiology & Mechanism
[107]
Simó R, Hernández C. “Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications.” The British journal of ophthalmology (2012). PMID: 22887976 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[108]
Stahl A, Krohne TU, Sapieha P et al.. “Lipid metabolites in the pathogenesis and treatment of neovascular eye disease.” The British journal of ophthalmology (2011). PMID: 21421650 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[109]
Gupta P, Yee KM, Garcia P et al.. “Vitreoschisis in macular diseases.” The British journal of ophthalmology (2010). PMID: 20584710 ↗
L4OTHERCited in: Pathophysiology & Mechanism
[110]
Zhang Y, Huang W, Tian Q et al.. “Network pharmacology and biochemical experiments reveal the antiapoptotic mechanism of huperzine A for treating diabetic retinopathy.” The British journal of ophthalmology (2024). PMID: 37339867 ↗
L5OTHERCited in: Pathophysiology & Mechanism
[111]
Jiang F, Lei C, Chen Y et al.. “The complement system and diabetic retinopathy.” Survey of ophthalmology (2024). PMID: 38401574 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[112]
Safi H, Safi S, Hafezi-Moghadam A et al.. “Early detection of diabetic retinopathy.” Survey of ophthalmology (2018). PMID: 29679616 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup
[113]
Takkar B, Sheemar A, Jayasudha R et al.. “Unconventional avenues to decelerate diabetic retinopathy.” Survey of ophthalmology (2022). PMID: 35803389 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Severity, Staging & Risk Stratification, Surgical, Laser & Procedural Considerations, Special Populations, Screening & Prevention
[114]
Sanfilippo PG, Hewitt AW, Hammond CJ et al.. “The heritability of ocular traits.” Survey of ophthalmology (2010). PMID: 20851442 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors
[115]
Rai BB, Maddess T, Nolan CJ. “Functional diabetic retinopathy: A new concept to improve management of diabetic retinal diseases.” Survey of ophthalmology (2024). PMID: 39581562 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation, Diagnosis & Workup, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations, Special Populations, Screening & Prevention
[116]
Chychko L, Son HS, Friedrich M et al.. “The diagnostic potential of aqueous humor: Unlocking ocular and systemic insights.” Survey of ophthalmology (2025). PMID: 41419165 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[117]
Kovoor E, Chauhan SK, Hajrasouliha A. “Role of inflammatory cells in pathophysiology and management of diabetic retinopathy.” Survey of ophthalmology (2022). PMID: 35914582 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[118]
Nebbioso M, Lambiase A, Armentano M et al.. “Diabetic retinopathy, oxidative stress, and sirtuins: an in depth look in enzymatic patterns and new therapeutic horizons.” Survey of ophthalmology (2021). PMID: 33864872 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[119]
Lauwen S, de Jong EK, Lefeber DJ et al.. “Omics Biomarkers in Ophthalmology.” Investigative ophthalmology & visual science (2017). PMID: 28525563 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[120]
Li S, Sun D, Chen S et al.. “UCP2-SIRT3 Signaling Relieved Hyperglycemia-Induced Oxidative Stress and Senescence in Diabetic Retinopathy.” Investigative ophthalmology & visual science (2024). PMID: 38175638 ↗
L5OTHERCited in: Pathophysiology & Mechanism, Special Populations, Screening & Prevention
[121]
Stitt AW. “AGEs and diabetic retinopathy.” Investigative ophthalmology & visual science (2010). PMID: 20876889 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management
[122]
Liu L, Gao Y, Yao S. “Transthyretin-Regulated Diabetic Retinopathy Through the VEGFA/PI3K/AKT Pathway.” Investigative ophthalmology & visual science (2024). PMID: 38289614 ↗
L5OTHERCited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification
[123]
Lopes de Faria JM, Duarte DA, Montemurro C et al.. “Defective Autophagy in Diabetic Retinopathy.” Investigative ophthalmology & visual science (2016). PMID: 27564518 ↗
L5OTHERCited in: Pathophysiology & Mechanism, Diagnosis & Workup
[124]
He Y, Zhou J, Wang J et al.. “Novel Visceral Obesity Indicators and Associated Metabolic Fingerprint in Incident Diabetic Retinopathy.” Investigative ophthalmology & visual science (2025). PMID: 40919861 ↗
L2OTHERCited in: Pathophysiology & Mechanism, Diagnosis & Workup, Special Populations, Screening & Prevention
[125]
Liu D, Meng Z, Jin C et al.. “Fibronectin Mediates Endothelial-to-Mesenchymal Transition in Retina Angiogenesis.” Investigative ophthalmology & visual science (2025). PMID: 40042877 ↗
L5OTHERCited in: Pathophysiology & Mechanism, Long-term & Definitive Management
[126]
Vujosevic S, Simó R. “Local and Systemic Inflammatory Biomarkers of Diabetic Retinopathy: An Integrative Approach.” Investigative ophthalmology & visual science (2017). PMID: 28510630 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification
[127]
Kirthi V, Zuckerman BP, Alam U et al.. “ASSOCIATIONS BETWEEN DYSGLYCEMIA, RETINAL NEURODEGENERATION, AND MICROALBUMINURIA IN PREDIABETES AND TYPE 2 DIABETES.” Retina (Philadelphia, Pa.) (2022). PMID: 35188489 ↗
L4OTHERCited in: Pathophysiology & Mechanism
[128]
Hillier RJ, Ojaimi E, Wong DT et al.. “AQUEOUS HUMOR CYTOKINE LEVELS AS BIOMARKERS OF DISEASE SEVERITY IN DIABETIC MACULAR EDEMA.” Retina (Philadelphia, Pa.) (2017). PMID: 27471825 ↗
L4OTHERCited in: Pathophysiology & Mechanism
[129]
Nassisi M, Wohlschlegel J, Liu B et al.. “DEEP PHENOTYPING AND FURTHER INSIGHTS INTO ITM2B-RELATED RETINAL DYSTROPHY.” Retina (Philadelphia, Pa.) (2021). PMID: 32826790 ↗
L4OTHERCited in: Pathophysiology & Mechanism
[130]
Li Z, Yang F, Deng X et al.. “ASSOCIATIONS BETWEEN CHOROIDAL ALTERATIONS AND EARLY NEURODEGENERATION IN DIABETES WITHOUT DIABETIC RETINOPATHY: Insights From Ultra-Widefield Optical Coherence Tomography Angiography Imaging.” Retina (Philadelphia, Pa.) (2024). PMID: 39047123 ↗
L4OTHERCited in: Pathophysiology & Mechanism
[131]
Taşlipinar Uzel AG, UĞurlu N, Toklu Y et al.. “RELATIONSHIP BETWEEN STAGES OF DIABETIC RETINOPATHY AND LEVELS OF BRAIN-DERIVED NEUROTROPHIC FACTOR IN AQUEOUS HUMOR AND SERUM.” Retina (Philadelphia, Pa.) (2020). PMID: 30300266 ↗
L4OTHERCited in: Pathophysiology & Mechanism
[132]
Lin P, Zhang N, Zhang W et al.. “Comprehensive proteomic meta-analysis identifies novel proteomics alterations in proliferative diabetic retinopathy.” Experimental eye research (2026). PMID: 42208844 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism
[133]
Sivaprasad S, Sen S, Cunha-Vaz J. “Perspectives of diabetic retinopathy-challenges and opportunities.” Eye (London, England) (2022). PMID: 36494431 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management
[134]
Al-Janabi A, Lightman S, Tomkins-Netzer O. “'Statins in retinal disease'.” Eye (London, England) (2018). PMID: 29556012 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification
[135]
Yerramothu P, Vijay AK, Willcox MDP. “Inflammasomes, the eye and anti-inflammasome therapy.” Eye (London, England) (2017). PMID: 29171506 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[136]
Calderon GD, Juarez OH, Hernandez GE et al.. “Oxidative stress and diabetic retinopathy: development and treatment.” Eye (London, England) (2017). PMID: 28452994 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup, Surgical, Laser & Procedural Considerations
[137]
Sorrentino FS, Matteini S, Bonifazzi C et al.. “Diabetic retinopathy and endothelin system: microangiopathy versus endothelial dysfunction.” Eye (London, England) (2018). PMID: 29520046 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification
[138]
Hannig L, Braunger BM, Kleefeldt N et al.. “Deletion of CEACAM1 does not affect retinal and choroidal morphology or transcriptome.” Cell and tissue research (2026). PMID: 42360388 ↗
L5OTHERCited in: Pathophysiology & Mechanism
[139]
Zhao J, Cao Y, Chai Z et al.. “Early proteomic and metabolomic signatures in diabetes associated with progression to diabetic retinopathy over 1-2 years.” Frontiers in endocrinology (2026). PMID: 42358678 ↗
L2OTHERCited in: Pathophysiology & Mechanism
[140]
Ramos H, Simó-Servat O, Hernández C et al.. “Neuroprotection in Early Diabetic Retinal Disease Using Eyedrop Delivery.” International journal of molecular sciences (2026). PMID: 42353267 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Surgical, Laser & Procedural Considerations
[141]
Fedotkina O, Begum MC, Trinh XT et al.. “Genome-wide association and interaction analysis for proliferative retinopathy in adults with type 2 diabetes born during famine: The DOLCE study in Ukraine.” Acta ophthalmologica (2026). PMID: 42348306 ↗
L2OTHERCited in: Pathophysiology & Mechanism, Long-term & Definitive Management
[142]
Hou Y, Chen T, Zhou J et al.. “The Mechanism of TNF-α Combined With High Glucose in Regulating Calnexin Aggravates Endoplasmic Reticulum Stress in Endothelial Cell Injury of Diabetic Retinopathy.” Diabetes (2026). PMID: 42330304 ↗
L5OTHERCited in: Pathophysiology & Mechanism
[143]
Wang L, Zhang C, Li N et al.. “Research Advances in Claudin-1 in the Eye.” Experimental eye research (2026). PMID: 42320872 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[144]
Liu C, Wang X, Li Y et al.. “Minocycline as a therapeutic candidate in diabetic retinopathy: insights into pathophysiology and translational potential.” Experimental eye research (2026). PMID: 42320189 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
[145]
Heier JS, Korobelnik JF, Brown DM et al.. “Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies.” Ophthalmology (2016). PMID: 27651226 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
[146]
Newman-Casey PA, Niziol LM, Elam AR et al.. “Michigan Screening and Intervention for Glaucoma and Eye Health through Telemedicine Program: Impact on Vision, Follow-up, and Costs.” Ophthalmology (2025). PMID: 40311700 ↗
L2RCTCited in: Epidemiology, Etiology & Risk Factors, Special Populations, Screening & Prevention
[147]
Bressler SB, Barve A, Ganapathi PC et al.. “Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema: The INSIGHT Randomized Clinical Trial.” JAMA ophthalmology (2024). PMID: 39264599 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
[148]
Singh RP, Barakat MR, Ip MS et al.. “Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial.” JAMA ophthalmology (2023). PMID: 37971723 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Prognosis & Natural History
[149]
Teo ZL, Tham YC, Yu M et al.. “Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-analysis.” Ophthalmology (2021). PMID: 33940045 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Surgical, Laser & Procedural Considerations, Special Populations, Screening & Prevention
[150]
Lee CT, Gayton EL, Beulens JW et al.. “Micronutrients and diabetic retinopathy a systematic review.” Ophthalmology (2009). PMID: 19900709 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Surgical, Laser & Procedural Considerations
[151]
Chia MA, Taylor JR, Stuart KV et al.. “Prevalence of Diabetic Retinopathy in Indigenous and Non-Indigenous Australians: A Systematic Review and Meta-analysis.” Ophthalmology (2022). PMID: 35931223 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[152]
Brown DM, Emanuelli A, Bandello F et al.. “KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema.” American journal of ophthalmology (2022). PMID: 35038415 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
[153]
Williams ZR, Morgenstern R, Erekat AN et al.. “Progression of Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Occurs Early and Is Unassociated With Modifiable Risk Factors.” American journal of ophthalmology (2026). PMID: 41544737 ↗
L3RCTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management
[154]
Prasad M, Agrón E, Vitale S et al.. “Diabetic Retinopathy Incidence, Progression, and Health-Related Quality of Life From the ACCORD Trial.” American journal of ophthalmology (2025). PMID: 40712766 ↗
L3RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[155]
Shah J, Razavi P, Festok M et al.. “Tirzepatide and Reduced Risk of Diabetic Retinopathy and Related Complications: A Multicenter US Cohort Study.” Ophthalmology (2026). PMID: 41577258 ↗
L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification
[156]
Sun D, Tseng VL, Yu F et al.. “Cardiovascular Risk and Eye Health: A Cohort Study of the Pooled Cohort Equations and Ocular Disease Incidence.” Ophthalmology (2025). PMID: 41475545 ↗
L3COHORTCited in: Epidemiology, Etiology & Risk Factors
[157]
Natividade GR, Spiazzi BF, Baumgarten MW et al.. “Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis.” JAMA ophthalmology (2025). PMID: 40810985 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Surgical, Laser & Procedural Considerations
[158]
Liu TYA, Ko S, Rosettie KL et al.. “Prevalence and Health Care Disparities of Retinal Conditions: A Meta-Analysis.” JAMA ophthalmology (2026). PMID: 41854587 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[159]
Lee SH, Tseng BY, Wu MC et al.. “Incidence and Progression of Diabetic Retinopathy After Cataract Surgery: A Systematic Review and Meta-Analysis.” American journal of ophthalmology (2024). PMID: 39179126 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations
[160]
Virk SA, Donaghue KC, Wong TY et al.. “Interventions for Diabetic Retinopathy in Type 1 Diabetes: Systematic Review and Meta-Analysis.” American journal of ophthalmology (2015). PMID: 26210869 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Surgical, Laser & Procedural Considerations
[161]
Chai YH, Zhang YP, Qiao YS et al.. “Association Between Diabetic Retinopathy, Brain Structural Abnormalities, and Cognitive Impairment for Accumulated Evidence in Observational Studies.” American journal of ophthalmology (2022). PMID: 35063409 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[162]
Yu CW, Park LJ, Pinto A et al.. “The Impact of Bariatric Surgery on Diabetic Retinopathy: A Systematic Review and Meta-Analysis.” American journal of ophthalmology (2021). PMID: 33428884 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[163]
Keeffe J, Taylor HR, Fotis K et al.. “Prevalence and causes of vision loss in Southeast Asia and Oceania: 1990-2010.” The British journal of ophthalmology (2014). PMID: 24407561 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation
[164]
Naidoo K, Gichuhi S, Basáñez MG et al.. “Prevalence and causes of vision loss in sub-Saharan Africa: 1990-2010.” The British journal of ophthalmology (2014). PMID: 24568870 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[165]
Kai JY, Zhou M, Li DL et al.. “Smoking, dietary factors and major age-related eye disorders: an umbrella review of systematic reviews and meta-analyses.” The British journal of ophthalmology (2023). PMID: 36575624 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[166]
Nangia V, Jonas JB, George R et al.. “Prevalence and causes of blindness and vision impairment: magnitude, temporal trends and projections in South and Central Asia.” The British journal of ophthalmology (2018). PMID: 30409914 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation
[167]
Cheng CY, Wang N, Wong TY et al.. “Prevalence and causes of vision loss in East Asia in 2015: magnitude, temporal trends and projections.” The British journal of ophthalmology (2019). PMID: 31462416 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation
[168]
Kahloun R, Khairallah M, Resnikoff S et al.. “Prevalence and causes of vision loss in North Africa and Middle East in 2015: magnitude, temporal trends and projections.” The British journal of ophthalmology (2018). PMID: 30209082 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation
[169]
Bourne RR, Jonas JB, Flaxman SR et al.. “Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990-2010.” The British journal of ophthalmology (2014). PMID: 24665132 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation
[170]
Wang TW, Luo WT, Tu YK et al.. “Prospective validation of deep-learning algorithms for diabetic retinopathy screening: A systematic review and meta-analysis.” Survey of ophthalmology (2025). PMID: 41344407 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Special Populations, Screening & Prevention
[171]
Miele A, Govetto A, Fumagalli C et al.. “OCULAR HYPERTENSION AND GLAUCOMA FOLLOWING VITRECTOMY: A Systematic Review.” Retina (Philadelphia, Pa.) (2018). PMID: 28426628 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[172]
Simunovic MP, Maberley DA. “ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR PROLIFERATIVE DIABETIC RETINOPATHY: A Systematic Review and Meta-Analysis.” Retina (Philadelphia, Pa.) (2015). PMID: 26398553 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Acute & Vision-Threatening Management, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[173]
Testa F, Carreño E, van den Born LI et al.. “Multicentric Longitudinal Prospective Study in a European Cohort of MYO7A Patients: Disease Course and Implications for Gene Therapy.” Investigative ophthalmology & visual science (2024). PMID: 38884554 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Long-term & Definitive Management, Prognosis & Natural History
[174]
Balas M, Issa M, Popovic MM et al.. “ADAPTIVE OPTICS IMAGING IN DIABETIC RETINOPATHY: A Prospective Cohort Study.” Retina (Philadelphia, Pa.) (2024). PMID: 38478760 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Severity, Staging & Risk Stratification
[175]
Gilead N, Chong YJ, Yamaguchi TCN et al.. “Incidence of Visual Loss in Patients with Diabetic Macular Ischemia (DMI) A 1- year Prospective Study.” Retina (Philadelphia, Pa.) (2025). PMID: 40334126 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation
[176]
. “Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 2000 to 2020.” Eye (London, England) (2024). PMID: 38937557 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup
[177]
Xu Y, Phu J, Aung HL et al.. “Frequency of coexistent eye diseases and cognitive impairment or dementia: a systematic review and meta-analysis.” Eye (London, England) (2023). PMID: 36922645 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Acute & Vision-Threatening Management
[178]
Haider S, Sadiq SN, Moore D et al.. “Prognostic prediction models for diabetic retinopathy progression: a systematic review.” Eye (London, England) (2019). PMID: 30651592 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History, Special Populations, Screening & Prevention
[179]
Trott M, Smith L, Veronese N et al.. “Eye disease and mortality, cognition, disease, and modifiable risk factors: an umbrella review of meta-analyses of observational studies.” Eye (London, England) (2021). PMID: 34272511 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Surgical, Laser & Procedural Considerations
[180]
Ong AY, Kiire CA, Frise C et al.. “Intravitreal anti-vascular endothelial growth factor injections in pregnancy and breastfeeding: a case series and systematic review of the literature.” Eye (London, England) (2023). PMID: 37980398 ↗
L4SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Acute & Vision-Threatening Management, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Special Populations, Screening & Prevention
[181]
Lundeen EA, Burke-Conte Z, Rein DB et al.. “Prevalence of Diabetic Retinopathy in the US in 2021.” JAMA ophthalmology (2023). PMID: 37318810 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Surgical, Laser & Procedural Considerations, Special Populations, Screening & Prevention
[182]
Alsoudi AF, Wai KM, Koo E et al.. “Initial Therapy of Panretinal Photocoagulation vs Anti-VEGF Injection for Proliferative Diabetic Retinopathy.” JAMA ophthalmology (2024). PMID: 39207799 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Long-term & Definitive Management
[183]
Pardue MT, Allen RS. “Neuroprotective strategies for retinal disease.” Progress in retinal and eye research (2018). PMID: 29481975 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management, Prognosis & Natural History
[184]
Bearse MA, Adams AJ, Han Y et al.. “A multifocal electroretinogram model predicting the development of diabetic retinopathy.” Progress in retinal and eye research (2006). PMID: 16949855 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
[185]
Cunha-Vaz J, Ribeiro L, Lobo C. “Phenotypes and biomarkers of diabetic retinopathy.” Progress in retinal and eye research (2014). PMID: 24680929 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management
[186]
Pan WW, Lin F, Fort PE. “The innate immune system in diabetic retinopathy.” Progress in retinal and eye research (2021). PMID: 33429059 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
[187]
Ting DSW, Peng L, Varadarajan AV et al.. “Deep learning in ophthalmology: The technical and clinical considerations.” Progress in retinal and eye research (2019). PMID: 31048019 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Special Populations, Screening & Prevention
[188]
Jonas JB, Wang N, Yang D et al.. “Facts and myths of cerebrospinal fluid pressure for the physiology of the eye.” Progress in retinal and eye research (2015). PMID: 25619727 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
[189]
Sunaga T, Maeda M, Saulle R et al.. “Anti-vascular endothelial growth factor biosimilars for neovascular age-related macular degeneration.” The Cochrane database of systematic reviews (2024). PMID: 38829176 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Acute & Vision-Threatening Management, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
[190]
Kataoka SY, Lois N, Kawano S et al.. “Fenofibrate for diabetic retinopathy.” The Cochrane database of systematic reviews (2023). PMID: 37310870 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations
[191]
Do DV, Han G, Abariga SA et al.. “Blood pressure control for diabetic retinopathy.” The Cochrane database of systematic reviews (2023). PMID: 36975019 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, Surgical, Laser & Procedural Considerations
[192]
Martinez-Zapata MJ, Salvador I, Martí-Carvajal AJ et al.. “Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.” The Cochrane database of systematic reviews (2023). PMID: 36939655 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management
[193]
Do DV, Wang X, Vedula SS et al.. “Blood pressure control for diabetic retinopathy.” The Cochrane database of systematic reviews (2015). PMID: 25637717 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup
[194]
Myint KT, Sahoo S, Thein AW et al.. “Laser therapy for retinopathy in sickle cell disease.” The Cochrane database of systematic reviews (2015). PMID: 26451693 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Acute & Vision-Threatening Management, Long-term & Definitive Management, Prognosis & Natural History
[195]
Schwartz SG, Wang X, Chavis P et al.. “Vitamin A and fish oils for preventing the progression of retinitis pigmentosa.” The Cochrane database of systematic reviews (2020). PMID: 32573764 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[196]
Braithwaite T, Nanji AA, Lindsley K et al.. “Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion.” The Cochrane database of systematic reviews (2014). PMID: 24788977 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors
[197]
Lakhani M, Kwan ATH, Mihalache A et al.. “Association of Glucagon-Like Peptide-1 Receptor Agonists With Optic Nerve and Retinal Adverse Events: A Population-Based Observational Study Across 180 Countries.” American journal of ophthalmology (2025). PMID: 40383360 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup
[198]
Iyer SSR, Regan KA, Burnham JM et al.. “Surgical management of diabetic tractional retinal detachments.” Survey of ophthalmology (2019). PMID: 31077688 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[199]
Sadeghi E, Rahmanipour E, Valsecchi N et al.. “An update on ocular effects of antidiabetic medications.” Survey of ophthalmology (2025). PMID: 39855606 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
[200]
Sivaprasad S, Gupta B, Crosby-Nwaobi R et al.. “Prevalence of diabetic retinopathy in various ethnic groups: a worldwide perspective.” Survey of ophthalmology (2012). PMID: 22542913 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
[201]
Tan R, Shahidzadeh A, Collazo A et al.. “The Association of Retinal Capillary Density and Retinal Thickness in Diabetic Retinopathy.” Investigative ophthalmology & visual science (2025). PMID: 41182028 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup
[202]
Shah J, Zhuang K, Kakihara S et al.. “Understanding How Low Luminance Visual Deficit Progresses With Advancing Diabetic Macular Ischemia and Diabetic Retinopathy.” Investigative ophthalmology & visual science (2025). PMID: 41134256 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Long-term & Definitive Management
[203]
Wang Q, Wang YX, Wu SL et al.. “Ocular Axial Length and Diabetic Retinopathy: The Kailuan Eye Study.” Investigative ophthalmology & visual science (2019). PMID: 31469896 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors
[204]
Prasad R, Asare-Bediko B, Harbour A et al.. “Microbial Signatures in The Rodent Eyes With Retinal Dysfunction and Diabetic Retinopathy.” Investigative ophthalmology & visual science (2022). PMID: 34985498 ↗
L5OTHERCited in: Epidemiology, Etiology & Risk Factors
[205]
Chen Y, Xiong R, Zhang J et al.. “Ten-Year Change in Visual Function and Incidence of Visual Impairment in Highly Myopic Children and Adults.” Investigative ophthalmology & visual science (2025). PMID: 39745680 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation
[206]
Klein R, Klein BE. “The prevalence of age-related eye diseases and visual impairment in aging: current estimates.” Investigative ophthalmology & visual science (2013). PMID: 24335069 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
[207]
Oncel D, Minaker S, Shepherd EA et al.. “RISK FACTORS FOR PROLIFERATIVE VITREORETINOPATHY IN A LARGE CLINICAL DATABASE.” Retina (Philadelphia, Pa.) (2025). PMID: 39752596 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Acute & Vision-Threatening Management, Special Populations, Screening & Prevention
[208]
Borrelli E, Palmieri M, Viggiano P et al.. “PHOTORECEPTOR DAMAGE IN DIABETIC CHOROIDOPATHY.” Retina (Philadelphia, Pa.) (2020). PMID: 30986798 ↗
L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup
[209]
Timtim E, Ji X, Bejjani R et al.. “Progression, Treatment, and Outcomes of Retinal Vascular Diseases in Pregnancy.” Retina (Philadelphia, Pa.) (2025). PMID: 40239168 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Surgical, Laser & Procedural Considerations, Special Populations, Screening & Prevention
[210]
Talebi R, Fortes BH, Yu F et al.. “Real-world Associations Between GLP-1 Receptor Agonist Use and Diabetic Retinopathy Accounting for Longitudinal Glycemic Control.” Retina (Philadelphia, Pa.) (2025). PMID: 40334190 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Prognosis & Natural History
[211]
Fu JJ, Applebaum SS, Granados A et al.. “Diabetic retinopathy treatment cascade and care continuum in the USA: a systematic review.” BMJ open (2026). PMID: 42270111 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Long-term & Definitive Management, Special Populations, Screening & Prevention
[212]
Jiang J, Guo W, Ding Z. “Risk factors for the occurrence and progression of diabetic retinopathy in children and adolescents: a systematic review and meta-analysis.” Frontiers in public health (2026). PMID: 42254634 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations, Special Populations, Screening & Prevention
[213]
Chen KY, Chan HC, Chan CM. “Efficacy and safety of AAV-mediated gene therapy for choroideremia: a systematic review and meta-analysis.” EClinicalMedicine (2026). PMID: 42180403 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Acute & Vision-Threatening Management
[214]
West SD, Turnbull C. “Obstructive sleep apnoea.” Eye (London, England) (2018). PMID: 29391572 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
[215]
Irodi A, Zhu Z, Grzybowski A et al.. “The evolution of diabetic retinopathy screening.” Eye (London, England) (2025). PMID: 39910282 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations, Special Populations, Screening & Prevention
[216]
Cheon S, Kim Y, Kang ES et al.. “Noncombustible Nicotine or Tobacco Product Use after Smoking Cessation and Major Vision-Impairing Diseases: A Nationwide Cohort Study.” American journal of ophthalmology (2026). PMID: 42288324 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup
[217]
Wang Y, Zang B, Zhao J et al.. “Triglyceride-Glucose Indexes Are Predictive of Early and Severe Diabetic Retinal Microvascular Abnormalities: A Prospective Cohort Study.” Ophthalmology science (2026). PMID: 42199730 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Surgical, Laser & Procedural Considerations
[218]
Ul-Haq I, Alqahtani HS, Shaheen NA et al.. “Incidence and Risk Factors of Diabetic Retinopathy in Patients with Type 1 Diabetes Mellitus: A Retrospective Study in NGHA, Riyadh, Saudi Arabia.” Journal of clinical medicine (2026). PMID: 42194771 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations, Special Populations, Screening & Prevention
[219]
Aiello LP, Beck RW, Bressler NM et al.. “Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema.” Ophthalmology (2011). PMID: 22136692 ↗
L5GUIDELINECited in: Clinical Presentation, Prognosis & Natural History
[220]
Heier JS, Brown DM, Chong V et al.. “Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.” Ophthalmology (2012). PMID: 23084240 ↗
L1RCTCited in: Clinical Presentation, Diagnosis & Workup, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
[221]
Holekamp NM, Campochiaro PA, Chang MA et al.. “Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.” Ophthalmology (2021). PMID: 34597713 ↗
L1RCTCited in: Clinical Presentation, Diagnosis & Workup, Acute & Vision-Threatening Management, Long-term & Definitive Management, Prognosis & Natural History, Special Populations, Screening & Prevention
[222]
Hillier RJ, Felfeli T, Berger AR et al.. “The Pneumatic Retinopexy versus Vitrectomy for the Management of Primary Rhegmatogenous Retinal Detachment Outcomes Randomized Trial (PIVOT).” Ophthalmology (2018). PMID: 30468761 ↗
L1RCTCited in: Clinical Presentation, Diagnosis & Workup, Acute & Vision-Threatening Management, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
[223]
Sahni J, Patel SS, Dugel PU et al.. “Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial.” Ophthalmology (2019). PMID: 30905643 ↗
L1RCTCited in: Clinical Presentation, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[224]
Lam BL, Pennesi ME, Kay CN et al.. “Assessment of Visual Function with Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa in the Randomized XIRIUS Phase 2/3 Study.” Ophthalmology (2024). PMID: 38423215 ↗
L1RCTCited in: Clinical Presentation, Diagnosis & Workup, Long-term & Definitive Management
[225]
Mitchell P, Wong TY. “Management paradigms for diabetic macular edema.” American journal of ophthalmology (2013). PMID: 24269850 ↗
L5GUIDELINECited in: Clinical Presentation, Diagnosis & Workup, Acute & Vision-Threatening Management, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
[226]
Brown DM, Wykoff CC, Boyer D et al.. “Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial.” JAMA ophthalmology (2021). PMID: 34351414 ↗
L1RCTCited in: Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
[227]
Lee WK, Iida T, Ogura Y et al.. “Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial.” JAMA ophthalmology (2018). PMID: 29801063 ↗
L1RCTCited in: Clinical Presentation, Diagnosis & Workup, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
[228]
Gross JG, Glassman AR, Liu D et al.. “Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.” JAMA ophthalmology (2018). PMID: 30043039 ↗
L1RCTCited in: Clinical Presentation, Diagnosis & Workup, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
[229]
Maguire MJ, Laidlaw A, Hammond C et al.. “Vitrectomy as an Adjunct to Treat-and-Extend Anti-VEGF Injections for Diabetic Macular Edema: The Vitrectomy in Diabetic Macular Oedema (VIDEO) Randomized Clinical Trial.” JAMA ophthalmology (2024). PMID: 39115867 ↗
L1RCTCited in: Clinical Presentation, Diagnosis & Workup, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
[230]
Pieramici DJ, Awh CC, Chang M et al.. “Port Delivery System With Ranibizumab vs Monitoring in Nonproliferative Diabetic Retinopathy Without Macular Edema: The Pavilion Randomized Clinical Trial.” JAMA ophthalmology (2025). PMID: 40048178 ↗
L1RCTCited in: Clinical Presentation, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Long-term & Definitive Management, Prognosis & Natural History
[231]
Chhablani J, Sambhana S, Mathai A et al.. “Clinical efficacy of navigated panretinal photocoagulation in proliferative diabetic retinopathy.” American journal of ophthalmology (2015). PMID: 25703478 ↗
L1RCTCited in: Clinical Presentation
[232]
Trejo Corona S, Villanueva Boone C, Ali AM et al.. “Randomized Trial of Treat-and-Extend Intravitreal Aflibercept for Radiation Retinopathy: 1-Year Outcomes.” Investigative ophthalmology & visual science (2023). PMID: 37351877 ↗
L1RCTCited in: Clinical Presentation, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
[233]
Ng Yin Ling C, Seshasai S, Chee ML et al.. “Visual Impairment, Major Eye Diseases, and Mortality in a Multi-Ethnic Asian Population and a Meta-analysis of Prospective Studies.” American journal of ophthalmology (2021). PMID: 33965416 ↗
L2SR_OBSCited in: Clinical Presentation
[234]
Zhao LQ, Zhu H, Zhao PQ et al.. “A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy.” The British journal of ophthalmology (2011). PMID: 21278146 ↗
L2SR_OBSCited in: Clinical Presentation, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
[235]
Murakami T, Kato S, Shigeeda T et al.. “Intensive treat-to-target statin therapy and severity of diabetic retinopathy complicated by hypercholesterolaemia.” Eye (London, England) (2020). PMID: 33106609 ↗
L1RCTCited in: Clinical Presentation
[236]
Nanji K, Hatamnejad A, Grad J et al.. “Visual outcomes associated with optical coherence tomography biomarkers in diabetic macular edema: A systematic review.” Survey of ophthalmology (2025). PMID: 40967513 ↗
L2SR_OBSCited in: Clinical Presentation
[237]
Sarohia GS, Nanji K, Khan M et al.. “Treat-and-extend versus alternate dosing strategies with anti-vascular endothelial growth factor agents to treat center involving diabetic macular edema: A systematic review and meta-analysis of 2,346 eyes.” Survey of ophthalmology (2022). PMID: 35476929 ↗
L1SR_OBSCited in: Clinical Presentation, Prognosis & Natural History
[238]
Jackson TL, Haller J, Blot KH et al.. “Ocriplasmin for treatment of vitreomacular traction and macular hole: A systematic literature review and individual participant data meta-analysis of randomized, controlled, double-masked trials.” Survey of ophthalmology (2021). PMID: 34480895 ↗
L1SR_OBSCited in: Clinical Presentation, Prognosis & Natural History
[239]
Bowe T, Mahmoudzadeh R, Soares RR et al.. “CHARACTERISTICS OF PARTICIPANTS IN DIABETIC RETINOPATHY CLINICAL RESEARCH CLINICAL TRIALS WHO WERE LOST TO FOLLOW-UP.” Retina (Philadelphia, Pa.) (2024). PMID: 37603443 ↗
L2TRIAL_NONRANDOMCited in: Clinical Presentation
[240]
Chaudhary V, Sarohia GS, Phillips MR et al.. “Role of anti-vascular endothelial growth factor in the management of non-proliferative diabetic retinopathy without centre-involving diabetic macular oedema: a meta-analysis of trials.” Eye (London, England) (2022). PMID: 36369263 ↗
L1SR_OBSCited in: Clinical Presentation
[241]
Tomkins-Netzer O, Ismetova F, Bar A et al.. “Functional outcome of macular edema in different retinal disorders.” Progress in retinal and eye research (2015). PMID: 26014685 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[242]
Nowak-Sliwinska P, van den Bergh H, Sickenberg M et al.. “Photodynamic therapy for polypoidal choroidal vasculopathy.” Progress in retinal and eye research (2013). PMID: 24140257 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Long-term & Definitive Management
[243]
Kaur C, Foulds WS, Ling EA. “Blood-retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management.” Progress in retinal and eye research (2008). PMID: 18940262 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[244]
Yusuf AM, Bizrah M, Bunce C et al.. “Surgery for idiopathic epiretinal membrane.” The Cochrane database of systematic reviews (2021). PMID: 33760235 ↗
L1SR_OBSCited in: Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations
[245]
Do DV, Gichuhi S, Vedula SS et al.. “Surgery for post-vitrectomy cataract.” The Cochrane database of systematic reviews (2013). PMID: 24357418 ↗
L1SR_OBSCited in: Clinical Presentation, Diagnosis & Workup, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
[246]
Zhang HW, Zhang H, Grant SJ et al.. “Single herbal medicine for diabetic retinopathy.” The Cochrane database of systematic reviews (2018). PMID: 30566763 ↗
L1SR_OBSCited in: Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management
[247]
Anguita R, Ferro Desideri L, Schwember P et al.. “Early Versus Delayed Vitrectomy for Vitreous Hemorrhage Secondary to Proliferative Diabetic Retinopathy.” American journal of ophthalmology (2024). PMID: 39471907 ↗
L2OTHERCited in: Clinical Presentation, Diagnosis & Workup, Acute & Vision-Threatening Management, Long-term & Definitive Management, Prognosis & Natural History
[248]
Pas JAAH, Valkenburg D, Li CHZ et al.. “The Visual Acuity Course in Stargardt Disease.” American journal of ophthalmology (2025). PMID: 40714056 ↗
L2OTHERCited in: Clinical Presentation, Long-term & Definitive Management
[249]
Watanabe T, Keino H, Nakayama K et al.. “Clinical features of patients with diabetic anterior uveitis.” The British journal of ophthalmology (2018). PMID: 29563110 ↗
L4OTHERCited in: Clinical Presentation
[250]
Wolf S, Chen Y, Li X et al.. “Brolucizumab in the Treatment of Proliferative Diabetic Retinopathy: The CONDOR Randomized Clinical Trial.” JAMA ophthalmology (2026). PMID: 42024409 ↗
L1RCTCited in: Clinical Presentation, Prognosis & Natural History
[251]
Sinclair SH, Schwartz S. “Diabetic retinopathy: New concepts of screening, monitoring, and interventions.” Survey of ophthalmology (2024). PMID: 38964559 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Special Populations, Screening & Prevention
[252]
Chang JH, Garg NK, Lunde E et al.. “Corneal neovascularization: an anti-VEGF therapy review.” Survey of ophthalmology (2012). PMID: 22898649 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Long-term & Definitive Management
[253]
Chen XD, Gardner TW. “A critical review: Psychophysical assessments of diabetic retinopathy.” Survey of ophthalmology (2020). PMID: 32866468 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[254]
Kakihara S, Busza A, Yamaguchi TC et al.. “Posterior Retinal Ischemia Correlates With Vision in Patients With Diabetes.” Investigative ophthalmology & visual science (2025). PMID: 40455041 ↗
L4OTHERCited in: Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification
[255]
Lu ZL, Zhao Y, Lesmes LA et al.. “Quantifying the Functional Relationship Between Visual Acuity and Contrast Sensitivity Function.” Investigative ophthalmology & visual science (2024). PMID: 39436371 ↗
L4OTHERCited in: Clinical Presentation
[256]
Ramtohul P, Au A, Kunkler AL et al.. “CENTRAL BOUQUET HEMORRHAGE: Clinical and Multimodal Imaging Features.” Retina (Philadelphia, Pa.) (2024). PMID: 38109663 ↗
L4OTHERCited in: Clinical Presentation, Long-term & Definitive Management
[257]
Lee T, Robbins CB, Wisely CE et al.. “CLINICAL CHARACTERISTICS AND VISUAL OUTCOMES IN ENDOPHTHALMITIS AFTER KERATOPROSTHESIS IMPLANTATION.” Retina (Philadelphia, Pa.) (2022). PMID: 34483314 ↗
L4OTHERCited in: Clinical Presentation, Acute & Vision-Threatening Management
[258]
Rohowetz LJ, Shaheen A, Magraner M et al.. “SURGICAL OUTCOMES IN CONCURRENT SICKLE CELL AND DIABETIC RETINOPATHY.” Retina (Philadelphia, Pa.) (2024). PMID: 39167577 ↗
L4OTHERCited in: Clinical Presentation, Diagnosis & Workup, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
[259]
Shiraki A, Hara C, Akasaka H et al.. “Effect of Nicotinamide Mononucleotide on Retinal Thickness of Older Patients With Diabetes Mellitus: A Placebo-Controlled, Double-Blind Study.” Geriatrics & gerontology international (2026). PMID: 42082179 ↗
L2RCTCited in: Clinical Presentation, Prognosis & Natural History
[260]
Shao Y, Li H, Xu S et al.. “Efficacy of traditional Chinese medicine combined with Western drugs for the treatment of non-proliferative diabetic retinopathy: a meta-analysis.” Frontiers in medicine (2026). PMID: 42100286 ↗
L1SR_OBSCited in: Clinical Presentation
[261]
Yang Q, Teo KYC, Hong Y et al.. “Flow and ischemic changes in retina and choroid across diabetic retinopathy spectrum: a SS-OCTA study.” Eye (London, England) (2025). PMID: 40016519 ↗
L4OTHERCited in: Clinical Presentation
[262]
Bikbov MM, Kazakbaeva GM, Rakhimova EM et al.. “Mortality and ocular parameters and diseases.” Eye (London, England) (2025). PMID: 39856428 ↗
L2OTHERCited in: Clinical Presentation
[263]
Liu Y, Huang J, Ao M et al.. “Real-world effect of vitrectomy combined with intravitreal conbercept for treatment of vitreous haemorrhage in proliferative diabetic retinopathy (QILIN I): a prospective cohort study.” The British journal of ophthalmology (2026). PMID: 41986090 ↗
L2COHORTCited in: Clinical Presentation
[264]
Markan A, Agarwal A, Katoch D et al.. “Assessing the Role of Statins as an Adjunctive Anti-VEGF Therapy for Clinically Significant Macular Edema (CSME) in Type 2 Diabetes Mellitus.” Romanian journal of ophthalmology (2025). PMID: 41971206 ↗
L1RCTCited in: Clinical Presentation
[265]
Zarbin M, Tabano D, Ahmed A et al.. “Efficacy of Faricimab versus Aflibercept in Diabetic Macular Edema in the 20/50 or Worse Vision Subgroup in Phase III YOSEMITE and RHINE Trials.” Ophthalmology (2024). PMID: 38852921 ↗
L1RCTCited in: Diagnosis & Workup, Long-term & Definitive Management, Prognosis & Natural History
[266]
Levin LA, Bhatti MT, Klier S et al.. “A Randomized Sham-Controlled Phase 2/3 Trial of QPI-1007 for Acute Nonarteritic Anterior Ischemic Optic Neuropathy.” Ophthalmology (2025). PMID: 40816607 ↗
L1RCTCited in: Diagnosis & Workup, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations, Special Populations, Screening & Prevention
[267]
Zayed MG, Karsan W, Peto T et al.. “Diabetic Retinopathy and Quality of Life: A Systematic Review and Meta-Analysis.” JAMA ophthalmology (2024). PMID: 38300578 ↗
L2SR_OBSCited in: Diagnosis & Workup, Severity, Staging & Risk Stratification
[268]
Blinder KJ, Wykoff CC, Ferencz JR et al.. “IMPACT OF THE DEXAMETHASONE IMPLANT ON SLOWING DIABETIC RETINOPATHY PROGRESSION: Post Hoc Analysis of the MEAD Study.” Retina (Philadelphia, Pa.) (2025). PMID: 40712145 ↗
L1RCTCited in: Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Prognosis & Natural History
[269]
Endo H, Kase S, Saito M et al.. “Choroidal Thickness in Diabetic Patients Without Diabetic Retinopathy: A Meta-analysis.” American journal of ophthalmology (2020). PMID: 32574782 ↗
L2SR_OBSCited in: Diagnosis & Workup
[270]
Wang TW, Luo WT, Tu YK et al.. “Diagnostic Accuracy of EyeArt for Fundus-Based Detection of Diabetic Retinopathy: A Systematic Review and Meta-analysis.” American journal of ophthalmology (2025). PMID: 41052568 ↗
L2SR_OBSCited in: Diagnosis & Workup, Special Populations, Screening & Prevention
[271]
Joseph S, Selvaraj J, Mani I et al.. “Diagnostic Accuracy of Artificial Intelligence-Based Automated Diabetic Retinopathy Screening in Real-World Settings: A Systematic Review and Meta-Analysis.” American journal of ophthalmology (2024). PMID: 38438095 ↗
L2SR_OBSCited in: Diagnosis & Workup, Special Populations, Screening & Prevention
[272]
Shi L, Wu H, Dong J et al.. “Telemedicine for detecting diabetic retinopathy: a systematic review and meta-analysis.” The British journal of ophthalmology (2015). PMID: 25563767 ↗
L2SR_OBSCited in: Diagnosis & Workup, Special Populations, Screening & Prevention
[273]
Wong TY, Sun J, Kawasaki R et al.. “Guidelines on Diabetic Eye Care: The International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings.” Ophthalmology (2018). PMID: 29776671 ↗
L1REVIEW_NARRATIVECited in: Diagnosis & Workup, Long-term & Definitive Management, Special Populations, Screening & Prevention
[274]
Xu S, Ruan Z, Wang Y et al.. “Establishment of Myopia Occurrence Prediction Model in Children without Myopia Using Cycloplegic Refraction and Prior Axial Length Change.” Ophthalmology (2025). PMID: 40516576 ↗
L2OTHERCited in: Diagnosis & Workup, Long-term & Definitive Management
[275]
Varghese D, Abdelsalam D, Ibrahim S et al.. “Too much of a good thing.” Survey of ophthalmology (2026). PMID: 41520798 ↗
L4CASE_REPORTCited in: Diagnosis & Workup, Acute & Vision-Threatening Management
[276]
Cozzi M, Ziegler A, Fasler K et al.. “Sterile Intraocular Inflammation Associated With Faricimab.” JAMA ophthalmology (2024). PMID: 39388167 ↗
L4OTHERCited in: Diagnosis & Workup, Long-term & Definitive Management
[277]
Tesfaye H, Paik JM, Roh M et al.. “Empagliflozin and the Risk of Retinopathy in Patients With Type 2 Diabetes.” JAMA ophthalmology (2025). PMID: 39636645 ↗
L2OTHERCited in: Diagnosis & Workup
[278]
Spaide RF, Fujimoto JG, Waheed NK et al.. “Optical coherence tomography angiography.” Progress in retinal and eye research (2017). PMID: 29229445 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup
[279]
Waheed NK, Rosen RB, Jia Y et al.. “Optical coherence tomography angiography in diabetic retinopathy.” Progress in retinal and eye research (2023). PMID: 37499857 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management
[280]
Savastano MC, Rizzo C, Fossataro C et al.. “Artificial intelligence in ophthalmology: Progress, challenges, and ethical implications.” Progress in retinal and eye research (2025). PMID: 40473198 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Special Populations, Screening & Prevention
[281]
Jia Y, Hormel TT, Hwang TS et al.. “Widefield OCT angiography.” Progress in retinal and eye research (2025). PMID: 40517946 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup
[282]
Dysli C, Wolf S, Berezin MY et al.. “Fluorescence lifetime imaging ophthalmoscopy.” Progress in retinal and eye research (2017). PMID: 28673870 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Acute & Vision-Threatening Management
[283]
Virgili G, Menchini F, Casazza G et al.. “Optical coherence tomography (OCT) for detection of macular oedema in patients with diabetic retinopathy.” The Cochrane database of systematic reviews (2015). PMID: 25564068 ↗
L1SR_OBSCited in: Diagnosis & Workup, Special Populations, Screening & Prevention
[284]
Evans JR, Michelessi M, Virgili G. “Laser photocoagulation for proliferative diabetic retinopathy.” The Cochrane database of systematic reviews (2014). PMID: 25420029 ↗
L1SR_OBSCited in: Diagnosis & Workup, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[285]
Sarwar S, Clearfield E, Soliman MK et al.. “Aflibercept for neovascular age-related macular degeneration.” The Cochrane database of systematic reviews (2016). PMID: 26857947 ↗
L1SR_OBSCited in: Diagnosis & Workup, Special Populations, Screening & Prevention
[286]
Wang LZ, Cheung CY, Tapp RJ et al.. “Availability and variability in guidelines on diabetic retinopathy screening in Asian countries.” The British journal of ophthalmology (2017). PMID: 28292772 ↗
L2REVIEW_NARRATIVECited in: Diagnosis & Workup, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations, Special Populations, Screening & Prevention
[287]
Gupta P, Gan ATL, Man REK et al.. “Association between diabetic retinopathy and incident cognitive impairment.” The British journal of ophthalmology (2019). PMID: 31645330 ↗
L2OTHERCited in: Diagnosis & Workup, Severity, Staging & Risk Stratification, Prognosis & Natural History
[288]
Lee PK, Ra H, Baek J. “Automated segmentation of ultra-widefield fluorescein angiography of diabetic retinopathy using deep learning.” The British journal of ophthalmology (2023). PMID: 36241374 ↗
L3OTHERCited in: Diagnosis & Workup
[289]
Ghasemi Falavarjani K, Al-Sheikh M, Akil H et al.. “Image artefacts in swept-source optical coherence tomography angiography.” The British journal of ophthalmology (2016). PMID: 27439739 ↗
L4OTHERCited in: Diagnosis & Workup
[290]
Stino H, Niederleithner M, Iby J et al.. “Detection of diabetic neovascularisation using single-capture 65°-widefield optical coherence tomography angiography.” The British journal of ophthalmology (2023). PMID: 36376062 ↗
L3OTHERCited in: Diagnosis & Workup
[291]
Sultan MB, Starita C, Huang K. “Epidemiology, risk factors and management of paediatric diabetic retinopathy.” The British journal of ophthalmology (2012). PMID: 22241926 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Acute & Vision-Threatening Management, Surgical, Laser & Procedural Considerations
[292]
Parravano M, Cennamo G, Di Antonio L et al.. “Multimodal imaging in diabetic retinopathy and macular edema: An update about biomarkers.” Survey of ophthalmology (2024). PMID: 38942124 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Severity, Staging & Risk Stratification
[293]
Nouri H, Abtahi SH, Mazloumi M et al.. “Optical coherence tomography angiography in diabetic retinopathy: A major review.” Survey of ophthalmology (2024). PMID: 38521424 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup
[294]
McAnany JJ, Persidina OS, Park JC. “Clinical electroretinography in diabetic retinopathy: a review.” Survey of ophthalmology (2021). PMID: 34487740 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Acute & Vision-Threatening Management, Prognosis & Natural History
[295]
Sambhav K, Grover S, Chalam KV. “The application of optical coherence tomography angiography in retinal diseases.” Survey of ophthalmology (2017). PMID: 28579550 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup
[296]
Pujari A, Bhaskaran K, Sharma P et al.. “Optical coherence tomography angiography in neuro-ophthalmology: Current clinical role and future perspectives.” Survey of ophthalmology (2020). PMID: 33157113 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup
[297]
Lai C, Su T, Cao J et al.. “Retinal Neurovascular Impairment in Full-Course Diabetic Retinopathy: The Guangdong Diabetic Retinopathy Multiple-Omics Study.” Investigative ophthalmology & visual science (2024). PMID: 39656471 ↗
L3OTHERCited in: Diagnosis & Workup, Long-term & Definitive Management
[298]
Sadeghi E, Du K, Ajayi O et al.. “Three-Dimensional Choroidal Vessels Assessment in Diabetic Retinopathy.” Investigative ophthalmology & visual science (2025). PMID: 40131298 ↗
L3OTHERCited in: Diagnosis & Workup
[299]
Zhou L, Fan S, Lu H et al.. “Retinal and Choriocapillaris Thickness Changes in Spontaneously Diabetic Macaques.” Investigative ophthalmology & visual science (2025). PMID: 39908131 ↗
L3OTHERCited in: Diagnosis & Workup
[300]
Wang J, Hormel T, Park DW et al.. “Quantifying Choriocapillaris Flow Deficits in Diabetic Retinopathy Using Projection-Resolved OCT Angiography.” Investigative ophthalmology & visual science (2025). PMID: 40905756 ↗
L4OTHERCited in: Diagnosis & Workup
[301]
Liu H, Tang J, Lee CA et al.. “Metanx and early stages of diabetic retinopathy.” Investigative ophthalmology & visual science (2015). PMID: 25574044 ↗
L2OTHERCited in: Diagnosis & Workup, Acute & Vision-Threatening Management
[302]
Kakihara S, Zhuang K, AbdelSalam M et al.. “The Importance of Matching Optical Coherence Tomography Angiography Metrics to Diabetic Retinopathy Severity for Detecting Progression.” Investigative ophthalmology & visual science (2025). PMID: 40838939 ↗
L2OTHERCited in: Diagnosis & Workup
[303]
Spaide RF, Barquet LA. “RETINAL CAPILLARY MACROANEURYSMS.” Retina (Philadelphia, Pa.) (2019). PMID: 30489449 ↗
L4OTHERCited in: Diagnosis & Workup, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[304]
Kesim C, Bektas SN, Kulali Z et al.. “HENLE FIBER LAYER MAPPING WITH DIRECTIONAL OPTICAL COHERENCE TOMOGRAPHY.” Retina (Philadelphia, Pa.) (2022). PMID: 35504010 ↗
L4OTHERCited in: Diagnosis & Workup
[305]
Hwang TS, Jia Y, Gao SS et al.. “OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY FEATURES OF DIABETIC RETINOPATHY.” Retina (Philadelphia, Pa.) (2015). PMID: 26308529 ↗
L4OTHERCited in: Diagnosis & Workup
[306]
Tavares Ferreira J, Vicente A, Proença R et al.. “CHOROIDAL THICKNESS IN DIABETIC PATIENTS WITHOUT DIABETIC RETINOPATHY.” Retina (Philadelphia, Pa.) (2018). PMID: 28267113 ↗
L2OTHERCited in: Diagnosis & Workup
[307]
Le D, Son T, Lim JI et al.. “QUANTITATIVE OPTICAL COHERENCE TOMOGRAPHY REVEALS ROD PHOTORECEPTOR DEGENERATION in EARLY DIABETIC RETINOPATHY.” Retina (Philadelphia, Pa.) (2022). PMID: 35316256 ↗
L2OTHERCited in: Diagnosis & Workup
[308]
Lin CC, Cheng CK, Peng PH et al.. “REAL-WORLD PRACTICE OF ARTIFICIAL INTELLIGENCE DIAGNOSTIC SYSTEM FOR DIABETIC RETINOPATHY IN TAIWAN.” Retina (Philadelphia, Pa.) (2026). PMID: 41818422 ↗
L3OTHERCited in: Diagnosis & Workup, Special Populations, Screening & Prevention
[309]
Rohart C, Le HM, Estrada-Walker J et al.. “LONG-TERM PROGNOSIS OF CHOROIDAL NEOVASCULARIZATION COMPLICATING ANGIOID STREAKS.” Retina (Philadelphia, Pa.) (2023). PMID: 36727798 ↗
L3OTHERCited in: Diagnosis & Workup, Acute & Vision-Threatening Management, Long-term & Definitive Management, Prognosis & Natural History
[310]
KamaliZonouzi S, Semnani F, Mahiny D et al.. “Retinal and choroidal optical coherence tomography findings in gestational diabetes mellitus: a systematic review and meta-analysis.” Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2026). PMID: 42270918 ↗
L1SR_OBSCited in: Diagnosis & Workup
[311]
Mikhail D, Tao BK, Yu P et al.. “Risk of Retinal Detachment After Intravitreal Injection of Anti-VEGF: A Systematic Review and Meta-Analysis.” American journal of ophthalmology (2026). PMID: 42219076 ↗
L1SR_OBSCited in: Diagnosis & Workup, Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
[312]
Sun Z, Yang D, Tang Z et al.. “Optical coherence tomography angiography in diabetic retinopathy: an updated review.” Eye (London, England) (2020). PMID: 33099579 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup
[313]
Zhao X, Lin S, Lu L et al.. “Associations between sleep patterns and diabetic retinopathy: insights from cross-sectional and longitudinal evidence.” Eye (London, England) (2025). PMID: 41102556 ↗
L2OTHERCited in: Diagnosis & Workup
[314]
Ong JX, Fawzi AA. “Perspectives on diabetic retinopathy from advanced retinal vascular imaging.” Eye (London, England) (2022). PMID: 34987198 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Prognosis & Natural History
[315]
Hormenu T, Antiri EO, Ocansey S et al.. “Impact of physical activity on visual outcomes among persons with type 2 diabetes: A scoping review of randomized controlled trials.” Dialogues in health (2026). PMID: 42238251 ↗
L2RCTCited in: Diagnosis & Workup, Severity, Staging & Risk Stratification, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[316]
Xiang F, Li M, Li R et al.. “Macular microcirculation changes in incident type 2 diabetes without fundus Photography-Detectable diabetic Retinopathy: A 6-Year nested Case-Control study.” Diabetes research and clinical practice (2026). PMID: 42361856 ↗
L3CASE_CONTROLCited in: Diagnosis & Workup
[317]
Li X, Yang L, Long H et al.. “Baseline predictors of visual response and treatment burden after ranibizumab therapy in macular edema secondary to retinal vein occlusion.” Frontiers in medicine (2026). PMID: 42359082 ↗
L3OTHERCited in: Diagnosis & Workup, Long-term & Definitive Management
[318]
Yan M, Zhang X, Li R et al.. “Automated Identification and Segmentation of Diabetic Macular Edema Subtypes Using Deep Learning.” Translational vision science & technology (2026). PMID: 42345636 ↗
L4OTHERCited in: Diagnosis & Workup
[319]
Zheng C, Liu Y, Ling R et al.. “Widefield SS-OCTA-detected retinal vascular changes and their correlation with DME in diabetes.” Frontiers in endocrinology (2026). PMID: 42339092 ↗
L2OTHERCited in: Diagnosis & Workup
[320]
He Q, Jiang H, Fang D et al.. “A Graph Neural Network-Based Multispectral-View Learning Model for Diabetic Macular Ischemia Detection From Color Fundus Photographs.” Translational vision science & technology (2026). PMID: 42334126 ↗
L4OTHERCited in: Diagnosis & Workup, Special Populations, Screening & Prevention
[321]
Ip MS, Zhang J, Ehrlich JS. “The Clinical Importance of Changes in Diabetic Retinopathy Severity Score.” Ophthalmology (2017). PMID: 28284785 ↗
L1RCTCited in: Severity, Staging & Risk Stratification
[322]
Ehlers JP, Josic K, Aiello LP et al.. “Ultra-Widefield Fluorescein Angiographic Quantitative Leakage Parameters and Clinical Outcomes in Nonproliferative Diabetic Retinopathy.” JAMA ophthalmology (2026). PMID: 41609778 ↗
L2RCTCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management
[323]
Sasako T, Ueki K, Miyoshi K et al.. “Effect of a Multifactorial Intervention on Retinopathy in People With Type 2 Diabetes: A Secondary Analysis of the J-DOIT3 Randomized Clinical Trial.” JAMA ophthalmology (2025). PMID: 41129145 ↗
L1RCTCited in: Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Long-term & Definitive Management, Special Populations, Screening & Prevention
[324]
Hou XW, Wang Y, Pan CW. “Metabolomics in Diabetic Retinopathy: A Systematic Review.” Investigative ophthalmology & visual science (2021). PMID: 34347011 ↗
L2SR_OBSCited in: Severity, Staging & Risk Stratification, Surgical, Laser & Procedural Considerations
[325]
Feng Y, Zhu S, Skiadaresi E et al.. “PHACOEMULSIFICATION CATARACT SURGERY WITH PROPHYLACTIC INTRAVITREAL BEVACIZUMAB FOR PATIENTS WITH COEXISTING DIABETIC RETINOPATHY: A Meta-Analysis.” Retina (Philadelphia, Pa.) (2019). PMID: 29975344 ↗
L1SR_OBSCited in: Severity, Staging & Risk Stratification, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
[326]
Xu H, Chen M, Forrester JV. “Para-inflammation in the aging retina.” Progress in retinal and eye research (2009). PMID: 19560552 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification
[327]
Moutray T, Evans JR, Lois N et al.. “Different lasers and techniques for proliferative diabetic retinopathy.” The Cochrane database of systematic reviews (2018). PMID: 29543992 ↗
L1SR_OBSCited in: Severity, Staging & Risk Stratification, Acute & Vision-Threatening Management, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[328]
Lopes de Jesus CC, Atallah AN, Valente O et al.. “Pentoxifylline for diabetic retinopathy.” The Cochrane database of systematic reviews (2008). PMID: 18425965 ↗
L1SR_OBSCited in: Severity, Staging & Risk Stratification, Prognosis & Natural History
[329]
Lin Z, Wen L, Wang Y et al.. “Incidence, progression and regression of diabetic retinopathy in a northeastern Chinese population.” The British journal of ophthalmology (2022). PMID: 35864776 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification
[330]
Cheung N, Chee ML, Klein R et al.. “Incidence and progression of diabetic retinopathy in a multi-ethnic US cohort: the Multi-Ethnic Study of Atherosclerosis.” The British journal of ophthalmology (2021). PMID: 33741582 ↗
L2OTHERCited in: Severity, Staging & Risk Stratification
[331]
Benet D, Pellicer-Valero OJ. “Artificial intelligence: the unstoppable revolution in ophthalmology.” Survey of ophthalmology (2021). PMID: 33741420 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification, Special Populations, Screening & Prevention
[332]
Wang J, Yin Z, Yang J et al.. “BCAT1 Activation Reprograms Branched-Chain Amino Acid Metabolism and Epigenetically Promotes Inflammation in Diabetic Retinopathy.” Investigative ophthalmology & visual science (2025). PMID: 40530920 ↗
L5OTHERCited in: Severity, Staging & Risk Stratification, Special Populations, Screening & Prevention
[333]
Majidova SR. “Evaluation of Hypoxia and Microcirculation Factors in the Progression of Diabetic Retinopathy.” Investigative ophthalmology & visual science (2024). PMID: 38241030 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification
[334]
Anatriello A, Liguori V, Cagnotta C et al.. “Ocular disorders during treatment with GLP-1 receptor agonists: a systematic review and meta-analysis of observational studies.” Frontiers in pharmacology (2026). PMID: 42311413 ↗
L2SR_OBSCited in: Severity, Staging & Risk Stratification, Surgical, Laser & Procedural Considerations
[335]
Wykoff CC, Yu HJ, Avery RL et al.. “Retinal non-perfusion in diabetic retinopathy.” Eye (London, England) (2022). PMID: 35017700 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification, Prognosis & Natural History
[336]
Sun JK, Wang PW, Taylor S et al.. “Durability of Diabetic Retinopathy Improvement with As-Needed Ranibizumab: Open-Label Extension of RIDE and RISE Studies.” Ophthalmology (2018). PMID: 30419298 ↗
L2RCTCited in: Acute & Vision-Threatening Management
[337]
Regillo C, Berger B, Brooks L et al.. “Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results.” Ophthalmology (2023). PMID: 36870451 ↗
L1RCTCited in: Acute & Vision-Threatening Management
[338]
Wykoff CC, Croft DE, Brown DM et al.. “Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results.” Ophthalmology (2015). PMID: 26391465 ↗
L1RCTCited in: Acute & Vision-Threatening Management
[339]
Yu HJ, Ehlers JP, Sevgi DD et al.. “Real-Time Photographic- and Fluorescein Angiographic-Guided Management of Diabetic Retinopathy: Randomized PRIME Trial Outcomes.” American journal of ophthalmology (2021). PMID: 33529593 ↗
L1RCTCited in: Acute & Vision-Threatening Management, Prognosis & Natural History
[340]
Ha A, Kim SH, Kang G et al.. “Association between Sight-Threatening Eye Diseases and Death by Suicide in South Korea: A Nationwide Population-based Cohort Study.” Ophthalmology (2023). PMID: 37001591 ↗
L2COHORTCited in: Acute & Vision-Threatening Management
[341]
Widyaputri F, Rogers SL, Kandasamy R et al.. “Global Estimates of Diabetic Retinopathy Prevalence and Progression in Pregnant Women With Preexisting Diabetes: A Systematic Review and Meta-analysis.” JAMA ophthalmology (2022). PMID: 35357410 ↗
L2SR_OBSCited in: Acute & Vision-Threatening Management
[342]
Teo ZL, Tham YC, Yu M et al.. “Do we have enough ophthalmologists to manage vision-threatening diabetic retinopathy? A global perspective.” Eye (London, England) (2020). PMID: 31992863 ↗
L2SR_OBSCited in: Acute & Vision-Threatening Management
[343]
Gurudas S, Frudd K, Maheshwari JJ et al.. “Multicenter Evaluation of Diagnostic Circulating Biomarkers to Detect Sight-Threatening Diabetic Retinopathy.” JAMA ophthalmology (2022). PMID: 35511139 ↗
L4OTHERCited in: Acute & Vision-Threatening Management
[344]
Meer E, Bavinger JC, Yu Y et al.. “Association of Fenofibrate Use and the Risk of Progression to Vision-Threatening Diabetic Retinopathy.” JAMA ophthalmology (2022). PMID: 35389455 ↗
L3OTHERCited in: Acute & Vision-Threatening Management
[345]
Sun Y, Li F, Liu Y et al.. “Targeting inflammasomes and pyroptosis in retinal diseases-molecular mechanisms and future perspectives.” Progress in retinal and eye research (2024). PMID: 38657834 ↗
L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management
[346]
Stitt AW, O'Neill CL, O'Doherty MT et al.. “Vascular stem cells and ischaemic retinopathies.” Progress in retinal and eye research (2011). PMID: 21352947 ↗
L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management, Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[347]
Kokavec J, Wu Z, Sherwin JC et al.. “Nd:YAG laser vitreolysis versus pars plana vitrectomy for vitreous floaters.” The Cochrane database of systematic reviews (2017). PMID: 28570745 ↗
L1SR_OBSCited in: Acute & Vision-Threatening Management, Long-term & Definitive Management
[348]
Lawrenson JG, Graham-Rowe E, Lorencatto F et al.. “Interventions to increase attendance for diabetic retinopathy screening.” The Cochrane database of systematic reviews (2018). PMID: 29333660 ↗
L1SR_OBSCited in: Acute & Vision-Threatening Management, Special Populations, Screening & Prevention
[349]
Grover D, Li TJ, Chong CC. “Intravitreal steroids for macular edema in diabetes.” The Cochrane database of systematic reviews (2008). PMID: 18254088 ↗
L1SR_OBSCited in: Acute & Vision-Threatening Management
[350]
Wong TY, Simó R, Mitchell P. “Fenofibrate - a potential systemic treatment for diabetic retinopathy?” American journal of ophthalmology (2012). PMID: 22709833 ↗
L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management, Long-term & Definitive Management
[351]
Koh BMQR, Banu R, Nusinovici S et al.. “100 most-cited articles on diabetic retinopathy.” The British journal of ophthalmology (2020). PMID: 32855165 ↗
L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management, Special Populations, Screening & Prevention
[352]
Ting DSJ, Foo VH, Yang LWY et al.. “Artificial intelligence for anterior segment diseases: Emerging applications in ophthalmology.” The British journal of ophthalmology (2020). PMID: 32532762 ↗
L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management
[353]
Thomas RL, Dunstan FD, Luzio SD et al.. “Prevalence of diabetic retinopathy within a national diabetic retinopathy screening service.” The British journal of ophthalmology (2014). PMID: 25091950 ↗
L2OTHERCited in: Acute & Vision-Threatening Management
[354]
Zatic T, Bendelic E, Paduca A et al.. “Rapid assessment of avoidable blindness and diabetic retinopathy in Republic of Moldova.” The British journal of ophthalmology (2014). PMID: 25550353 ↗
L2OTHERCited in: Acute & Vision-Threatening Management
[355]
Zhang G, Chen H, Chen W et al.. “Prevalence and risk factors for diabetic retinopathy in China: a multi-hospital-based cross-sectional study.” The British journal of ophthalmology (2017). PMID: 28855195 ↗
L2OTHERCited in: Acute & Vision-Threatening Management
[356]
Ooi KG, Khoo P, Vaclavik V et al.. “Statins in ophthalmology.” Survey of ophthalmology (2019). PMID: 30703407 ↗
L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management
[357]
Errera MH, Kohly RP, da Cruz L. “Pregnancy-associated retinal diseases and their management.” Survey of ophthalmology (2013). PMID: 23410822 ↗
L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management, Long-term & Definitive Management
[358]
Feizi S, Alemzadeh-Ansari M, Karimian F et al.. “Use of erythropoietin in ophthalmology: a review.” Survey of ophthalmology (2021). PMID: 34157346 ↗
L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management
[359]
Khan R, Sharma A, Ravikumar R et al.. “Association Between Gut Microbial Abundance and Sight-Threatening Diabetic Retinopathy.” Investigative ophthalmology & visual science (2021). PMID: 34132747 ↗
L3OTHERCited in: Acute & Vision-Threatening Management
[360]
Seddon JM. “Genetic and environmental underpinnings to age-related ocular diseases.” Investigative ophthalmology & visual science (2013). PMID: 24335064 ↗
L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management
[361]
Grassi MA, Tikhomirov A, Ramalingam S et al.. “Replication analysis for severe diabetic retinopathy.” Investigative ophthalmology & visual science (2012). PMID: 22427569 ↗
L3OTHERCited in: Acute & Vision-Threatening Management
[362]
Zhong X, Li H, Tan S et al.. “Initial Retinal Nerve Fiber Layer Loss and Risk of Diabetic Retinopathy Over a Four-Year Period.” Investigative ophthalmology & visual science (2024). PMID: 39365262 ↗
L2OTHERCited in: Acute & Vision-Threatening Management
[363]
Leclercq B, Mejlachowicz D, Zhu L et al.. “Differential Effect of Aldosterone or Mineralocorticoid Receptor Overexpression on Retinal Inflammation.” Investigative ophthalmology & visual science (2024). PMID: 39453673 ↗
L5OTHERCited in: Acute & Vision-Threatening Management
[364]
Tayyari F, Khuu LA, Flanagan JG et al.. “Retinal Blood Flow and Retinal Blood Oxygen Saturation in Mild to Moderate Diabetic Retinopathy.” Investigative ophthalmology & visual science (2015). PMID: 26567792 ↗
L4OTHERCited in: Acute & Vision-Threatening Management
[365]
Rajagopal R, McGill JB. “NOVEL AGENTS IN THE MANAGEMENT OF DIABETES AND RISK OF WORSENING DIABETIC RETINOPATHY.” Retina (Philadelphia, Pa.) (2024). PMID: 39151204 ↗
L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management
[366]
Jaulim A, Ahmed B, Khanam T et al.. “Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature.” Retina (Philadelphia, Pa.) (2013). PMID: 23609064 ↗
L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management
[367]
Moysidis SN, Vajzovic L, Gregori G et al.. “Acute retinal pigment epithelium detachments after photocoagulation.” Retina (Philadelphia, Pa.) (2014). PMID: 24013258 ↗
L2OTHERCited in: Acute & Vision-Threatening Management
[368]
Luo C, Ruby A, Neuwelt M et al.. “Transvitreal fibrinoid pseudoendophthalmitis after diabetic vitrectomy.” Retina (Philadelphia, Pa.) (2013). PMID: 23609127 ↗
L4OTHERCited in: Acute & Vision-Threatening Management
[369]
Wright AD, Dodson PM. “Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies.” Eye (London, England) (2011). PMID: 21436845 ↗
L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management, Long-term & Definitive Management
[370]
Rajalakshmi R, Prathiba V, Arulmalar S et al.. “Review of retinal cameras for global coverage of diabetic retinopathy screening.” Eye (London, England) (2020). PMID: 33168977 ↗
L5REVIEW_NARRATIVECited in: Acute & Vision-Threatening Management
[371]
Jin J, Ji F, Zhang J. “The Relationship between S100A9 Protein Levels and Diabetic Retinopathy among Type 2 Diabetes Patients: A Meta-Analysis.” Current protein & peptide science (2026). PMID: 42059242 ↗
L1SR_OBSCited in: Acute & Vision-Threatening Management
[372]
Cui C, Li Y, Zhang Q. “The impact of diabetes mellitus and diabetic retinopathy on prognosis and complications after cataract surgery: Retrospective cohort study.” Medicine (2026). PMID: 42116355 ↗
L2COHORTCited in: Acute & Vision-Threatening Management
[373]
Zhang Z, Zhang Q, Chen Y et al.. “Outer nuclear layer thinning as an in vivo biomarker for discriminating probable FTLD-tau from probable FTLD-TDP with PET-supported subtyping.” Alzheimer's research & therapy (2026). PMID: 42337644 ↗
L4OTHERCited in: Acute & Vision-Threatening Management
[374]
Korobelnik JF, Do DV, Schmidt-Erfurth U et al.. “Intravitreal aflibercept for diabetic macular edema.” Ophthalmology (2014). PMID: 25012934 ↗
L1RCTCited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[375]
Zhang ZH, Liu HY, Hernandez-Da Mota SE et al.. “Vitrectomy with or without preoperative intravitreal bevacizumab for proliferative diabetic retinopathy: a meta-analysis of randomized controlled trials.” American journal of ophthalmology (2013). PMID: 23791371 ↗
L1SR_MA_RCTCited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
[376]
Zhao XY, Xia S, Chen YX. “Antivascular endothelial growth factor agents pretreatment before vitrectomy for complicated proliferative diabetic retinopathy: a meta-analysis of randomised controlled trials.” The British journal of ophthalmology (2017). PMID: 29246890 ↗
L1SR_MA_RCTCited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
[377]
Takkar B, Ketkar MR, Narula R et al.. “A Pilot Randomized Controlled Trial Evaluating Hemostasis With Fibrin Glue During Surgery for Proliferative Diabetic Retinopathy.” American journal of ophthalmology (2025). PMID: 39884371 ↗
L1RCTCited in: Long-term & Definitive Management
[378]
Zhao S, Wu M, Zhong J et al.. “Efficacy and safety of anti-VEGF monoclonal antibody 601 for macular oedema in retinal vein occlusion: two phase IIa randomised clinical trials.” The British journal of ophthalmology (2026). PMID: 41448868 ↗
L1RCTCited in: Long-term & Definitive Management
[379]
Zhang W, Cheng S, Gu X et al.. “Simultaneous inhibition of fibroblast growth factor-2 and vascular endothelial growth factor-a with RC28-E in diabetic macular edema: a phase 2 randomised trial.” The British journal of ophthalmology (2025). PMID: 40122579 ↗
L1RCTCited in: Long-term & Definitive Management, Prognosis & Natural History
[380]
Chous AP, Richer SP, Gerson JD et al.. “The Diabetes Visual Function Supplement Study (DiVFuSS).” The British journal of ophthalmology (2015). PMID: 26089210 ↗
L1RCTCited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[381]
Casswell EJ, Cro S, Cornelius VR et al.. “Randomised controlled trial of adjunctive triamcinolone acetonide in eyes undergoing vitreoretinal surgery following open globe trauma: The ASCOT study.” The British journal of ophthalmology (2024). PMID: 36849205 ↗
L1RCTCited in: Long-term & Definitive Management, Prognosis & Natural History
[382]
Ockrim ZK, Sivaprasad S, Falk S et al.. “Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema.” The British journal of ophthalmology (2008). PMID: 18420749 ↗
L1RCTCited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[383]
González VH, Giuliari GP, Banda RM et al.. “Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy.” The British journal of ophthalmology (2009). PMID: 19692371 ↗
L1RCTCited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[384]
Khan MA, Hill L, Stoilov I et al.. “Race and Vision Outcomes in Ranibizumab-Treated Participants With Diabetic Macular Edema: A Meta-Analysis.” JAMA ophthalmology (2025). PMID: 40208611 ↗
L1SR_OBSCited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[385]
Brown DM, Boyer DS, Csaky K et al.. “INTRAVITREAL NESVACUMAB (ANTIANGIOPOIETIN 2) PLUS AFLIBERCEPT IN DIABETIC MACULAR EDEMA: Phase 2 RUBY Randomized Trial.” Retina (Philadelphia, Pa.) (2022). PMID: 35234673 ↗
L1RCTCited in: Long-term & Definitive Management
[386]
Pak K, Yoon C, Sadda SR. “Long term evolutions of hard exudates after anti-VEGF therapy for diabetic macular oedema.” Eye (London, England) (2026). PMID: 41904245 ↗
L2RCTCited in: Long-term & Definitive Management, Prognosis & Natural History
[387]
Narayanan SP, Rojas M, Suwanpradid J et al.. “Arginase in retinopathy.” Progress in retinal and eye research (2013). PMID: 23830845 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[388]
Purdy R, John M, Bray A et al.. “Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy.” Progress in retinal and eye research (2025). PMID: 40090458 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
[389]
Penn JS, Madan A, Caldwell RB et al.. “Vascular endothelial growth factor in eye disease.” Progress in retinal and eye research (2008). PMID: 18653375 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, Special Populations, Screening & Prevention
[390]
Laíns I, Gantner M, Murinello S et al.. “Metabolomics in the study of retinal health and disease.” Progress in retinal and eye research (2018). PMID: 30423446 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
[391]
Grossniklaus HE, Kang SJ, Berglin L. “Animal models of choroidal and retinal neovascularization.” Progress in retinal and eye research (2010). PMID: 20488255 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
[392]
Martinez-Zapata MJ, Martí-Carvajal AJ, Solà I et al.. “Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.” The Cochrane database of systematic reviews (2014). PMID: 25418485 ↗
L1SR_OBSCited in: Long-term & Definitive Management
[393]
Viggiano P, Carra A, Bruno G et al.. “Microaneurysm Reflectivity as a Prognostic Biomarker for Intravitreal Treatment Response in Diabetic Retinopathy.” American journal of ophthalmology (2026). PMID: 41617122 ↗
L2OTHERCited in: Long-term & Definitive Management
[394]
Sasongko MB, Wardhana FS, Febryanto GA et al.. “The estimated healthcare cost of diabetic retinopathy in Indonesia and its projection for 2025.” The British journal of ophthalmology (2019). PMID: 31285276 ↗
L2OTHERCited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[395]
Iacono P, Parodi MB, Scaramuzzi M et al.. “Morphological and functional changes in recalcitrant diabetic macular oedema after intravitreal dexamethasone implant.” The British journal of ophthalmology (2016). PMID: 27625164 ↗
L4OTHERCited in: Long-term & Definitive Management
[396]
Manousaridis K, Talks J. “Macular ischaemia: a contraindication for anti-VEGF treatment in retinal vascular disease?” The British journal of ophthalmology (2012). PMID: 22250209 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
[397]
Tan Y, Fukutomi A, Sun MT et al.. “Anti-VEGF crunch syndrome in proliferative diabetic retinopathy: A review.” Survey of ophthalmology (2021). PMID: 33705807 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
[398]
Sivaprasad S, Elagouz M, McHugh D et al.. “Micropulsed diode laser therapy: evolution and clinical applications.” Survey of ophthalmology (2010). PMID: 20850854 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
[399]
Stefánsson E. “Ocular oxygenation and the treatment of diabetic retinopathy.” Survey of ophthalmology (2006). PMID: 16818083 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
[400]
Lally DR, Shah CP, Heier JS. “Vascular endothelial growth factor and diabetic macular edema.” Survey of ophthalmology (2016). PMID: 27045225 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[401]
Bressler NM, Kaiser PK, Do DV et al.. “Biosimilars of anti-vascular endothelial growth factor for ophthalmic diseases: A review.” Survey of ophthalmology (2024). PMID: 38521423 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
[402]
Wei X, Balne PK, Meissner KE et al.. “Assessment of flow dynamics in retinal and choroidal microcirculation.” Survey of ophthalmology (2018). PMID: 29577954 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
[403]
Piroozmand S, Latifi-Navid H, Soheili ZS et al.. “Suboptimal Responses to Anti-VEGF in Retinal Neurovascular Diseases: Linking Aging and Alternative Angioinflammatory Pathways.” Investigative ophthalmology & visual science (2026). PMID: 42080790 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
[404]
Calton MA, Croze RH, Burns C et al.. “Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies.” Investigative ophthalmology & visual science (2024). PMID: 39620832 ↗
L5OTHERCited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations, Prognosis & Natural History
[405]
Park SS. “Cell Therapy Applications for Retinal Vascular Diseases: Diabetic Retinopathy and Retinal Vein Occlusion.” Investigative ophthalmology & visual science (2016). PMID: 27116667 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[406]
Skeie JM, Nishimura DY, Wang CL et al.. “Mitophagy: An Emerging Target in Ocular Pathology.” Investigative ophthalmology & visual science (2021). PMID: 33724294 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
[407]
Pauleikhoff L, Boneva S, Boeck M et al.. “Transcriptional Comparison of Human and Murine Retinal Neovascularization.” Investigative ophthalmology & visual science (2023). PMID: 38153746 ↗
L5OTHERCited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[408]
Viggiano P, Miere A, Borrelli E et al.. “The Impact of Diabetic Retinopathy on the Choriocapillaris in Neovascular AMD.” Investigative ophthalmology & visual science (2023). PMID: 37988106 ↗
L4OTHERCited in: Long-term & Definitive Management
[409]
Boscia G, Bacherini D, Vujosevic S et al.. “Long-Term Impact of Diabetic Retinopathy on Response to Anti-VEGF Treatment in Neovascular AMD.” Investigative ophthalmology & visual science (2024). PMID: 39093297 ↗
L3OTHERCited in: Long-term & Definitive Management, Prognosis & Natural History
[410]
Peyman GA, Lad EM, Moshfeghi DM. “Intravitreal injection of therapeutic agents.” Retina (Philadelphia, Pa.) (2009). PMID: 19584648 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[411]
Su T, Lai C, Du Z et al.. “RETINAL PHOTORECEPTORS AND ARTERIOLES ALTERATIONS DETECTED USING ADAPTIVE OPTICS SCANNING LASER OPHTHALMOSCOPY IN DIABETES AND DIABETIC RETINOPATHY.” Retina (Philadelphia, Pa.) (2026). PMID: 40865080 ↗
L4OTHERCited in: Long-term & Definitive Management
[412]
Osaadon P, Fagan XJ, Lifshitz T et al.. “A review of anti-VEGF agents for proliferative diabetic retinopathy.” Eye (London, England) (2014). PMID: 24525867 ↗
L2REVIEW_NARRATIVECited in: Long-term & Definitive Management
[413]
Chatziralli I, Touhami S, Cicinelli MV et al.. “Disentangling the association between retinal non-perfusion and anti-VEGF agents in diabetic retinopathy.” Eye (London, England) (2021). PMID: 34408316 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
[414]
Dinah C, Dodds M, Lotery A et al.. “Treatment patterns and long-term outcomes in anti-VEGF-treated macular oedema secondary to retinal vein occlusion: a retrospective observational study.” Eye (London, England) (2025). PMID: 41238745 ↗
L2OTHERCited in: Long-term & Definitive Management
[415]
Hari T, Elsherbiny S. “Bariatric surgery-what the ophthalmologist needs to know.” Eye (London, England) (2021). PMID: 34675393 ↗
L2REVIEW_NARRATIVECited in: Long-term & Definitive Management, Surgical, Laser & Procedural Considerations
[416]
Falavarjani KG, Nguyen QD. “Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature.” Eye (London, England) (2013). PMID: 23722722 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
[417]
Chong V. “Ranibizumab for the treatment of wet AMD: a summary of real-world studies.” Eye (London, England) (2015). PMID: 26634711 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
[418]
Wang Y, Zhang Q, Pan H et al.. “Chain mediating effect of social support and psychological resilience between quality of discharge teaching and readiness for hospital discharge in patients with diabetic retinopathy surgery.” Frontiers in public health (2026). PMID: 42359153 ↗
L4OTHERCited in: Long-term & Definitive Management
[419]
Heck K, Hatz K, Cattaneo M et al.. “Six-Month Real-World Data in Macular Edema Due to Retinal Vein Occlusion Treated with Faricimab: Swiss Retina Research Network Report.” Ophthalmology and therapy (2026). PMID: 42334530 ↗
L2OTHERCited in: Long-term & Definitive Management
[420]
Lee JY, Joo CK, Shawl AI et al.. “Local and Systemic Immunologic Profiles Differentiate Accepted and Rejected Islet Grafts in a Rat Anterior Chamber Model.” Journal of immunology research (2026). PMID: 42324809 ↗
L5OTHERCited in: Long-term & Definitive Management
[421]
Tang J, Sun Y, Jin E et al.. “A two-step approach for suprachoroidal delivery of dexamethasone implant using a custom-made injector.” International journal of retina and vitreous (2026). PMID: 42316264 ↗
L4OTHERCited in: Long-term & Definitive Management
[422]
Luu B, van Dijk EHC, Hein M et al.. “Predicting the progression of proliferative diabetic retinopathy: Pathophysiology, imaging phenotypes, and determinants of disease persistence despite therapy.” Survey of ophthalmology (2026). PMID: 42314860 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
[423]
Xia D, Li W, Xie J et al.. “Supramolecular peptide hydrogels for the treatment of ocular diseases: from tissue replacements to drug delivery systems.” Journal of materials chemistry. B (2026). PMID: 42300220 ↗
L5REVIEW_NARRATIVECited in: Long-term & Definitive Management
[424]
Zhang S, Ran A, Zhou J et al.. “An AI-Based OCT System to Detect Diabetic Macular Edema: A Prospective Validation and Noninferiority Randomized Clinical Trial.” JAMA (2026). PMID: 42295755 ↗
L1OTHERCited in: Long-term & Definitive Management
[425]
Su L, Ren X, Wei H et al.. “INTRAVITREAL CONBERCEPT (KH902) FOR SURGICAL TREATMENT OF SEVERE PROLIFERATIVE DIABETIC RETINOPATHY.” Retina (Philadelphia, Pa.) (2016). PMID: 26630313 ↗
L1RCTCited in: Surgical, Laser & Procedural Considerations
[426]
Chen GH, Tzekov R, Mao SH et al.. “Intravitreal conbercept as an adjuvant in vitrectomy for proliferative diabetic retinopathy: a meta-analysis of randomised controlled trials.” Eye (London, England) (2021). PMID: 33824510 ↗
L1SR_MA_RCTCited in: Surgical, Laser & Procedural Considerations
[427]
Kim LN, Mehta H, Barthelmes D et al.. “METAANALYSIS OF REAL-WORLD OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.” Retina (Philadelphia, Pa.) (2016). PMID: 27388744 ↗
L2SR_OBSCited in: Surgical, Laser & Procedural Considerations, Prognosis & Natural History
[428]
Cheung N, Wong TY. “Diabetic retinopathy and systemic vascular complications.” Progress in retinal and eye research (2007). PMID: 18249026 ↗
L5REVIEW_NARRATIVECited in: Surgical, Laser & Procedural Considerations
[429]
Roy S, Jiang JX, Li AF et al.. “Connexin channel and its role in diabetic retinopathy.” Progress in retinal and eye research (2017). PMID: 28602949 ↗
L5REVIEW_NARRATIVECited in: Surgical, Laser & Procedural Considerations
[430]
Padovani-Claudio DA, Ramos CJ, Capozzi ME et al.. “Elucidating glial responses to products of diabetes-associated systemic dyshomeostasis.” Progress in retinal and eye research (2023). PMID: 37028118 ↗
L5REVIEW_NARRATIVECited in: Surgical, Laser & Procedural Considerations
[431]
Mastropasqua R, Toto L, Cipollone F et al.. “Role of microRNAs in the modulation of diabetic retinopathy.” Progress in retinal and eye research (2014). PMID: 25128741 ↗
L5REVIEW_NARRATIVECited in: Surgical, Laser & Procedural Considerations
[432]
Carlà MM, Giannuzzi F, Boselli F et al.. “The applications of viscoelastic agents in vitreoretinal surgery.” Survey of ophthalmology (2025). PMID: 39952440 ↗
L5REVIEW_NARRATIVECited in: Surgical, Laser & Procedural Considerations, Prognosis & Natural History
[433]
Lai D, Wu Y, Shao C et al.. “The Role of Müller Cells in Diabetic Macular Edema.” Investigative ophthalmology & visual science (2023). PMID: 37418272 ↗
L5REVIEW_NARRATIVECited in: Surgical, Laser & Procedural Considerations
[434]
Thakur PS, Aggarwal D, Takkar B et al.. “Evidence Suggesting the Role of Gut Dysbiosis in Diabetic Retinopathy.” Investigative ophthalmology & visual science (2022). PMID: 35877085 ↗
L5REVIEW_NARRATIVECited in: Surgical, Laser & Procedural Considerations
[435]
Yan B, Qiu J, Yang Y et al.. “Exosomal miRNA Profiling in Liquid Biopsy of Vitreous in Proliferative Diabetic Retinopathy.” Investigative ophthalmology & visual science (2025). PMID: 40637511 ↗
L3OTHERCited in: Surgical, Laser & Procedural Considerations
[436]
Murphy DC, Al-Zubaidy M, Lois N et al.. “The Effect of Macular Hole Duration on Surgical Outcomes: An Individual Participant Data Study of Randomized Controlled Trials.” Ophthalmology (2022). PMID: 36058348 ↗
L1SR_MA_RCTCited in: Prognosis & Natural History
[437]
Sadda S, Sarraf D, Khanani AM et al.. “Comparative assessment of subretinal hyper-reflective material in patients treated with brolucizumab versus aflibercept in HAWK and HARRIER.” The British journal of ophthalmology (2024). PMID: 37669850 ↗
L1RCTCited in: Prognosis & Natural History
[438]
Gale R, Scanlon PH, Evans M et al.. “Action on diabetic macular oedema: achieving optimal patient management in treating visual impairment due to diabetic eye disease.” Eye (London, England) (2017). PMID: 28490797 ↗
L5GUIDELINECited in: Prognosis & Natural History
[439]
Wykoff CC, Ou WC, Khurana RN et al.. “Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study.” The British journal of ophthalmology (2017). PMID: 28814412 ↗
L4TRIAL_NONRANDOMCited in: Prognosis & Natural History
[440]
Khan Z, Gaidhane AM, Singh M et al.. “Diagnostic Accuracy of IDX-DR for Detecting Diabetic Retinopathy: A Systematic Review and Meta-Analysis.” American journal of ophthalmology (2025). PMID: 39986640 ↗
L2SR_OBSCited in: Prognosis & Natural History, Special Populations, Screening & Prevention
[441]
Zhang C, Xia Z, Mao W et al.. “Optical coherence tomography angiogropahy changes in patients with diabetic retinopathy treated with panretinal photocoagulation: A systematic review and meta-analysis.” Survey of ophthalmology (2025). PMID: 41207511 ↗
L2SR_OBSCited in: Prognosis & Natural History
[442]
Zhang SX, Wang JJ, Starr CR et al.. “The endoplasmic reticulum: Homeostasis and crosstalk in retinal health and disease.” Progress in retinal and eye research (2023). PMID: 38092262 ↗
L5REVIEW_NARRATIVECited in: Prognosis & Natural History
[443]
Nawaz IM, Rezzola S, Cancarini A et al.. “Human vitreous in proliferative diabetic retinopathy: Characterization and translational implications.” Progress in retinal and eye research (2019). PMID: 30951889 ↗
L5REVIEW_NARRATIVECited in: Prognosis & Natural History
[444]
Zaluski J, Bassetto M, Kiser PD et al.. “Advances and therapeutic opportunities in visual cycle modulation.” Progress in retinal and eye research (2025). PMID: 40280538 ↗
L5REVIEW_NARRATIVECited in: Prognosis & Natural History
[445]
Cundy O, Lange CA, Bunce C et al.. “Face-down positioning or posturing after macular hole surgery.” The Cochrane database of systematic reviews (2023). PMID: 37987517 ↗
L1SR_OBSCited in: Prognosis & Natural History
[446]
Lam FC, Chia SN, Lee RM. “Macular grid laser photocoagulation for branch retinal vein occlusion.” The Cochrane database of systematic reviews (2015). PMID: 25961835 ↗
L1SR_OBSCited in: Prognosis & Natural History
[447]
Lu S, Lin Y, Lin L et al.. “Efficacy and safety of different anti-VEGF agents combined with pars plana vitrectomy in proliferative diabetic retinopathy: a systematic review and network meta-analysis of randomized controlled trials.” Frontiers in endocrinology (2026). PMID: 41958881 ↗
L1SR_MA_RCTCited in: Prognosis & Natural History
[448]
Jiang W, Wang J, Li J et al.. “Cardiorenal risk stratification in high-risk type 2 diabetes using a simple clinical score: findings from the ELIXA trial.” Frontiers in endocrinology (2026). PMID: 41928879 ↗
L2RCTCited in: Prognosis & Natural History
[449]
Nakashima H, Ikeda S, Shinohara K et al.. “Prognostic Value of the Low-Density Lipoprotein Cholesterol/High-Density Lipoprotein Cholesterol Ratio for Cardiovascular Events in Statin-Treated Type 2 Diabetes With Diabetic Retinopathy Without Prior Cardiovascular Disease.” Circulation journal : official journal of the Japanese Circulation Society (2026). PMID: 41922276 ↗
L2RCTCited in: Prognosis & Natural History
[450]
Khayat M, Williams M, Lois N. “Ischemic retinal vein occlusion: characterizing the more severe spectrum of retinal vein occlusion.” Survey of ophthalmology (2018). PMID: 29705175 ↗
L5REVIEW_NARRATIVECited in: Prognosis & Natural History
[451]
Chang RC, Shi L, Huang CC et al.. “High-Fat Diet-Induced Retinal Dysfunction.” Investigative ophthalmology & visual science (2015). PMID: 25788653 ↗
L5OTHERCited in: Prognosis & Natural History, Special Populations, Screening & Prevention
[452]
Tang VTS, Symons RCA, Fourlanos S et al.. “Contrast Increment and Decrement Processing in Individuals With and Without Diabetes.” Investigative ophthalmology & visual science (2023). PMID: 37083950 ↗
L3OTHERCited in: Prognosis & Natural History
[453]
Fragiotta S, Costanzo E, Picconi F et al.. “Progression Biomarkers of Microvascular and Photoreceptor Changes Upon Long-Term Evaluation in Type 1 Diabetes.” Investigative ophthalmology & visual science (2023). PMID: 37227747 ↗
L2OTHERCited in: Prognosis & Natural History
[454]
Torres-Villaros H, Timoumi R, Fajnkuchen F et al.. “MACULAR THICKNESS FLUCTUATIONS AND VISUAL ACUITY OUTCOMES AFTER INTRAVITREAL DEXAMETHASONE IMPLANT FOR DIABETIC MACULAR EDEMA.” Retina (Philadelphia, Pa.) (2024). PMID: 39208410 ↗
L4OTHERCited in: Prognosis & Natural History
[455]
Sivaprasad S, Arden G. “Spare the rods and spoil the retina: revisited.” Eye (London, England) (2015). PMID: 26656085 ↗
L5REVIEW_NARRATIVECited in: Prognosis & Natural History
[456]
Hark LA, Katz LJ, Myers JS et al.. “Philadelphia Telemedicine Glaucoma Detection and Follow-up Study: Methods and Screening Results.” American journal of ophthalmology (2017). PMID: 28673747 ↗
L1RCTCited in: Special Populations, Screening & Prevention
[457]
Assi L, Chamseddine F, Ibrahim P et al.. “A Global Assessment of Eye Health and Quality of Life: A Systematic Review of Systematic Reviews.” JAMA ophthalmology (2021). PMID: 33576772 ↗
L2SR_OBSCited in: Special Populations, Screening & Prevention
[458]
Rahmati M, Smith L, Boyer L et al.. “Factors Affecting Global Adherence for the Uptake of Diabetic Retinopathy Screening: A Systematic Review and Meta-Analysis.” American journal of ophthalmology (2024). PMID: 39094991 ↗
L2SR_OBSCited in: Special Populations, Screening & Prevention
[459]
Sharafeldin N, Kawaguchi A, Sundaram A et al.. “Review of economic evaluations of teleophthalmology as a screening strategy for chronic eye disease in adults.” The British journal of ophthalmology (2018). PMID: 29680803 ↗
L5SR_OBSCited in: Special Populations, Screening & Prevention
[460]
Butt AB, Ahmed F, Mihalache A et al.. “SOCIODEMOGRAPHIC FACTORS AS PREDICTORS OF DIABETIC RETINOPATHY SCREENING: A Systematic Review.” Retina (Philadelphia, Pa.) (2026). PMID: 41874556 ↗
L2SR_OBSCited in: Special Populations, Screening & Prevention
[461]
Rathi S, Tsui E, Mehta N et al.. “The Current State of Teleophthalmology in the United States.” Ophthalmology (2017). PMID: 28647202 ↗
L5REVIEW_NARRATIVECited in: Special Populations, Screening & Prevention
[462]
Thomas CG, Channa R, Prichett L et al.. “Racial/Ethnic Disparities and Barriers to Diabetic Retinopathy Screening in Youths.” JAMA ophthalmology (2021). PMID: 34042939 ↗
L3OTHERCited in: Special Populations, Screening & Prevention
[463]
Li JO, Liu H, Ting DSJ et al.. “Digital technology, tele-medicine and artificial intelligence in ophthalmology: A global perspective.” Progress in retinal and eye research (2020). PMID: 32898686 ↗
L5REVIEW_NARRATIVECited in: Special Populations, Screening & Prevention
[464]
Kador PF, Wyman M, Oates PJ. “Aldose reductase, ocular diabetic complications and the development of topical Kinostat(®).” Progress in retinal and eye research (2016). PMID: 27102270 ↗
L5REVIEW_NARRATIVECited in: Special Populations, Screening & Prevention
[465]
Froger N, Moutsimilli L, Cadetti L et al.. “Taurine: the comeback of a neutraceutical in the prevention of retinal degenerations.” Progress in retinal and eye research (2014). PMID: 24721186 ↗
L5REVIEW_NARRATIVECited in: Special Populations, Screening & Prevention
[466]
Smith JM, Steel DH. “Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.” The Cochrane database of systematic reviews (2011). PMID: 21563165 ↗
L1SR_OBSCited in: Special Populations, Screening & Prevention
[467]
Smith JM, Steel DH. “Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.” The Cochrane database of systematic reviews (2015). PMID: 26250103 ↗
L1SR_OBSCited in: Special Populations, Screening & Prevention
[468]
Nwanyanwu K, Andoh J, Chen E et al.. “Social Determinants Associated with Diabetic Retinopathy Awareness: National Health and Nutrition Examination Survey (2005-2008).” American journal of ophthalmology (2025). PMID: 40550446 ↗
L4OTHERCited in: Special Populations, Screening & Prevention
[469]
Yang Z, Zhang J, Zheng Y. “Associations Between Life's Essential 8 and Major Ocular Diseases in the American Middle-Aged and Elderly Population.” American journal of ophthalmology (2024). PMID: 39089359 ↗
L4OTHERCited in: Special Populations, Screening & Prevention
[470]
Kakihara S, Zhuang K, Fawzi AA. “Macular Deep Capillary Plexus Ischemia as a Biomarker for Identifying Referable Diabetic Retinopathy.” Investigative ophthalmology & visual science (2025). PMID: 41251524 ↗
L4OTHERCited in: Special Populations, Screening & Prevention
[471]
Hussain R, Czanner G, Taktak A et al.. “MORTALITY OF PATIENTS WITH UVEAL MELANOMA DETECTED BY DIABETIC RETINOPATHY SCREENING.” Retina (Philadelphia, Pa.) (2020). PMID: 32032260 ↗
L3OTHERCited in: Special Populations, Screening & Prevention
[472]
He X, Deng X, Lin Z et al.. “SCREENING AND MONITORING OF DIABETIC RETINOPATHY IN COMMUNITY CARE: The Effectiveness of Single-Field Versus Multifield Fundus Photography.” Retina (Philadelphia, Pa.) (2025). PMID: 39437367 ↗
L2OTHERCited in: Special Populations, Screening & Prevention
[473]
Arruabarrena C, Rodríguez-Miguel A, Allendes G et al.. “EVALUATION OF THE INCLUSION OF SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY IN A TELEMEDICINE DIABETIC RETINOPATHY SCREENING PROGRAM: A Real Clinical Practice.” Retina (Philadelphia, Pa.) (2023). PMID: 37155959 ↗
L4OTHERCited in: Special Populations, Screening & Prevention
[474]
Aiello LP, Jacoba CMP, Ashraf M et al.. “INTEGRATING MACULAR OPTICAL COHERENCE TOMOGRAPHY WITH ULTRAWIDE-FIELD IMAGING IN A DIABETIC RETINOPATHY TELEMEDICINE PROGRAM USING A SINGLE DEVICE.” Retina (Philadelphia, Pa.) (2023). PMID: 37871272 ↗
L4OTHERCited in: Special Populations, Screening & Prevention
[475]
Wei C, Zhang L, Chen C et al.. “Quantifying the Economic Value of AI-Assisted Diabetic Retinopathy Screening: A Meta-Analysis Using the Incremental Net Benefit Framework.” Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research (2026). PMID: 42336317 ↗
L2SR_OBSCited in: Special Populations, Screening & Prevention
[476]
Kumari S, Venkatesh P, Tandon N et al.. “Selfie fundus imaging for diabetic retinopathy screening.” Eye (London, England) (2021). PMID: 34642496 ↗
L4OTHERCited in: Special Populations, Screening & Prevention
[477]
Grzybowski A, Brona P, Lim G et al.. “Artificial intelligence for diabetic retinopathy screening: a review.” Eye (London, England) (2019). PMID: 31488886 ↗
L5REVIEW_NARRATIVECited in: Special Populations, Screening & Prevention
[478]
Yalaev BI, Khusainova RI, Minniakhmetov IR et al.. “Genetic Determinants of Microvascular Complications of Type 1 Diabetes Mellitus: New Data from a Replication Study.” Biomedicines (2026). PMID: 42351627 ↗
L3OTHERCited in: Special Populations, Screening & Prevention
[479]
Samayamanthula S, Williams J, Markowski A et al.. “Blood Pressure Assessment in Ophthalmology Clinics for Patients With Diabetes.” JAMA ophthalmology (2026). PMID: 42348192 ↗
L4OTHERCited in: Special Populations, Screening & Prevention

Quick Reference

Overview and Recommendations

Background

Evaluation

Management

Board Review — High Yield

Deep Dive — Evidence Details

Definition, Classification & Nomenclature

Also Called / Synonyms

Classification Systems

Clinical Significance

Pathophysiology & Mechanism

Metabolic Pathways of Hyperglycaemic Damage

Neurodegeneration: The Earliest Retinal Injury

Inflammation and the Blood-Retinal Barrier

The VEGF Axis and Neovascularization

Capillary Nonperfusion and Ischaemia

Genetic and Epigenetic Modifiers

Epidemiology, Etiology & Risk Factors

Global Burden and Demographics

Temporal Trends

Risk Factors

Special Populations

Clinical Presentation

Presenting Symptoms

Ophthalmic Examination Findings

Phenotypic Variants

Red Flags

Atypical Presentations

Diagnosis & Workup

Optical Coherence Tomography (OCT)

Fluorescein Angiography (FA)

Optical Coherence Tomography Angiography (OCTA)

Functional Testing

Artificial Intelligence and Telemedicine

Diagnostic Algorithm

Severity, Staging & Risk Stratification

The ETDRS Severity Scale and Its Clinical Correlates

Risk Stratification: Predicting Progression

Staging-Driven Management Thresholds

Controversies and Guideline Disagreement

Acute & Vision-Threatening Management

Step 1: Initial Assessment and Severity Classification

Step 2: First-Line Intervention - Intravitreal Anti-VEGF Therapy

Step 3: Second-Line - Vitrectomy for Persistent VH or TRD

Step 4: Neovascular Glaucoma - Emergency IOP Control

Step 5: Monitoring and Transition to Maintenance

Controversies and Guideline Disagreement

What NOT to Do

Long-term & Definitive Management

Systemic Medical Management

Anti-VEGF Therapy for Diabetic Macular Edema

Anti-VEGF Therapy for Proliferative Diabetic Retinopathy

Panretinal Photocoagulation

Vitrectomy

What NOT to Do

Controversies and Guideline Disagreement

Surgical, Laser & Procedural Considerations

Laser for Diabetic Macular Edema

Intravitreal Injection Technique and Safety

Vitrectomy for Proliferative Diabetic Retinopathy

Postoperative Considerations

Procedural Considerations in Special Populations

Prognosis & Natural History

Prognostic Factors for Progression

Visual Outcomes with Treatment

Long-Term Outcomes and Recurrence

Controversies and Guideline Disagreement

Special Populations, Screening & Prevention

Screening Guidelines and Intervals

Artificial Intelligence and Telemedicine in Screening

Prevention Strategies

Special Populations

Pediatrics

Pregnancy

Elderly

Immunocompromised

Controversies and Guideline Disagreement

References

Staging-Driven Thresholds

Systemic Medical